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Throughout development, numerous binary cell fate decisions are made where cells 
activate competing transcriptional networks and subsequently upregulate one network 
over others based on extrinsic cues. Cell fate decisions are regulated by an interplay of 
different factors such as epigenetics and chromatin context. The multimeric cohesin 
complex has crucial roles in cell division and regulation of gene expression via chromatin 
organisation. Cohesin complexes obligatorily carry RAD21, SMC1 and SMC3A subunits 
and either STAG1 or STAG2. Given this interchangeability, homozygous loss of function 
mutations in STAG1 or STAG2 are generally compatible with life.   
Acute myeloid leukaemia (AML) is a haematopoietic malignancy characterised by 
increased proliferation of immature cells and decreased differentiation. STAG2 is the 
most commonly mutated cohesin gene in AML and also in other solid tumours, where 
mutations are acquired in somatic cells. Despite this, STAG2-mediated cancer 
pathogenesis remains underexplored. Besides, germline mutations in STAG1 and STAG2 
have been recently reported in patients with cohesinopathy, a group of developmental 
disorders caused by mutations in the cohesin subunit genes. Unlike in solid tumours, 
STAG2 mutations in both AML and cohesinopathies are not frequently associated with 
chromosomal aneuploidy suggesting transcriptional dysregulation as the key pathogenic 
mechanism here. Growing evidence supports shared and unique gene regulatory 
functions for STAG2 and its paralogue STAG1 in normal homeostasis and tumour 
suppression but the associated mechanisms are not completely understood. In this 
project, I investigated the role of Stag1/2 in development using zebrafish.  
Zebrafish have four copies of the Stag genes namely, stag1a, stag1b, stag2a and stag2b. 
I found all four paralogues to be expressed maternally and zygotically during zebrafish 
embryogenesis, suggesting crucial functions. Next, I generated loss of function germline 
zebrafish mutants for three of the four paralogues using CRISPR-Cas9 mutagenesis: 
stag1anz204, stag1bnz205 and stag2bnz207. No germline mutations could be recovered for 
stag2a paralogue. This paralogue showed high maternal expression, low but detectable 
zygotic expression and was also expressed in adult zebrafish ovary suggesting a possible 
role in germ cell development which might explain the inability to recover stable 
mutations. Loss of function for the remaining three Stag paralogue had different 
consequences on zebrafish embryonic development. stag1anz204 mutants were 
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phenotypically normal while stag1bnz205 and stag2bnz207 mutants had misplaced pigment 
cells, defective body axis patterning and notochord malformations. With respect to 
embryonic haematopoiesis, expanded runx1+ haematopoietic progenitors and primitive 
myeloid skewing followed by reduced definitive HSPCs were seen with stag1a loss. In 
contrast, stag1b loss did not impact embryonic haematopoiesis but altered the 
spatiotemporal expression of runx1 and sox2. In stag2bnz207 mutants, runx1+ 
haematopoietic precursors were reduced specifically in the posterior lateral mesoderm in 
a manner previously reported rad21 zebrafish mutants. The above results suggest that the 
four zebrafish stag paralogues are sub-functionalised during embryogenesis and that 
stag1a and stag2b have non-redundant haematopoietic functions. 
AML is a heterogeneous disease marked by the presence of combinatorial de novo 
mutations. I aimed to model combinatorial cohesin mutations with two frequent co-
occurring mutations that are found in AML namely, tet2 mutation and RUNX1-RUNX1T1 
translocation. For this, I generated a novel tet2nz207 mutant line carrying a disrupted 
functional oxygenase domain resulting in reduced primitive erythropoiesis and reduced 
definitive HSPC numbers. The haematopoietic defects in combinatorial tet2 and cohesin 
mutants remain to be evaluated. The RUNX1-RUNX1T1 fusion protein was expressed 
under the control of the Runx1+23 enhancer in the background of cohesin mutants. 
Abnormal expansion of posterior haematopoietic tissue and aberrant pu.1+ myeloid 
marker expression was seen in combinatorial mutants. While the above are preliminary 
observations, further characterisation of these novel mutant lines is expected to reveal 
common disease mechanisms. Existing AML animal models fail to capture the 
haematopoiesis-restricted and somatic nature of mutations. To address this problem, I 
generated macrophage-restricted tet2 mutant lines and draculin-restricted stag2b mutant 
lines that generate continual de novo mutations by tissue-specific production of Cas9 
mRNA. 
In summary, my research findings suggest that cohesin-STAG1 and cohesin-STAG2 
have non-overlapping roles in transcriptional regulation during embryonic development. 
The novel combinatorial and tissue-specific mutant lines generated will be useful to 
further elucidate the transcriptional dysregulation associated with STAG2 mutations in 
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The development of a multicellular organism starts with the division of a fertilised egg 
followed by specification into different cell types. How cells with equivalent 
developmental potency choose to be specified into one cell type over another has 
intrigued biologists for decades. During the embryonic phase, the most multipotent 
population of stem cells are the neural crest cells which give rise to various cell lineages 
such as neurons, glia, craniofacial cartilage, muscle and pigments. While all cells contain 
the same genetic material, differences in function arise based on which subsets of genes 
are turned on or off. Throughout development, numerous binary cell fate decisions are 
made where cells activate competing transcriptional networks and subsequently 
upregulate one network over others based on extrinsic cues. Cell fate decisions are 
regulated by an interplay of different factors such as epigenetics and chromatin context. 
Blood is one of the few adult somatic tissues that are capable of regeneration. Blood is 
replenished throughout life from a limited pool of progenitors called haematopoietic stem 
cells (HSCs). HSCs transition through a continuum of progenitor states ultimately 
resulting in differentiated blood lineages. Cell fate decisions that are taken at the HSC 
level and at every subsequent progenitor stage have to be tightly regulated to ensure 
adequate blood supply as well as to prevent uncontrolled proliferation. While blood 
development is the most well-studied adult stem cell system, a comprehensive 
understanding of how haematopoietic cell fate decisions are regulated is lacking.  
In this chapter, the cell fate decisions that occur during normal haematopoiesis and the 
current knowledge on associated regulatory factors are described followed by common 
mutations in acute myeloid leukaemia that disrupt this regulation. The use of zebrafish 
as a model to further understand these regulatory mechanisms is then discussed.   
 
1.1 Haematopoiesis 
Haematopoiesis is defined as the process of formation, development and differentiation 
of different blood components. The major sites of haematopoiesis in mammals include 
the bone marrow, liver, spleen, lymph nodes and thymus. Haematopoiesis begins during 
the early stages of embryonic development and continues into adulthood to maintain a 
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steady supply of blood cells throughout the lifespan of an individual. This is facilitated 
by a population of self-renewing multipotent cells called haematopoietic stem cells 
(HSCs). HSCs differentiate into different blood cell lineages that have specialised 
functions.  
Red blood cells or erythrocytes contain haemoglobin and function in transporting oxygen 
from the lungs to different sites of the body (Popel, 1989). These cells make up 40-45% 
of blood volume and have a life-span of approximately 120 days in humans.  
White blood cells or leukocytes which make up about ~1% of blood volume are involved 
in protection against infection and comprise both myeloid and lymphoid cell types. 
Among the myeloid leukocytes are neutrophils, basophils, eosinophils and monocytes. 
Neutrophils are short-lived immediate-responders to general infection whereas basophils 
and eosinophils are primarily associated with allergies and inflammation. Monocytes are 
circulating cells that differentiate to become tissue-resident macrophages and antigen-
presenting dendritic cells (Ginhoux & Jung, 2014; van Furth et al., 1972). Lymphoid 
leukocytes include B-lymphocytes, T-lymphocytes and natural killer cells. B-
lymphocytes produce antibodies and mediate humoral immune responses. T-
lymphocytes regulate other immune cells through direct cell-to-cell interactions or via 
the production of regulators such as cytokines. The T-lymphocytes and B-lymphocytes 
are central to adaptive immunity. Natural killer cells are innate cytotoxic cells that target 
virally infected and cancer cells through the presence of immunoglobulin or major 
histocompatibility complex class 1 receptors. Together with neutrophils and 
macrophages, they form the major part of the innate immune system (Lay & 
Nussenzweig, 1968; Trinchieri, 1989). 
Platelets or thrombocytes are membrane-bound cell fragments produced upon 
fragmentation of bone-marrow resident megakaryocytes during thrombopoiesis. Platelets 
are central to blood coagulation and wound healing (Schmid et al., 1962). 
 
1.1.1 Sites of haematopoiesis 
Mammalian haematopoiesis occurs in three waves. The first wave, known as ‘primitive’ 
haematopoiesis occurs in the extra-embryonic yolk sac where common endothelial-
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haematopoietic precursors are specified from the haemangioblast (Dzierzak et al., 1998; 
Ivanovs et al., 2017; Julien et al., 2016). This wave predominantly gives rise to 
erythroblasts. This is followed by a second wave of erythromyeloid progenitors and 
lymphoid progenitors (McGrath et al., 2015). Haematopoiesis then shifts to the embryo 
proper where, in a third wave known as ‘definitive’ haematopoiesis, HSCs are specified 
from the mesoderm in the aorta-gonad mesonephros (AGM) region (Medvinsky & 
Dzierzak, 1996). HSC production is also later seen in the fetal liver and bone marrow 
(Julien et al., 2016). 
 
1.1.2 Haematopoietic cell hierarchy 
The production of mature blood cells from HSCs is classically described as a multi-step 
process with cells becoming more lineage-specific at each step (Akashi et al., 2000; Chao 
et al., 2008; Morrison et al., 1995). Multipotent HSCs were thought to give rise to 
oligopotent intermediates like common myeloid progenitor (CMP) followed by bipotent 
intermediates like megakaryocyte-erythroid progenitors (MEP) (Orkin & Zon, 2008) 
(Figure 1.1). However, these models were based on the analysis of cell populations that 
were sorted using pre-defined markers. 
 Follow-up studies on such pre-sorted populations from the fetal liver and adult bone 
marrow identified a two-tier system in adult bone marrow with loss of oligopotent 
progenitors (Notta et al., 2016). Nevertheless, such studies do not necessarily capture 
transition states between populations. The advent of single cell-omics has challenged the 
concept of discrete hierarchical boundaries proposed by the classical model. These new 
studies show that haematopoiesis is characterised by a continuum of low-primed 
haematopoietic stem and progenitor cells (CLOUD-HSPCs) (Velten et al., 2017). The 
CLOUD-HSPCs are a heterogeneous population made of transitory populations like 
multipotent progenitors (MPPs) and multi-lymphoid progenitors (MLPs) supporting 





Figure 1.1. Classical haematopoietic hierarchy model. In this model, self-renewing 
LT-HSCs at the top of the hierarchy give rise to ST-HSCs which then differentiate into 
common progenitors for the myeloid (CMP) and lymphoid (CLP) lineages. Following this 
first step in lineage-restriction, CMPs give rise to MEPs that differentiate into 
erythrocytes and megakaryocytes and GMPs that differentiate into granulocytes, 
macrophages and mast cells. On the other hand, CLPs give rise to B- and T- 
lymphocytes. The transcription factors required at each stage are annotated in red. Dark 
red denotes factors that have thus far been found to be mutated in human or mouse 
haematological malignancies. LT-HSC, long-term haematopoietic stem cell; ST-HSC, 
short-term haematopoietic stem cell; CMP, common myeloid progenitor; CLP, common 
lymphoid progenitor; MEP, megakaryocyte/erythroid progenitor; GMP, 
granulocyte/macrophage progenitor; RBC, red blood cell. This figure was reproduced 
from (Orkin et al., 2008).  
 
Downstream of HSCs, four types of MPPs are present: MPP1, which are similar to short-
lived HSCs; MMP2, which predominantly differentiate into megakaryocytes and 
erythrocytes; MPP3 which give rise to granulocytes and monocytes; and MPP4, which 
form lymphocytes (Carrelha et al., 2018; Pietras et al., 2015). A revised hierarchy model 





Figure 1.2. Revised haematopoietic hierarchy model. In the revised model, HSCs 
first differentiate into multipotent self-renewing MPP1/ST-HSCs which later give rise to 
other multipotent MPPs which are preferentially biased towards the different blood cell 
lineages. HSC, haematopoietic stem cell; ST-HSC, short-term HSC; MPP, multipotent 
progenitor; LMPP, lymphoid-primed MPP; Pre MegR, megakaryocyte-erythrocyte 
progenitor; Pre GM, granulocyte-macrophage progenitor; CLP, common lymphoid 
progenitor; MkP, megakaryocyte progenitor; Pre CFU-E, erythrocyte progenitors; GMP, 
GM progenitor. This figure was adapted from (Cheng et al., 2019).  
 
1.1.3 Genetic regulation of haematopoiesis 
Transcription factors 
The regulation of processes such as HSC self-renewal and lineage commitment is carried 
out by transcription factors (Figure 1.1). Haematopoietic cell-fate specification from the 
mesoderm is mediated by the basic helix-loop-helix (bHLH) factors like SCL/TAL1 and 
LMO2 in both primitive and definitive haematopoiesis (S. I. Kim & Bresnick, 2007). 
Primitive haematopoiesis is predominantly regulated by two factors, GATA1 for 
erythroid and PU.1 for myeloid fates, respectively (Cantor & Orkin, 2002). Runt domain 
RUNX1 protein is crucial for HSC production in the AGM and its expression later in 
adults is required for proper functions of megakaryocytes and lymphocytes (Ichikawa et 
al., 2004; T. North et al., 1999; T. E. North et al., 2004). Transcription factors that are 
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important for HSC survival and self-renewal include ERG (Taoudi et al., 2011) and 
GATA2 (Ezoe et al., 2002).  
Maintenance of HSC self-renewal is also co-ordinated through signalling pathway 
factors such as Notch, Wnt and Hox. Notch signalling regulates RUNX1 expression and 
is important for both induction and maintenance of HSCs (Delaney et al., 2010; 
Guruharsha et al., 2012). Optimal levels of Wnt signals support HSC emergence and 
maintenance, while low levels induce differentiation (Luis et al., 2011; Trowbridge et 
al., 2006). Wnt proteins have been explored as potential growth factors for HSCs (Tajer 
et al., 2019; Willert et al., 2003). The Hox gene family encompasses conserved 
homeodomain-containing transcription factors and are organised into four clusters in 
mammals. While their major role is in embryo patterning, many Hox factors are 
expressed in haematopoietic cell lineages. HOXB3, HOXB4 and HOXA9 are expressed 
in haematopoietic progenitors whereas HOXA10 and HOXB8 are seen in myeloid-
committed cells (Alharbi et al., 2013). Transcription factors involved in lineage 
programming downstream of HSCs also exhibit cross-antagonism as described for 
GATA1 and PU.1 in specifying erythroid versus myeloid fates, respectively (Orkin et 
al., 2008). Neutrophil-specific GF1 antagonises monocyte-specific PU.1 (Dahl et al., 
2007); eosinophil-specific CEBPB antagonises the multipotent progenitor marker, FOG 
(Querfurth et al., 2000); and, erythrocyte-specific EKLF antagonises megakaryocyte-
specific FLI-1 (Starck et al., 2003).  
 
Epigenetic and chromatin modifiers 
Gene transcription can be modulated by changes in the chromatin, mediated by 
epigenetic factors and structural regulators. Eukaryotic DNA is compacted by folding 
around histone octamers called nucleosomes. The N-terminal histone tails protrude out 
from the nucleosome and are subject to modifications by epigenetic enzymes. These 
histone marks then regulate what regions stay open and accessible to transcription factors 
(Gates et al., 2017; Lawrence et al., 2016). Active transcription is associated with histone 
marks like trimethylation of histone H3 lysine 4 (H3K4me3) at active promoters, mono-
methylation of histone H3 lysine 4 (H3K4me1) at active enhancers and acetylation of 
histone H3 lysine 27 (H3K27ac) at both active promoters and enhancers. 
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Heterochromatic regions are zones of gene inactivation and are associated with 
trimethylation of histone H3 lysine 27 (H3K27me3) (Heintzman et al., 2007; Pokholok 
et al., 2005). CG dinucleotides called CpG sites are frequently found in proximity to 
transcription start sites (Deaton & Bird, 2011) and methylation at these sites is generally 
associated with gene silencing. 
Methylation marks are added by the DNA methyltransferase (DNMT) enzyme family 
and removed by the ten-eleven translocation (TET) enzyme family. DNMTs comprise 
two groups: de novo enzymes such as DNMT3A and DNMT3B that methylate 
unmodified DNA bases to establish new patterns of methylation, and maintenance 
enzymes such as DNMT1 that maintains methylation patterns during proliferation. 
DNMT3A and DNMT3B are important for silencing genes that encode factors 
responsible for self-renewal during HSC differentiation (Challen et al., 2011; Jeong et 
al., 2018; Trowbridge & Orkin, 2011). DNMT1 is required for HSC self-renewal and 
timely progression to myeloid progenitors (Bröske et al., 2009; Trowbridge et al., 2012). 
TET enzymes, namely TET1, TET2 and TET3 catalyse the oxidation of 5-
methylcytosine (5mC) to 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC) and 
5-carboxylcytosine (5caC). These oxidised products adapt passive mechanisms to 
prevent the methylation of newly synthesized DNA or auto-regulate their removal by 
recruiting the base excision repair pathway machinery. TET2 function is important to 
prevent aberrant increases in HSC lifespan and to demethylate the required 
differentiation factors (Buisman & de Haan, 2019).  
Higher-order chromatin structure is regulated by factors such as CCCTC-binding factor 
(CTCF) and cohesin. CTCF interacts with cohesin to form topologically associating 
domains (TADs) which spatially constrain interactions between promoters and 
regulatory elements (Pombo & Dillon, 2015). TADs span hundreds to thousands of bases 
and are formed by active loop extrusion (Sanborn et al., 2015). The process is mediated 
by loop extrusion factors (LEFs) such as structural maintenance protein complexes 
(SMC) including cohesin (Uhlmann, 2016). LEFs bind to and slide along chromatin 
fibres progressively extruding DNA loops until they are interrupted by other LEFs or 
particular orientations of CTCF sides. Genes present within the same TAD are co-
regulated and disruption of TAD boundaries leads to ectopic contacts with regulatory 
elements of neighbouring domains leading to misexpression of genes, including the 
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activation of oncogenes driving carcinogenesis (Kloetgen et al., 2019; Pope et al., 2014; 
Zhan et al., 2017). On a larger megabase scale, chromatin segregates into active ‘A’ 
compartments and inactive or repressive ‘B’ compartments that occupy distinct 
territories in the nucleus. ‘A’ compartments are located near the centre of the nucleus in 
proximity to transcription factors, RNA polymerase and other regulatory factors. ‘B’ 
compartments are present near the nucleolus and the nuclear lamina. Depletion of 
chromatin-associated cohesin reduced TADs and increases compartmentalisation 
(Nuebler et al., 2018). Binding of certain transcription factors such as the embryonic stem 
cell-associated Yamanaka factors, OCT4, SOX2, MYC and KLF4 can induce 
compartment switching (Stadhouders et al., 2018).  
Consistent with their crucial direct or indirect roles in haematopoiesis, mutations are 
frequently observed in transcription factors, epigenetic modifiers and structural 
chromatin regulators in haematological malignancies. 
 
1.2 Acute myeloid leukaemia 
Dysregulation of normal haematopoiesis leads to a diverse range of cancers collectively 
called haematological malignancies. Disorders arising from myeloid cells are referred to 
as myeloid neoplasms. These are heterogeneous disorders that include acute myeloid 
leukaemia (AML), myelodysplastic syndrome (MDS), myeloproliferative neoplasms 
(MPN) and MDS/MPN overlap syndromes. MPNs include chronic myeloid leukemia 
(CML), polycythaemia vera (PV), essential thrombocythaemia (ET), primary 
myelofibrosis (PMF), chronic neutrophilic leukaemia (CNL), and systemic mastocytosis 
(SM). MDS and MPN differ from AML in that they are characterized by dysplasia and 
increased production of blood cells, respectively. In addition, both MDS and MPN can 
progress to AML (Sperling et al., 2017). 
 
1.2.1 Clonal haematopoiesis and diagnosis of AML 
Most myeloid neoplasms arise from the gradual acquisition of somatic mutations in 
haematopoietic cells, the expansion of which can lead to a state of preleukaemia called 
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clonal haematopoiesis (CH). Preleukaemic clones are dynamic and can have hundreds of 
transient mutations (T. Kim et al., 2016). These mutations can persist through complete 
remission, and with accompanying secondary mutations, lead to relapse (Shlush et al., 
2014). With age, the haematopoietic cells of normal individuals become burdened with 
mutations typically seen in AML patients (Young et al., 2016; Zink et al., 2017). CH is 
seen in older healthy individuals at frequencies of 9.5% at ≥ 70 years and 18.4% at > 90 
years of age (Jaiswal et al., 2014).  
Besides aging, CH can also be induced by therapeutic stress elicited upon chemotherapy 
or radiation (Coombs et al., 2017; Gibson et al., 2017). CH is associated with normal 
bone marrow blast counts of < 5% and no signs of dysplasia and is categorised either as 
clonal haematopoiesis of indeterminate potential (CHIP) or clonal cytopenia of 
undetermined significance (CCUS) if presenting with additional cytopenia. Thresholds 
specified by World Health Organisation (WHO) for cytopenia in CCUS are haemoglobin 
<100 g/L, platelet count <100×109/L and absolute neutrophil count <1.5×109/L) (D. A. 
Arber et al., 2016; Bejar, 2017).  
The diversity of mutations and/or the variant allele frequency of the mutant clone 
influence the likelihood of CH progressing to MDS and/or AML (Steensma et al., 2015). 
VAF is defined as the proportion of sequences with variation at a locus divided by the 
total sequence coverage at that locus. The minimum diagnostic criteria for MDS is the 
presence of persistent cytopenia along with dysplasia (Daniel A. Arber et al., 2016; 
Valent et al., 2017). Blast counts of >20% are diagnosed as AML with exceptions being 
core-binding factor AML (CBF-AML), acute promyelocytic leukaemia (APL) and AML 
with NPM1 mutations, where diagnosis is made independent of the blast count. 
Mutations in CH and MDS overlap, making it difficult to distinguish the different 
subgroups. CHIP is associated with mutations in epigenetic modifiers such as TET2 and 
DNMT3A with a median VAF of 9%. In addition to mutations in TET2 and DNMT3A, 
CCUS is frequented by driver mutations such as in ASXL1, RUNX1 and TP53 with a 
higher median VAF of 38% (Bewersdorf et al., 2019; Bowman et al., 2018). Two studies 
reported hazard ratios (HR) of 11.1 and 12.9 (95% CI: 3.9–32.6 and 5.8–28.7, 
respectively) for CHIP-associated progression to haematological malignancies 
(Genovese et al., 2014; Jaiswal et al., 2014).  
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Following the acquisition of an initiating mutation, usually, a minimum of three mutation 
hits are needed for progression to leukaemia. Initiating mutations are largely represented 
by mutations in epigenetic modifier genes which are frequently seen in CH. Mutations in 
chromatin and RNA splicing-associated factors may occur later or concurrently with 
epigenetic gene mutations. Subsequently, additional mutations in transcription factors 
such as RUNX1 and NPM1 or TP53 are acquired. Mutations in genes encoding signalling 
proteins such as those involved in the receptor tyrosine kinase-RAS pathway occur as 
late events leading to AML transformation (Papaemmanuil et al., 2016). In a study of 
188 patients with CHIP-evolved AML, mutations in epigenetic genes and splicing factors 
were detectable up to 9.6 years before AML onset while mutations in FLT3 and NPM1 
were found to be late events (Desai et al., 2018). Thus, AML is characterised by 
combinatorial mutations that are acquired in a hierarchical manner (Figure 1.3). 
 
 
Figure 1.3. A model for the acquisition of mutations in acute myeloid leukaemia. 
Clonal haematopoiesis is characterised by the acquisition of mutations in epigenetic 
modifiers (TET2 or DNMT3A) conferring selective advantages such as enhanced self-
renewal in progenitors. Acquisition of additional mutations in transcription and chromatin 
regulatory factors (Cohesin or NPM1) leads to MDS. Mutations in signalling factors are 
acquired as late events and cause leukaemic transformation to AML. Clonal 
haematopoiesis can also directly lead to AML without accompanying bone marrow 
dysplasia. CH, clonal haematopoiesis; CCUS, clonal cytopenia of undetermined 




1.2.2 Genomic classification of AML  
Genetic mutations and chromosomal abnormalities identified within and across myeloid 
malignancies have led to well-defined genomic classifications. Mutational subsets 
overlap in primary AML and AML with myelodysplasia-related changes. Mutations in 
EZH2, ASXL1, STAG2 and SRSF2 are frequent in MDS and AML with myelodysplasia-
related changes (Lindsley et al., 2015), whereas mutations in FLT3, CEBPA, RUNX1, 
NPM1, IDH1/2 and PTPN11 commonly occur as driver mutations in de novo AML 
(Koeffler & Leong, 2017).  
A recent comprehensive analysis of the landscape of 5234 driver mutations in 1540 AML 
patients revealed that 40% of driver mutations constituted complex cytogenetic 
abnormalities and mutations in the single genes, FLT3, NPM1, TET2, DNMT3, NRAS, 
CEBPA. Co-mutational patterns gave rise to 11 classes with distinct diagnostic and 
prognostic features. In addition to previously defined groups, three new genomic classes 
were identified: 1) mutations in genes regulating RNA splicing segregated with 
chromatin regulators including genes encoding the cohesin complex and associated 
transcription modifiers such as RUNX1; 2) AML with TP53 mutations and/or 
chromosomal aneuploidies; and 3) a provisional IDH2R172 entity (Papaemmanuil et al., 
2016). The proposed genomic subgroups in AML are listed in Table 1.1 together with 
risk prognosis based on the European Leukaemia Net (ELN) 2019 guideline updates 
(Estey, 2018). 
 
1.2.3 Mutational landscape of AML 
Mutations in epigenetic and chromatin modifiers  
TET2: TET2 is mutated in ~10% de novo AML, ~30% MDS and ~50% chronic 
myelomonocytic leukaemia (CMML). 67% of the mutations are somatic deletions and 
loss of function mutations (Guillamot et al., 2016). TET2 mutations are among the first 
to be acquired in leukaemogenesis, as reflected by their high VAFs. In addition, they 
have also been identified in the leukocytes of healthy adults in a clonal state (Sperling et 
al., 2017).   
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Table 1.1. Genomic subgroups and associated prognosis in AML. 
Genomic subgroup (% frequency) Most Frequently Mutated Genes (% frequency) ELN prognosis 
AML with NPM1 mutation (27) NPM1 (100), DNMT3A (54), FLT3ITD (39), NRAS (19), TET2 (16), PTPN11 (15) Favourable* 
AML with mutated chromatin, RNA‐splicing 
genes, or both (18) 
RUNX1 (39), MLLPTD (25), SRSF2 (22), DNMT3A (20), ASXL1 (17), STAG2 
(16), NRAS (16), TET2 (15), FLT3ITD (15) 
Intermediate to 
adverse 
AML with TP53 mutations, chromosomal 
aneuploidy, or both (13) 
Complex karyotype (68), −5/5q (47), −7/7q (44), TP53 (44), −17/17p (31), 
−12/12p (17), +8/8q (16)  
Adverse 
AML with inv(16)(p13.1q22) or 
t(16;16)(p13.1;q22); CBFB–MYH11 (81) 
inv(16) (100), NRAS (53), +8/8q (16), +22 (16), KIT (15), FLT3TKD (15) Favourable 
AML with biallelic CEBPA mutations (4) CEBPAbiallelic (100), NRAS (30), WT1 (21), GATA2 (20) Favourable 
AML with t(15;17)(q22;q12); PML–RARA (4) t(15;17) (100), FLT3ITD (35), WT1 (17) Favourable*  
AML with t(8;21)(q22;q22); RUNX1–RUNX1T1 (4) t(8;21) (100), KIT (38), −Y (33), −9q (18) Favourable 
AML with MLL fusion genes; t(x;11)(x;q23) (3) t(x;11q23) (100), NRAS (23) Intermediate 
AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); 
GATA2, MECOM (EVI1) (1) 
inv(3) (100), −7 (85), KRAS (30), NRAS (30), PTPN11 (30), ETV6 (15), PHF6 
(15), SF3B1 (15) 
Adverse 
AML with IDH2R172 mutations and no other class-
defining lesions (1) 
IDH2R172 (100), DNMT3A (67), +8/8q (17) Adverse with 
DNMT3A 
AML with t(6;9)(p23;q34); DEK–NUP214 (1) t(6;9) (100), FLT3ITD (80), KRAS (20) Adverse 
AML with driver mutations but no detected class-
defining lesions (11) 
FLT3ITD (39), DNMT3A (16) Intermediate 
AML meeting criteria for ≥2 subgroups (4) Predominantly chromatin-spliceosome and TP53 Adverse 
AML with no detected driver mutations (4) NA Intermediate 
*Adverse with ≥ 0.5 FLT3ITD. Genes in bold are key contributing genes for each class. ELN, European Leukaemia Net. Based on data from (Estey, 
2018; Papaemmanuil et al., 2016)
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The catalytic domain of TET2 often contains missense mutations that affect the binding 
ability of TET2 to its cofactors Fe2+ and α-ketoglutarate (α-KG). TET2 function can also 
be compromised indirectly by mutations in IDH1/IDH2 genes. The presence of TET2 
mutations in cytogenetically-normal AML confers a poor prognosis (Patel  et al., 2012). 
Contradicting data exist for whether demethylating therapies may be useful in patients 
with TET2 mutations (Itzykson et al., 2011; Pollyea et al., 2011). This could be attributed 
to a diverse architecture of co-existing mutations. In mice with Tet2 knockdown, 
treatment with vitamin C, a co-factor of α-ketoglutarate-dependent enzymes, was also 
able to restore oxidation. Additionally, vitamin C-mediated Tet2 restoration rendered the 
cells sensitive to PARP inhibitors (PARPi) (Cimmino et al., 2017). The oxidised products 
5fC and 5caC actively recruit the base excision repair pathway for their removal, by 
upregulating the base excision repair (BER) pathway mediating genes Parp and Gadd45, 
upon vitamin C restoration. Depriving the cell of repair machinery through PARPi 
treatment leads to synthetic lethality.  
 
DNMT3A: Mutations in the DNA methyltransferase 3A gene (DNMT3A) occur in 30% 
of AML, 8% MDS and 7-15% MPN cases (Liubin Yang et al., 2015) and 60% of 
mutations alter the arginine residue on codon 882 (Russler-Germain et al., 2014). 
DNMT3A loss results in enhanced HSC self-renewal with an expansion of LT-HSCs and 
blocked differentiation (Challen et al., 2011). DNMT3A mutations are early events 
associated with shorter overall survival and high relapse rates (Y. Sun et al., 2016). When 
present together with other ELN-stratified favourable and intermediate group mutations, 
they confer an adverse risk prognosis (Shin et al., 2016).  
 
IDH1/2: Isocitrate dehydrogenase -1/2 (IDH1/2) encode enzymes that convert isocitrate 
to α-ketoglutarate, a co-factor for enzymes like TET2. IDH mutations comprise ~16% of 
AML and 3% MDS. These present as gain of function mutations with a novel ability to 
convert alpha-ketoglutarate to 2-hydroxyglutarate (2-HG). Accumulation of 2-HG 
inhibits TET enzymes and blocks myeloblast maturation. Mutational hotspots include the 
conserved domains: IDH1R132, IDH2R140 and IDH2R172. IDH mutations are more frequent 
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in older patients. In CN-AML, the presence of IDH1/2 mutations with a wildtype FLT3 
status has an adverse prognosis (Medinger & Passweg, 2017; Paschka et al., 2010). 
  
ASXL1: The ASXL1 (Additional sex comb-like 1) gene encodes a polycomb chromatin-
binding protein that regulates chromatin binding through its C-terminal plant 
homeodomain (PHD) finger. ASXL1 mutations are seen in 5-15% AML and 15-20% 
MDS, in the form of heterozygous missense, nonsense and frameshift mutations 
predominantly in exon 12 close to the PHD finger (Larsson et al., 2013). The presence 
of ASXL1 mutations is associated with a poor prognosis especially in AML with 
myelodysplasia-related changes and MDS (Daniel A. Arber et al., 2016; Patnaik et al., 
2014). ASXL1 silencing in CD34+ progenitor cells reduced granulomonocytic 
differentiation with a concurrent increase in myeloid progenitors (Davies et al., 2013).  
 
Mutations in transcription factors 
RUNX1: RUNX1 regulates haematopoiesis through the formation of a core-binding 
factor (CBF) complex with CBFβ. In AML, RUNX1 mutations occur in the form of 
chromosomal translocations that confer a favourable prognosis or somatic mutations 
associated with a poor prognosis. The most common translocation, t(8;21) or RUNX1-
RUNX1T1, occurs at a frequency of 5 – 10% in AML (Reikvam et al., 2011). Somatic 
point mutations are detected in 3% of paediatric and 15% of adult de novo AML patients 
(Raman Sood et al., 2017). Mutations are significantly associated with increasing age 
and higher platelet counts (Khan et al., 2017). RUNX1 mutations are frequently 
accompanied by mutations in ASXL1 and therapeutic sensitivity is compromised in the 
double mutants (Chou et al., 2010; Schnittger et al., 2013). Mutations co-occurring with 
RUNX1 include MLL duplications, FLT3ITD and mutations in NRAS. Notably, RUNX1 
mutations are rarely associated with favourable mutations such as biallelic CEBPA and 
mutations in NPM1 (Tang et al., 2009).  
While RUNX1 binds core enhancer elements and upregulates gene expression, the 
CBFA2T1 protein encoded by RUNX1T1, binds nuclear receptor co-repressors, such as 
histone deacetylase (HDAC), and downregulates gene expression. The t(8;21) 
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translocation juxtaposes the core-binding domain of RUNX1 with near-complete 
RUNX1T1 resulting in the down-regulation of different gene targets. Mutations in the 
RAS/RTK pathways, epigenetic regulators and loss of a sex chromosome are commonly 
seen with RUNX1-RUNX1T1 translocations at frequencies of 63%, 45% and 48% 
respectively. The presence of ASXL1 mutations in combination with RUNX1-RUNX1T1 
translocations does not have any prognostic significance (Christen et al., 2019). 
 
 NPM1: Nucleophosmin 1 (NPM1) is a phosphoprotein that shuttles between the nucleus 
and cytoplasm and regulates ribosome biogenesis, apoptosis and DNA repair. Mutations 
alter the nuclear import: export signal ratio of NPM1 and restrict the protein to the 
cytoplasm (NPM1c). NPM1 mutations occur in 25-35% of AML cases and co-occurring 
mutations influence the prognosis they confer (Marcucci et al., 2011). The favourable 
prognosis associated with NPM1 mutations arises from increased sensitivity to 
cytarabine-based therapy and higher complete remission rates (Liu et al., 2014). A third 
of NPM1-mutated AML cases also have FLT3ITD mutations which occur as late events in 
leukaemogenesis (Metzeler et al., 2016). FLT3ITD mutations portend a poor prognosis in 
adult AML and an intermediate prognosis in paediatric AML. NPM1 mutations have 
been reported to persist in ~15% of NPM1-mutated AML cases after a second cycle of 
intensive chemotherapy and are hence particularly useful for minimal residual disease 
monitoring (Ivey et al., 2016).  
 
Mutations in signalling genes 
FLT3: FLT3 (Fms-like tyrosine kinase 3) mutations are present as internal tandem 
duplications (ITD) in 28-34% and as tyrosine kinase domain (TKD) mutations in 28% of 
cytogenetically normal AML cases, respectively. The FLT3ITD mutation causes 
constitutive tyrosine kinase activation resulting in enhanced STAT5, RAS and MAPK 
signalling. When present at a higher allelic ratio (>0.5) FLT3ITD mutations confer adverse 
prognosis in AML. Tyrosine kinase inhibitors (TKI) provide only a transient reduction 
in blast cells as the acquisition of additional secondary mutations compromise TKI 
activity. A combination of multi-kinase inhibitors is the current mainstay of treatment in 
these cases (Medinger et al., 2017).  
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RAS oncogenes: The RAS family is composed of three GTPase proteins namely, 
NRAS, HRAS and KRAS that are involved in various signalling pathways regulating 
normal cell growth, differentiation and survival. NRAS mutations occur in 24% of MDS 
and 15 % of AML cases (Ahuja et al., 1990; Radich et al., 1990). KRAS mutations are 
relatively rare and occur in 5% of AML patients (Bowen et al., 2005). RAS mutations do 
not have independent prognostic significance (Bacher et al., 2006; Bowen et al., 2005).  
 
1.2.4 Clinical significance of mutational profiling  
Mutational profiling of patients is useful for the diagnosis of disease subtypes and 
subsequent monitoring. Besides conferring an advantage for leukaemic transformation, 
some mutations may preferentially associate with specific AML subtypes. Mutations in 
ASXL1 are commonly seen in AML with minimal differentiation while mutations in 
RUNX1 are more frequent in AML with maturation. NPM1 mutations in isolation lead to 
heterogeneous phenotypes but gain specificity when evaluated together with co-
occurring mutations. TET2 and DNMT3A mutations co-occur frequently in acute 
myelomonocytic leukaemia (Rose et al., 2017). In the presence of chromosomal 
anomalies, mutations in the cohesin complex genes almost always lead to AML with 
maturation. In contrast, cohesin mutations in the absence of co-occurring chromosomal 
abnormalities predominantly lead to AML without maturation (Welch et al., 2012). 
Preleukaemic clones have been reported to persist at complete remission, for up to 8 
years, unaccompanied by additional AML mutations (Shlush et al., 2014). Such clones 
are resistant to chemotherapy and lead to lower event-free survival in affected individuals 
(Klco et al., 2015). Upon detection of preleukaemic mutations in complete remission, 
monitoring for the acquisition of additional mutations is required to indicate relapse (Ivey 
et al., 2016). Targeting single-gene mutations such as FLT3, IDH and CKIT mutations 
for therapy has not been tremendously efficient (Kindler et al., 2004; Stein et al., 2015; 
Uy et al., 2015). This could be attributed to the genetic heterogeneity and the 
combinatorial nature of mutations seen in AML. Although mutational profiling is clearly 
useful, further clarification of directionality and cooperativity of clonal mutations using 




1.3 Zebrafish as a model organism 
The haematopoietic system is complex and is associated with maintaining homeostasis 
of different organs of the body. Studying the development of such a multisite system 
logically requires the use of in vivo models. Mice and zebrafish have been predominantly 
used to study various haematopoietic processes. Zebrafish (Danio rerio) are freshwater 
teleost fish discovered in the Ganges river of India. They were first used as a model 
organism by George Streisinger in the 1970’s (Walker & Streisinger, 1983). Zebrafish 
share orthologues for 70% of protein-coding genes and 83% of disease-associated genes 
in humans making them a reliable tool for understanding the genetic basis of human 
diseases (Howe et al., 2013).  
Zebrafish embryogenesis is charted into seven broad periods namely the zygote, 
cleavage, blastula, gastrula, segmentation, pharyngula, and hatching periods. Following 
fertilisation in the zygotic period from 0 to 0.75 hours post-fertilisation (hpf), the 
cytoplasm migrates to the animal pole to form the blastodisc which then divides into two 
cells. The cleavage period (0.75 to 2.25 hpf) is marked by six meroblastic divisions 
resulting in a total of 64 cells. Four crucial processes occur during the blastula period 
(2.25 to 5.25 hpf); the embryo undergoes three mid-blastula transition, the zygotic 
genome is activated, the yolk syncytial forms and epiboly initiates. Morphogenetic cell 
movements that occur during the gastrula period (5.25 to 10.33 hpf) lead to formation of 
the three primary germ layers namely the ectoderm, mesoderm and endoderm. The 
dorsoventral and anteroposterior axes are discernible during this period; formation of the 
neural plate marks the dorsal side posterior to which the tail bud emerges. 
The segmentation period (10.33 to 24 hpf) is marked by lengthening and straightening of 
the tail bud and the sequential appearance of somites along the trunk followed by 
specification of the sclerotome, myotome and dermatome. The neural plate thickens into 
the neural tube, neural crest cells develop from the neural plate border and migrate 
actively throughout the segmentation period. By 24 hpf (Figure 1.4A), the notochord is 
well-developed, somite formation is complete, the olfactory placode is discernible and 
the brain is sculpted into five lobes. During the pharyngula period (24 to 48 hpf), the 
embryonic axis is straightened and the pharyngeal arches form rapidly. The circulatory 
system forms; the heart begins to beat and blood circulates within closed vessels. The tail 




Figure 1.4. Drawings of zebrafish embryos with landmark structures at key 
embryonic developmental stages. Lateral views of embryos at A) 24 hpf, B), B’) 48 
hpf and C), C’) 5 dpf. Pigmentation patterns at 48 hpf and 5 dpf are shown in B’ and C’, 
respectively. This figure was adapted from (Haffter et al., 1996).  
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Zebrafish have three types of pigment cells namely, melanophores, xanthophores and 
iridophores. Although melanocyte formation begins by 24 hpf, the first melanophores are 
visible only at 28 hpf. Melanophores appear in the retina followed by seeding on the 
dorsal side from the head to the tip of the tail forming the ‘dorsal stripe’ and on the ventral 
side beginning just posterior to the eye forming the ‘ventral stripe’ (Figure 1.4B’). 
Melanophores are also seen on the yolk ball and extension. Yellow hue-imparting 
xanthophores in the head and reflective iridophores on the dorsal side appear next and 
progressively increase as the embryo develops. The development of most primary organs 
begins during the hatching period (48 to 72 hpf). Jaw development ensues, the pharyngeal 
arches are established and the mouth protrudes prominently beyond the eye. 
All major organs are formed by 5 days post-fertilisation (dpf); the gut and liver are fully 
developed and the swim bladder inflates (Figure 1.4C). Melanophores accumulate on the 
lateral midline of the embryo forming a continuous lateral stripe by 5 dpf (Figure 1.4C’). 
Zebrafish have a short generation time with fish reaching sexual maturity by three months 
post-fertilisation (Haffter et al., 1996). They have high fecundity with a single mating 
pair producing several hundred eggs from a single breeding event. This makes the 
zebrafish a useful model system for carrying out high-throughput forward and reverse 
genetic screens.  
Zebrafish can also serve as whole-animal platforms for evaluating the efficacy and off-
target toxicity of drugs (Cagan et al., 2019). As mammals, mice are valuable for their 
highly similar haematopoietic programme. However, mice are expensive and in utero 
development hinders the study of haematopoiesis during early embryogenesis. On the 
other hand, zebrafish husbandry is simple and cheap, and external fertilisation coupled 
with the transparency of embryos facilitates the study of early haematopoietic processes. 
For example, various complex HSC processes including specification from the ventral 
wall of the dorsal aorta (VDA) and their interaction with endothelial cells in the caudal 
haematopoietic tissue (CHT) were characterised using zebrafish embryos (Kissa & 
Herbomel, 2010; Tamplin et al., 2015). 
Early access to embryos has allowed researchers to microinject genetic constructs into 
zebrafish embryos at the single-cell stage to generate transgenic and gene-edited mutant 
lines. Efficient genomic integration of transgenes has been possible using the Tol2 
transposon (Urasaki et al., 2006) (Ni et al., 2016) and the I-SceI meganuclease systems 
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(Grabher et al., 2004). The availability of transgenic fluorescent reporter lines combined 
with transparent embryos allows for the follow-up of different haematopoietic cell fates. 
Lineage tracing using the Zebrabow and ScarTrace systems quantified the number of 
embryonic progenitors that give rise to the haematopoietic system (Alemany et al., 2018; 
Henninger et al., 2017).  
With the advent of the CRISPR -Cas9 system, genome editing in zebrafish has become 
faster and more accurate. The clustered regularly interspaced short palindromic repeats 
(CRISPR) is a bacterial defence system which uses CRISPR-associated proteins (Cas) to 
target and cleave phage DNA. In the type II CRISPR system in Streptococcus pyogenes, 
Cas9 protein is guided by two small RNAs, namely, a CRISPR RNA (crRNA) and a 
trans-acting RNA (tracrRNA), to GC-rich DNA targets and induces double-strand 
breaks. CRISPR-Cas9 mutagenesis was first tested in zebrafish by Hwang et al.; this was 
also the first study to demonstrate the in vivo efficiency of the CRISPR-Cas9 mutagenesis 
in vertebrates (Hwang et al., 2013). In zebrafish, double-strand breaks are dominantly 
repaired by non-homologous end-joining repair (NHEJ) which generates random 
insertion and deletion mutations. Subsequent efforts to improve NHEJ-mediated editing 
efficiency resulted in the development of a zebrafish codon-optimised Cas9 protein 
which allowed for the simultaneous generation of biallelic mutations in multiple genes 
(Jao et al., 2013). Further, spatiotemporal restriction of Cas9 expression under heat-shock 
and tissue-specific promoters was shown to be successful in generating stable tissue-
specific zebrafish mutants (Ablain et al., 2015; Yin et al., 2015).  
Recent advances in the field include the optimization of homology-directed repair (HDR) 
for precise genome editing and engineering of Cas proteins to expand the genomic 
coverage. HDR requires the delivery of a donor reference template, which has not been 
very successful in zebrafish. A recent study reported that inhibiting NHEJ-mediated 
repair can significantly enhance HDR efficiency (Aksoy et al., 2019). Other methods for 
precise genomic editing include the base editing technologies devised by David Liu’s 
group which have reasonable editing efficiencies in zebrafish (Komor et al., 2016) 
(Yihan Zhang et al., 2017). Prime editing is a newer tool developed by the Liu group, in 
which the guide RNA encodes the desired variation and is inserted at the site of cleavage 
following conversion to DNA by a reverse transcriptase fused to the Cas9 protein 
(Anzalone et al., 2019). As the major limitation for HDR in zebrafish is the delivery of 
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long reference templates, prime editing may be a suitable alternative. Cas variants such 
as Cas12a efficiently cleave AT-rich targets in zebrafish thereby increasing the number 
of genomic loci that can be targeted and enhancing the utility of zebrafish as a model 
organism (Miguel A. Moreno-Mateos et al., 2017). 
 
1.3.1 Haematopoiesis in zebrafish 
Although the sites of haematopoiesis in zebrafish are different from that in humans, the 
same blood cell types are generated and the associated genetic programmes are well-
conserved. Like in other vertebrates, haematopoiesis in zebrafish occurs in waves as 
primitive and definitive haematopoiesis (Figure 1.5) (Paik & Zon, 2010; Rasighaemi et 
al., 2015). The first haematopoietic cells are bipotential haemangioblasts that are 
specified from the ventral lateral mesoderm at ~10 hpf. They give rise to both 
haematopoietic and endothelial cells. This is followed by primitive haematopoiesis in the 
anterior lateral mesoderm (ALM) and posterior lateral mesoderm (PLM). At 12 hpf, 
haemangioblasts differentiate into pu.1+ (also known as spi1+ ) myeloid precursors in the 
ALM which migrate to the yolk sac and express mature myeloid cell markers such as 
macrophage-specific l-plastin and granulocyte-specific myeloperoxidase (mpo) 
(Herbomel et al., 2001; Lieschke et al., 2001). Concurrently, primitive erythropoiesis is 
characterised by the generation of gata1+ erythroid cells in the PLM which differentiate 
into mature erythrocytes expressing hbbe3 and enter circulation at 24 hpf (Brownlie et 
al., 2003).  
Production of erythroid and myeloid cells is also facilitated by a second and transient 
wave of erythromyeloid progenitors (EMP) in the rostral blood island (RBI). The final 
wave involves the production of definitive haematopoietic stem cells (HSC). At ~32 hpf, 
HSCs expressing runx1 and cmyb are specified from the VDA, the counterpart of AGM 
in mammals (Burns et al., 2002; Kalev-Zylinska et al., 2002). From ~48 hpf, HSCs 
migrate to colonise the CHT, the counterpart of the foetal liver in mammals. This is 
shortly followed by the migration of a small number of HSCs to the thymus by 54 hpf, 
to generate ikaros+ lymphoid progenitors (Willett et al., 2001). Lymphoid differentiation 
is complete by 7 dpf and is marked by the presence of interleukin-2-receptor (IL-2R) 




Figure 1.5. Haematopoietic development in zebrafish. Haematopoiesis in zebrafish 
occurs in two major waves, primitive and definitive. Primitive myelopoiesis commences 
in the cephalic mesoderm (orange) and primitive erythropoiesis in the intermediate cell 
mass (violet) by 24 hpf. A transient wave producing erythromyeloid progenitors occurs 
in the rostral blood island (grey). Definitive haematopoietic stem cell (HSC) production 
begins around 32 hpf in the ventral wall of the dorsal aorta (VDA) (blue). HSCs migrate 
to the caudal haematopoietic tissue (yellow) and thymus (pink), and subsequently, also 
seed the kidney marrow (green). The kidney and thymus produce all haematopoietic 
cells throughout adulthood. Transcription factors regulating the different processes are 
annotated in red. Hemangio, haemangioblast; EMP, erythromyeloid progenitor; MP, 
myeloid progenitor; EP, erythroid progenitor; Mono, monocyte; Ery, erythrocyte; Hetero, 
heterophil; HSC, haematopoietic stem cell; LP, lymphoid progenitor; CLP, common 
lymphoid progenitor; CMP, common myeloid progenitor; GMP, granulocyte-macrophage 
progenitor; TP, T cell progenitor; BP, B cell progenitor. This figure was reproduced from 
(Rasighaemi et al., 2015).  
 
Definitive myelopoiesis commences in the CHT at 3 dpf indicated by the presence of l-
plastin+ macrophages. Definitive erythropoiesis commences in the CHT by 3.5 dpf 
23 
 
indicated by the presence of gata1+ and hbbe3+ (globin) mature erythrocytes which 
gradually replace the primitive erythrocytes in circulation (Jin et al., 2009). Post-
amplification in the CHT, HSCs migrate to seed the pronephros or developing kidney 
marrow (Murayama et al., 2006). Some HSCs also migrate directly to the kidney 
immediately after specification from the VDA (Bertrand et al., 2008). HSC seeding 
continues till 8 dpf and the kidney marrow becomes the site of development for all 
haematopoietic lineages. The kidney and the thymus are the major organs involved in 
adult haematopoiesis in zebrafish (Paik et al., 2010). 
Defects in embryonic myelopoiesis are routinely evaluated with whole-mount in situ 
hybridisation (WISH) using riboprobes to detect the expression of selected 
haematopoietic genes.  
(i) runx1 expression at 12 somites. At this stage runx1 expression marks primitive 
myeloid precursors in the anterior lateral mesoderm and erythroid precursors in the 
bilateral stripes of the posterior lateral mesoderm. At 12 somites, runx1 is also expressed 
in the olfactory placode and in the Rohon-Beard neurons (RBN) which later give rise to 
the spinal cord.  
(ii) gata1a expression at 24 hpf. At this time point, gata1a expression marks primitive 
erythrocytes in the intermediate cell mass.  
(iii) pu.1 expression at 24 hpf. At this time point pu.1 expression marks primitive myeloid 
cells in the yolk and rostral blood island.  
(iv) runx1 expression at 36 hpf. At this time point, runx1 expression marks HSCs 
emerging from the ventral wall of the dorsal aorta. 
(v) cmyb expression at 36 hpf. At this time point, cmyb expression marks HSCs that have 
seeded the caudal haematopoietic tissue.   
 
1.3.2 Zebrafish models of leukaemia  
The first zebrafish models of leukaemia were generated by expressing the murine c-Myc 
oncogene under the zebrafish rag2 promoter. These fish developed T-cell acute 
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lymphoblastic leukaemia (T-ALL) tumours with a short latency of 52 days post-
fertilisation (Langenau et al., 2003). Due to the tumour being aggressive and the fish 
dying before attaining sexual maturity, this line was modified to include tamoxifen-
inducible (Gutierrez et al., 2011) or Cre-inducible promoters to prevent tumour 
extravasation (Langenau et al., 2005). A second T-ALL line was developed by 
expressing ICN1, a constitutive transcriptional activator of the Notch pathway, under the 
rag2 promoter (J. Chen et al., 2007). While this line showed a long latency of 11 months 
and lower incidence, the disease was accelerated in combination with bcl2 
overexpression and cmyc expression (Blackburn et al., 2012). Overall, the success with 
these lines is partially attributable to the rag2 promoter.    
  
Acute myeloid leukaemia models  
Myeloid leukaemia has been modelled in zebrafish by expressing fusions proteins 
commonly implicated in leukaemia. To date, only three zebrafish lines have been 
reported to show evidence of myeloid leukaemia in adult fish. Zhuravleva et al. 
developed an AML line expressing human MYST3/NCOA2 fusion protein under the 
control of the pu.1 promoter. An accumulation of immature myelomonocytes in the 
zebrafish kidney marrow was reported but with a low incidence of 1% which could not 
replicated, and a long latency period of 14-26 months (Zhuravleva et al., 2008). The first 
proper report of myeloid disease in a zebrafish model was from the Zon lab where heat-
shock induction of KRASG12D in zebrafish caused myeloid expansion in the kidney 
marrow (Le et al., 2007). MPN was reported at an incidence of 53% with a short latency 
of 66 days. Endothelial-specific expression of HRASV12G led to hyperproliferation of 
erythroid and myeloid progenitors in the CHT. Oncogene expression downregulated the 
Notch pathway leading to aberrant specification of EMPs instead of HSCs from the 
hemogenic endothelium (Alghisi et al., 2013).  
The pu.1 promoter was used to drive the human NUP8-HOXA9 (NHA9) fusion protein 
in another zebrafish line. Transgenic NHA9 fish developed MPN at an incidence of 23% 
with a long latency period of 19-23 months. MPN phenotypes were discernible in 
embryonic haematopoiesis with skewing towards myelopoiesis. This study identified 
dnmt1-mediated methylation as an oncogenic vulnerability that could be leveraged for 
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epigenetic therapy (Forrester et al., 2011). Overexpression of cAMP response element 
binding (CREB) protein under the spi1 promoter by Tregnago et al. led to defects in adult 
myelopoiesis which further progressed to monocytic leukaemia in 66% of the fish with 
a long latency of 9-14 months (Tregnago et al., 2016). Although an endogenous myeloid 
promoter, pu.1 may not be effective given the low penetrance and long latency periods 
reported in these studies. A reason for this could be because pu.1 expression is limited to 
a small population of cells. Expression begins at 16 hpf and is downregulated during 
terminal myeloid differentiation. In the adult kidney marrow only 1.8% of cells express 
pu.1 (Hsu et al., 2004).   
Defects in haematopoiesis caused by most leukaemic genes are discernible during early 
development. Given the accessibility and transparency of zebrafish embryos, 
characterising embryonic haematopoiesis in mutants can provide valuable insight into 
the nature of disease and its underlying mechanisms. In zebrafish, expression of the 
RUNX1-RUNX1T1 fusion protein downregulated erythroid-lineage specifiers, scl and 
gata-1, promoting granulopoiesis at the expense of erythropoiesis with an increase in 
expression of pu.1 (Yeh et al., 2008). In addition, definitive haematopoiesis was 
disrupted and defects in vascular patterning were reported in other studies. Consistent 
with studies in mice, runx1 knockdown did not significantly affect erythropoiesis but 
blocked HSC formation and differentiation to multiple lineages (Kalev-Zylinska et al., 
2002). Definitive haematopoiesis was also disrupted in zebrafish runx1w84x mutants with 
embryos exhibiting a bloodless phenotype. However, 20% of the embryos could develop 
into fertile adults with active multilineage haematopoiesis raising the possibility of an 
alternative salvage pathway in the absence of Runx1 (R. Sood et al., 2010). Morpholino 
and TALEN-mediated knockdown of idh1 in zebrafish led to primitive myeloid skewing 
and compromised differentiation with reduced definitive HSCs. Overexpression of 
human IDH1R132H mutant protein in zebrafish also recapitulated these myeloid expansion 
phenotypes (Shi et al., 2015). 
Morpholino-induced double knockdowns of zebrafish npm1a and npm1b lead to a loss 
of differentiated myeloid cells and a gain of primitive myeloid cells, with phenotypes 
being amplified in a mutant p53 background. As in humans, NPM1c localizes to the 
cytoplasm. Mutant embryos exhibited developmental abnormalities such as small head 
and eyes, and a shortened yolk extension (Bolli et al., 2010). Injection of NPM1c mRNA 
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into 1-cell zebrafish embryos resulted in impaired formation of the anteroposterior axis 
development. Wnt signalling was activated in NPM1c embryos resulting in the abnormal 
expansion of blast cells which could be rescued by dkk1b expression, an inhibitor of the 
canonical Wnt pathway. Consistently, blast cells of NPM1c AML patients also exhibit 
active Wnt signalling (Barbieri et al., 2016).  
Morpholino-mediated knockdown of flt3 in zebrafish led to a reduction of primitive 
macrophage markers. Definitive HSCs and T-lymphocyte markers were also reduced. 
Expression of human FLT3WT in zebrafish accentuated primitive myelopoiesis through 
conserved downstream signalling pathways while expression of human FLT3ITD 
recapitulated inherent flt3 knockdown phenotypes and could be rescued by TKI 
inhibition (He et al., 2014). Expression of human FLT3ITD transgene in spi1+ myeloid 
cells in zebrafish led to an expansion of myeloid blasts and precursors in the kidney 
marrow. Myeloid hyperplasia occurred at 6 months followed by the development of 
leukaemia by 9 months. Combined expression of human FLT3ITD and NPM1mut 
transgenes accelerated disease onset supporting a synergistic role for the two mutations 
(J. W. Lu et al., 2016). 
Most of the AML models described above were generated to carry germline mutations 
and failed to develop AML. Others that carried somatic mutations driven by the pu.1 
promoter developed AML however after long latency periods. AML modelling in 
zebrafish could largely benefit from the generation of somatic combinatorial mutants. 
Co-expression or sequential expression of common AML mutations under 
haematopoietic tissue-specific promoters could improve AML penetrance and shorten 
latency times. The use of a promoter that is expressed early in haematopoiesis and/or in 
most haematopoietic cell types such as draculin or runx1 could further improve disease 
penetrance.  
 
Myelodysplastic syndrome models 
The MDS phenotype conferred by TET2 mutations in humans has been closely 
recapitulated in tet2 mutant zebrafish. Ubiquitous tet2 loss in zebrafish results in clonal 
myelodysplasia progressing to MDS by 24 months. A gradual reduction of 5hmC in the 
aorta-gonad-mesonephros and caudal haematopoietic tissue was reported. Embryonic 
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haematopoiesis was found to be normal is these mutants.  (E. Gjini et al., 2015). In 
contrast, a study by Li et al. showed embryonic functions for Tet2 and Tet3 in regulating 
HSC–based definitive haematopoiesis. Mutations compromising the dioxygenase 
activities of the two genes disrupted Notch signalling leading to defective HSC 
specification in the dorsal aorta (C. Li et al., 2015). 
Zebrafish carrying the pu.1G242D variant allele showed an expansion of immature myeloid 
cells in the kidney marrow by 18 months. Lymphoid cells were reduced consistent with 
an MDS phenotype. Moreover, expansion of immature granulocytes was seen in the CHT 
during embryonic haematopoiesis by 3 dpf and mutant embryos were sensitive to anti-
proliferative cytarabine therapy (J. Sun et al., 2013). 
 
1.4 Mutations in cohesin complex genes 
Cohesin is a multiprotein ring complex made up of four major subunits, two structural 
maintenance subunits, SMC1A and SMC3, which form a closed ring together with 
RAD21 and STAG1 or STAG2 (Figure 1.5A). Cohesin proteins were first identified by 
genetic screens for mutants with precocious sister chromatid separation during cell 
division in yeast and Drosophila (Michaelis et al., 1997; Miyazaki & Orr-Weaver, 1992; 
Peters et al., 2008). While the core subunits are well-conserved across most organisms, 
Stag proteins have evolutionarily diverged with additional copies present in zebrafish 
owing to gene duplication (Table 1.2).  
Cohesin is important for proper sister chromatid segregation during mitosis and meiosis. 
During the G1 phase of cell division, cohesin is loaded onto the chromatin by NIPBL-
MAU2 and following DNA replication in the S phase, cohesion is established between 
the two newly formed sister chromatids (Uhlmann & Nasmyth, 1998). Cohesion is 
maintained until the beginning of prophase. Cohesin is first displaced from the 
chromosome arms by WAPL followed by removal of residual cohesin bound at the 
centromeric regions (Gandhi et al., 2006; Hauf et al., 2005).  
Besides proper sister chromatid cohesion and segregation during mitosis, cohesin is 
involved in DNA repair and mitotic bookmarking (J. Yan et al., 2013). Cohesin also 
plays crucial roles in regulating gene expression through three-dimensional genome 
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organisation. Cohesin interacts with CTCF to spatially restrict interactions between gene 
promoters and their regulators through the formation TADs and contact domains 
(Merkenschlager & Nora, 2016). While recurrent somatic mutations in all cohesin 
complex members are found in myeloid malignancies, mutations in STAG2 also occur at 
high frequencies in solid tumours such as Ewing sarcoma, glioblastoma, urothelial 
bladder cancer and melanoma (Kandoth et al., 2013; Romero-Perez et al., 2019).  
 
Table 1.2. Cohesin complex subunits and accessory factors. 
Generic Sc Dm Dr Xt Mm Hs Function 
Smc1 
Smc1β* 






















































































*subunits involved in meiosis. Sc, Saccharomyces cerevisiae; Dm, Drosophila 
melanogaster; Dr, Danio rerio; Xt, Xenopus tropicalis; Mm, Mus musculus; Hs, Homo 
sapiens. 
 
1.4.1 Germline mutations in human developmental syndromes 
Germline mutations in cohesin and cohesin-associated genes cause developmental 
disorders known as cohesinopathies, the best known of which is Cornelia de Lange 
Syndrome (CdLS). Given the essential role of cohesin, mutations lead to a reduced 
dosage or haploinsufficiency rather than a complete loss of function. Classical CdLS 
29 
 
cases exhibit characteristic facial features, reduced growth, limb defects and intellectual 
disability in addition to congenital heart defects and gastrointestinal disorders. About 
50% of cases are due to mutations in NIPBL and present either with classical CdLS 
symptoms or mild phenotypes (Krantz et al., 2004) (Tonkin et al., 2004). The remaining 
cases are due to mutations in SMC1A (3-5%), SMC3 (3%), RAD21 (1%) or HDAC8 (4%) 
(Piche et al., 2019). Whereas HDAC8 mutations lead to classical CdLS (M. A. Deardorff 
et al., 2012), RAD21 mutations cause milder intellectual disability (Matthew A. 
Deardorff et al., 2012) and, SMC1 and SMC3 mutations cause subtle abnormalities (M. 
A. Deardorff et al., 2012; Deardorff et al., 2007). Therefore, despite being part of the 
same functional complex, mutations in cohesin genes lead a wide spectrum of 
phenotypes. 
Data from CdLS patients (Castronovo et al., 2009) and mouse models of Nipbl loss 
(Kawauchi et al., 2009) showed changes in gene expression profiles but no significant 
increase in chromatid defects. Zebrafish can effectively model genetic haploinsufficiency 
through the use of morpholinos that allow for controlled reduction of gene dosage. 
Morpholino-induced nibpl reduction in zebrafish resulted in smaller body size, defects in 
pectoral fin (analogous to mammalian limb), heart and gut development (Muto et al., 
2011). In a study that characterised rad21-depleted embryos, cardiac defects were the 
main abnormality observed, consistent with the congenital heart defects seen in CdLS 
patients (Schuster et al., 2015). 
More recently, mutations in STAG1 and STAG2 have been identified in patients with 
CdLS-like symptoms. Once again no evidence of premature sister chromatid separation 
but a higher number of G2/M cells but a transcriptional signature associated with 
increased cell division and DNA replication was reported (Soardi et al., 2017). Whether 
such transcriptional dysregulation is a consequence or cause of observed cell cycle 
defects remains to be investigated. Overall, these data suggest that cohesin-mediated 
gene regulation is the underlying pathogenic mechanism in these syndromes and that 
subtle cohesin dysfunction is sufficient to disrupt a wide range of developmental 




1.4.2 Somatic mutations in myeloid malignancies 
Recurrent somatic heterozygous/ hemizygous mutations are present in genes encoding 
subunits of the cohesin complex in myeloid malignancies. Mutations in genes encoding 
different subunits are mutually exclusive owing to functional redundancy. Cohesin 
mutations are present in about 10-20% of AML, 50% of Down syndrome-associated 
acute megakaryoblastic leukaemia (DS-AMKL), 5-15% of MDS and 10% of MPN cases 
(Figure 1.5C-D) (Mullenders et al., 2015; Thota et al., 2014). Among the various MDS 
subtypes, refractory cytopenia with multilineage dysplasia and refractory anaemia with 
excessive blasts have a significantly higher proportion of cohesin mutations (Kon et al., 
2013). Also, STAG2 mutations are frequent in high-risk MDS (17%), and RAD21 and 
SMC3 mutations are relatively more prevalent in transformed AML (20%). Mutations 
are scattered across the length of genes encoding cohesin subunits and not concentrated 
at specific hotspots (Figure 1.5B) (Thol et al., 2014; Thota et al., 2014). Mutations in 
RAD21 and STAG2 predominantly occur as truncations or frameshift alterations; large 
deletions are rarely seen. In contrast, mutations in SMC1A and SMC3 are usually 
missense. 
 With respect to clonality, cohesin mutations are rarely seen in founding clones but rather 
as mutant sub-clones that expand to achieve clonal dominance at the time of 
transformation. Consistent with this, VAF of cohesin mutations is comparable to that of 
NPM1 mutations but is lower than that of other early events like TET2 mutations (Thota 
et al., 2014). While NPM1 mutations are the most common co-occurring mutations, other 
co-occurring mutations such as TET2, RUNX1, ASXL1, EZH2 and RAS have also been 
frequently identified in cohesin-mutant AML (Papaemmanuil et al., 2016). In DS-
AMKL, the most frequently co-occurring mutations are in EZH2, JAK2, JAK3, ASXL1 
and RAS (Cancer Genome Atlas Research, 2013). Despite the crucial role of cohesin in 
sister chromatid cohesion, cytogenetic abnormalities in cohesin mutants are not present 
at frequencies that are significantly greater than in leukaemia where cohesin mutations 





Figure 1.6. Distribution of cohesin mutations in myeloid malignancies. A) Structure 
of the cohesin ring complex. B) Distribution of mutations along the length of (i) SMC3, 
(ii) STAG2 and (iii) RAD21 genes. C) Frequency of mutations in cohesin and accessory 
factors across various myeloid malignancies. D) Overall frequency of mutations in the 
different cohesin genes. MDS, myelodysplastic syndrome; Low MDS, refractory 
anaemia with ringed sideroblasts, and refractory cytopenia with multilineage dysplasia; 
High MDS, refractory anaemia with excess blasts; sAML, secondary acute myeloid 
leukaemia; MPN, myeloproliferative neoplasm; pAML, primary AML. This figure was 
reproduced from (Thota et al., 2014).  
 
1.4.3 Pathogenicity of cohesin mutations in myeloid malignancies 
Given the lack of gross cytogenetic abnormalities, cohesin mutations have been proposed 
to contribute to leukaemogenesis through other mechanisms such as aberrant 
transcriptional regulation. Mullenders et al. observed that cohesin knockdown in c-kit+ 
mouse HSPCs led to an increase in self-renewal markers and a decrease in lineage-
commitment factors (Mullenders et al., 2015). This study was the first to show 
involvement of cohesin in stem cell homeostasis and myeloid development. A genome-
wide RNAi screen in human cord blood derived CD34+ cells selecting for shRNAs that 
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enhance the expansion of stem and progenitor cells identified RAD21, STAG2 and SMC3 
among its top hits. Knockdown of individual cohesin subunits led to HSPC expansion 
and increased replating capacity, especially pronounced with STAG2 knockdown 
(Galeev et al., 2016). Expression of common patient mutations of the cohesin complex, 
namely RAD21 E212*, RAD21 L255*, STAG2 R614*, STAG2 H738* and SMC3 R245*, 
in 293T cells was associated with a complete or partial loss of cohesin complex 
formation. These mutations upregulated stem cell signatures and reduced differentiation, 
presumably facilitated by changes in chromatin accessibility (Mazumdar et al., 2015). 
Complementary studies in mice with shRNA-mediated knockdown of cohesin led to 
HSPC expansion and changes in chromatin accessibility in genes involved in 
myelomonocytic maturation and differentiation (Mullenders et al., 2015). Similarly, Cre-
mediated Smc3 conditional knockout mice developed by Viny et al. had bone marrow 
aplasia, peripheral blood pancytopenia and premature sister chromatid separation. Smc3 
haploinsufficiency represented by a 50% loss in Smc3 mRNA expression led to HSPC 
expansion and reduced chromatin accessibility at lineage-specifying genes. Genes with 
complex local regulatory domains were unaffected, as disruption of these complex 
networks would require a huge amount of cohesin to be titrated to these loci. Aberrant 
self-renewal phenotypes were synergistically amplified in mice with an additional Flt3ITD 
mutation via a gain in Stat signalling (A. D. Viny et al., 2015). 
The mechanistic basis of altered haematopoietic homeostasis seen with cohesin depletion 
was explored in two studies. Fisher et al. showed that HSPC expansion resulted from 
dysregulated polycomb repressor complex 2 (PRC2) interactions. In Rad21 depleted 
murine HSPCs, self-renewal genes escaped PRC2-mediated repression (Fisher et al., 
2016). In a recent study, Sasca et al. observed increased cohesin binding at active 
regulatory elements pre-marked by the repressive factor Etv6 during erythroid 
differentiation. Cohesin depletion in murine HSPCs resulted in a failure to evict 
chromatin-bound Etv6 translating to impaired erythroid differentiation (Sasca et al., 
2019). The effects of cohesin loss on early embryonic haematopoiesis were elucidated 
by rad21 null zebrafish mutants. In mutant embryos, the progenitor marker runx1 was 
reduced selectively in haematopoietic PLM but maintained at normal levels in neuronal 
Rohon-Beard neuronal cells. Furthermore, no other haematopoiesis-associated PLM 
markers were disrupted (Horsfield et al., 2007). In summary, a complete loss of cohesin 
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is not permissible for survival and cells with reduced cohesin are quickly out-competed 
by wildtype cells. On the other hand, cohesin mutations that lead to haploinsufficiency 
confer a survival advantage in the form of enhanced self-renewal.  
 
1.4.4 Synthetic lethality between the STAG subunits 
Cohesin complexes containing STAG1 preferentially mediate telomere and chromosome 
arm cohesion, while complexes containing STAG2 mediate centromeric cohesion 
(Cuadrado et al., 2012; Daniloski & Smith, 2017). Aberrant telomeres resembling a 
fragile-site phenotype were seen in Stag1 null mice that undergo early embryonic 
lethality at 12-18 dpf. Mutant cells acquired chromosome bridges in anaphase similar to 
those observed upon treatment with DNA replication inhibitors and failed to divide 
resulting in cell death or binucleated cells (Remeseiro, Cuadrado, Carretero, et al., 2012). 
Daniloski et al. observed premature separation of chromatids at centromeres but 
persistent cohesion at telomeres and chromosome arms in cells with STAG2 loss. Cancer 
cells use two types of telomere recovery mechanisms: 85% of tumours upregulate the 
telomerase enzyme while 15% use the alternative lengthening of telomeres (ALT) 
mechanism. STAG2 mutant tumours had upregulated telomerase expression in addition 
to exhibiting certain ALT-specific properties, and hence treatment with telomerase 
inhibitors was not effective. Delayed cell senescence could allow for the acquisition of 
pathogenic driver mutations (Daniloski et al., 2017).  
In addition to chromosome cohesion, STAG1 and STAG2 also appear to play different 
roles in gene regulation. STAG1 preferentially binds gene promoters and gene bodies 
whereas STAG2 binds intergenic spaces. In the absence of STAG1, STAG2 undergoes a 
significant re-distribution in binding at more than 50% of its sites but remains restricted 
to intergenic domains (Remeseiro, Cuadrado, Gomez-Lopez, et al., 2012). STAG1 
preferentially interacts with CTCF in the organisation of TADs while STAG2 mediates 
short-range cell-specific interactions (Cuadrado et al., 2012; Kojic et al., 2018). In the 
absence of STAG1, STAG2 is able to mediate TAD formation but with significantly 
reduced loop strength. Consistent with its cell-autonomous role, STAG2 is also involved 
in mediating interactions with super-enhancers and in establishing polycomb domains 
(Cuadrado et al., 2019).  
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In murine HSPCs Stag2 loss disrupted lineage-specific intra-TADs leading to an 
expansion of progenitors and reduced differentiation. While the unaffected STAG1 
paralogue could rescue TADs, it could not restore tissue-specific interactions mediated 
by STAG2 such as with the myeloid transcription factor Pu.1. In vivo, Stag2 deficient 
mice developed an MDS-like phenotype while additional heterozygous loss of Stag1 
leading to thrombocytopenia and impaired survival (Aaron D. Viny et al., 2019). 
Depletion of STAG2 in slightly more committed human progenitor cells also upregulated 
stemness factors with concurrent loss of lineage status, accompanied by changes in 
chromatin accessibility at proximal super-enhancers (Antony et al., 2019). Exposure to 
differentiation stimulus transiently accelerated enhancer dysregulation at stem cell genes 
such as RUNX1 and ERG and could be rescued by inhibiting the enhancer-stabilisation 
protein bromodomain 4 (BRD4). 
 
 
Figure 1.7. Synthetic lethality between STAG1 and STAG2. In normal cells, as 
STAG1 and STAG2 have distinct and overlapping functions including in cell division, 
loss of one paralogue tolerable. In cancer cells with a STAG2 loss, additional loss of the 





STAG1 and STAG2 have their own distinct functions in chromosome cohesion and gene 
regulation. When one of the paralogues is lost or mutated, the other paralogue acquires 
additional functions required to maintain cell survival. Therefore, targeting both 
paralogues would cause lethality (Figure 1.6). STAG2 is frequently mutated in cancers, 
therefore, a common synthetic lethal target in the form of STAG1 can be used in STAG2-
mutant cancers. Lelij et al. demonstrated this STAG paralogue dependency in bladder 
cancer and Ewing sarcoma (van der Lelij et al., 2017). Benedetti et al. showed that 
STAG2 loss created a dependency on STAG1 in various cancer cell lines. 
Counterselection of simultaneous knockdown of STAG1 and STAG2 with gradual loss of 
cell viability and proliferation was seen (Benedetti et al., 2017). 
 
1.4.5 Clinical significance of cohesin mutations 
The prognostic value of cohesin mutations as independent markers in AML remains 
ambiguous. However, when present with other mutations they almost always trend 
towards poor survival. In MDS, where different co-mutational subsets are present, 
cohesin mutations especially mutations in STAG2 are associated with lower overall 
survival (Thota et al., 2014). In CBF-AML, cohesin mutations accompanied by 
mutations in the tyrosine kinase pathway genes had the worst prognosis among t(8;21) 
AML patients (Duployez et al., 2016).  
The chromatin-spliceosome subgroup in AML is associated with intermediate to adverse 
prognosis indicating the differential effects imparted by co-existing mutations. However, 
cohesin mutations always confer a favourable prognosis when they co-occur with NPM1 
mutations including in older AML patients (Thol et al., 2014; Tsai et al., 2017). It is 
evident that although cohesin is a crucial factor in the dysregulation of haematopoiesis, 
it is not sufficient to drive leukaemic transformation. Hence to make an accurate 
diagnosis or to predict prognosis, the mutation status of cohesin should be used in 
conjunction with the status of co-occurring mutations.  
Given that the presence of cohesin mutations in AML is a relatively new finding and the 
associated pathogenic consequences are not clearly known, no specific inhibitors for the 
cohesin complex members exist. Among drugs that are currently under investigation for 
cohesin mutant cancers are inhibitors of BRD4 proteins that disrupt enhancer looping (H. 
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S. Chen et al., 2017) and poly ADP-ribose polymerases (PARP) inhibitors that cause 
replication fork stalling. Cells with defective cohesin depend on base excision repair 
machinery proteins like PARP to ensure correct replication of the genome. The addition 
of PARP inhibitors to these cells causes double-stranded breaks and lead to cell death 
(O'Neil et al., 2013). Inhibitors targeting cohesin regulatory proteins such as Aurora B, 
Polo-like kinase 1, Cyclin-dependent kinase and Separase have been evaluated in a 
number of cancers. Furthermore, the synthetic lethality seen between the Stag subunits 
can be exploited by use of antisense oligonucleotides (ASOs) (Mintzas & Heuser, 2019). 
 
1.5 Hypothesis and aims of the study 
Somatic mutations in cohesin STAG2 are recurrently seen in myeloid malignancies and 
in several solid tumour types. Germline STAG1 and STAG2 mutations are implicated in 
CdLS-like human developmental syndromes. As mentioned above, transcriptional 
dysregulation rather than chromosomal instability appears to be the underlying 
mechanism in these diseases. However, the distinct functions of STAG1 and STAG2 in 
transcriptional regulation are not fully understood.  
In AML, cohesin mutations co-operate with mutations in other genes to cause leukaemic 
transformation. How these secondary mutations synergise with cohesin mutations to 
cause leukaemia is unexplored. 
I hypothesise that cohesin-STAG1 and cohesin-STAG2 play non-redundant roles in the 
transcriptional regulation of cell fate determination.  
I proposed to exploit the advantages offered by the zebrafish model to examine this 
hypothesis through the following aims. 
First, I aimed to understand the specific requirements of stag1/2 in global embryonic 
development. For this, I characterised the Stag homologues in wildtype zebrafish. I then 
generated germline zebrafish mutants using CRISPR-Cas9 and evaluated the 
consequences of Stag loss on morphological development. 
37 
 
Second, I aimed to investigate the consequences of Stag loss on embryonic 
haematopoiesis. For this, I carried out WISH analysis of haematopoietic lineage-specific 
markers. 
Third, I sought to evaluate the effects of common co-occurring mutations with cohesin 
mutations on haematopoiesis. For this, I created a novel germline zebrafish mutant for 
tet2 using CRISPR-Cas9. I then assessed the consequence of different mutation 
combinations by crossing with the stag1/2 mutants generated in Aim 1 and other existing 
rad21 and RUNX1-RUNX1T1 mutants. I also created tissue-restricted models of cohesin 




2 Materials and methods 
2.1 Reagents 
All reagents and equipment used are listed in Appendix 1. All chemicals used were of 
analytical grade. Reagents for PCR were prepared using UltrapureTM DNase/RNase-Free 
Distilled Water (Life Technologies). Reagents used in in situ protocols were prepared 
using DEPC-treated water (Biochemica, AppliChem, Germany). All other reagents were 
prepared using deionised Milli-QTM water (Millipore Corporation). 
 
2.2 General zebrafish procedures 
Wild type (WIK), mutant and transgenic zebrafish lines were maintained according to 
established protocols (Westerfield, 1995). Zebrafish were housed in the Otago Zebrafish 
Facility (Department of Pathology, University of Otago, Dunedin, New Zealand). 
Zebrafish procedures were carried out in accordance with the Otago Zebrafish Facility 
Standard Operating Procedures. Zebrafish research was approved under approval AUP-
19-17 and AUP-19-14 by the University of Otago Animal Ethics Committee. 
Development, breeding and import of transgenic fish were carried out under 
Environmental Risk Management Authority approval numbers GMC005627, 
GMD100922 and GMC001366, respectively.  
 
2.2.1 Breeding and collection of embryos 
Breeding of adult zebrafish was carried out as previously described (Westerfield, 1995). 
Pairs of adult fish were set up in breeding boxes on the afternoon before breeding with 
the male and female fish separated by an insert. In the morning of the following day, the 
insert was removed and the fish were allowed to breed. The fish were then returned to 
their tanks and eggs collected at the bottom of the breeding box were recovered using a 
mesh strainer. Embryos were transferred to 10 cm petri dishes containing 1xE3 at a 




2.2.2 Genomic DNA extraction from embryos and fin clips 
The protocol for extraction of genomic DNA from single embryos or fin clips was 
adapted from an existing protocol (Jing, 2012). Embryos or fin clips were transferred to 
0.2 mL PCR tubes containing 16 µL of water and 2 µL of 10x PCR buffer (200 mM Tris 
HCl - pH 8.4, 500 mM KCl) (Invitrogen, Life Technology, USA). 2 µL of 20 mg/mL 
Proteinase K (Roche Diagnostics, Germany) was added and the tubes were incubated in 
a thermocycler at 55 °C for 50 minutes followed by 98 °C for 10 minutes. Concentration 
and purity were determined using NanoDrop ND-1000 spectrophotometer (Nanodrop 
Technologies Inc., USA). A 260/280 absorbance ratio of 1.8 was considered optimal.  
  
2.2.3 RNA extraction and cDNA synthesis from embryos 
Wild type or mutant pools of 30 embryos at 48 hpf were collected for RNA extraction in 
biological replicates. Embryos were transferred to an Eppendorf tube and excess E3 was 
removed. 350 µL of lysis buffer RA1 (from Macherey-Nagel Nucleospin® RNA kit, 
USA) was added. Embryos were used immediately or snap frozen in liquid nitrogen and 
stored at -80 °C until extraction. RNA extraction was carried out as per the 
manufacturer’s recommendations. RNA was eluted in 30 µL of UltrapureTM water. 
Concentration and purity were determined using NanoDrop ND-1000 spectrophotometer 
(Nanodrop Technologies Inc., USA). A 260/280 absorbance ratio of 2.0 was considered 
optimal.   
1 µg of RNA was used as template for cDNA synthesis. Synthesis was carried out using 
qScriptTM cDNA SuperMix (Quanta BiosciencesTM, USA) as per the manufacturer’s 
recommendations. 
 
2.2.4 Imaging of embryos 
For all assays zebrafish embryos were imaged using a Leica M205FA epifluorescence 
with a DFC490 camera and Leica Applications Suite software (Leica Microsystems, 
Germany). Embryos were imaged embedded in 3% methyl cellulose for morphological 
analysis and in 80% glycerol after in situ hybridisation. 
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2.3 Whole-mount in situ hybridisation of zebrafish embryos 
Colourimetric whole-mount in situ hybridisation (WISH) was carried out using 
riboprobes to determine the spatiotemporal gene expression in zebrafish embryonic 
tissue. 
  
2.3.1 Riboprobe synthesis 
cDNA obtained from wild type embryos at 24 hpf was used for cloning to make plasmid 
templates for the synthesis of the following riboprobes: stag1a, stag1b, stag2a, stag2b, 
gata1a, col2a1 and sox2. For all other probes, plasmids with an inserted template were 
readily available for use. Location of the riboprobe templates for the stag genes are 
shown in Appendix figures 1-4. Sequences for all primers used are listed in Appendix 
table 2.  
cDNA templates were amplified using Platinum® Taq DNA polymerase (Invitrogen, 
Life Technologies, USA) as per the manufacturer’s instructions. Annealing temperatures 
used were 68 °C for gata1a and 60 °C for the rest. The resulting PCR products were 
purified using QIAquick® PCR purification kit (Qiagen, Netherlands) and ligated with 
linear pGEM®-T Easy vectors (Promega, USA). A molar ratio of 3:1 insert:vector was 
found to be optimal. 2 µL of ligated reactions were transformed into 100 µL of 
chemically competent E. coli cells made in-house using established protocols (Inoue et 
al., 1990; Sambrook & Russell, 2006). Plasmid DNA was recovered from overnight 
cultures using Nucleospin® plasmid DNA purification kit (Macherey-Nagel, USA). The 
presence of inserts was confirmed by amplifying a stretch of DNA spanning the insertion 
site using M13 primers. Sanger sequencing (Genetic Analysis Services, University of 
Otago) was used to determine the direction of insertion. 
For templates inserted in the forward direction, plasmid DNA was linearised with ApaI-
High Fidelity restriction enzyme (New England BioLabs Inc., UK) at 25 °C for 2 hours. 
For templates inserted in the reverse direction, plasmid DNA was linearised with SpeI-
High Fidelity restriction enzyme (New England BioLabs Inc., UK) at 37 °C for 2 hours. 
Linearised plasmid DNA was purified using phenol-chloroform extraction based on 
established protocols (Sambrook, 2001). Antisense dioxygenin (DIG)-labelled probes 
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were synthesised by in vitro transcription using either SP6 (forward) or T7 RNA 
polymerase (reverse) (Roche Diagnostics, Germany) with DIG-labelled NTPs (Roche 
Diagnostics, Germany) as per the manufacturer’s instructions. Riboprobes were purified 
using the Nucleospin® RNA kit (Macherey-Nagel, USA). Concentration and purity were 
determined using NanoDrop-1000. 
 
2.3.2 Hybridisation of embryos 
Wild type or mutant zebrafish embryos were collected at desired stages and fixed in 4% 
(wt/vol) paraformaldehyde (PFA) in 1x PBS at 4 °C overnight. Hybridisation was 
performed using 0.5 ng/µL of probe based on established protocols (C. Thisse & Thisse, 
2008). Post-hybridisation, anti-DIG-alkaline phosphatase antibody (Roche Diagnostics, 
Germany) was used for detection. Staining was visualised using nitro blue tetrazolium 
and 5-bromo-4-chloro-3-indolylphosphate (NBT/BCIP) (Roche Diagnostics, Germany).  
 
2.4 Real-time PCR (RT-PCR) 
Primers for RT-PCR were designed to span exon-intron boundaries of the desired targets. 
Primer locations for the four zebrafish stag paralogues are shown in Appendix figures 1-
4. Sequences for all RT-PCR primers used are listed in Appendix table 2. Optimal 
annealing temperatures and target specificity were evaluated for each primer set. RT-
PCR was performed using SYBR Premix Ex Taq II (Takara Bio Inc., Japan) on Roche 
LightCycler400 (Roche Life Science, USA). 1 µL of undiluted cDNA was mixed with 3 
µM each of forward and reverse primers and 10 µL of SYBR Premix and made up to a 
final reaction volume of 20 µL using UltapureTM water. Reactions were assembled in 
technical duplicates on a LightCycler® 480 Multiwell Plate 96 (Roche Diagnostics, 
Germany). The cycling parameters used were: denaturation for 1 cycle of 95 °C for 30 
seconds; PCR for 40 cycles of 95 °C for 5 seconds and 60 °C for 30 seconds with single 
acquisitions; melting for 1 cycle of 95°C for 5 seconds, 60 °C for 1 minute and 95 °C at 
a ramp rate of 0.11 °C/second with 5 acquisitions per °C and hold at 50 °C. 
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Crossing point (Cp) values were calculated by the 2nd derivative method using the 
LightCycler® 480 Software (Roche Diagnostics, Germany). Relative expression was 
normalised to the reference genes β-actin and ribosomal protein L13a (rpl13a). 
Normalisation was performed using Microsoft® Excel and plots were generated with 
GraphPad PRISM 7. Unpaired t-tests were used for estimating statistical significance. 
 
2.5 CRISPR-Cas9 mutagenesis 
CRISPR-Cas9 editing was carried out for five target genes: stag1a, stag1b, stag2a, 
stag2b and tet2. Single guide RNAs were identified through in silico analysis as 
described in Chapter sections 3.4.1 and 5.2.1. Sequences for all sgRNAs are listed in 
Appendix table 4. Editing was carried out using recombinant Cas9 protein obtained 
commercially (PNA Bio Inc., USA) or by using Cas9 mRNA synthesised in-house. 
 
2.5.1 Synthesis of sgRNAs 
Synthesis of sgRNAs was carried out by a cloning-free approach using commercial oligos 
(Varshney et al., 2016). A target-specific top strand oligo contained the following 
sequences (in the order, 5’ to 3’): a 17 nucleotide long T7 promoter, an 18-20 nucleotide 
long target sgRNA sequence (without the PAM) and a 20 nucleotide long overlapping 
sequence (in italics below). A generic bottom strand oligo contained an 80 nucleotide 
long sgRNA scaffold sequence including the complementary overlapping sequence.















The two strands were annealed and extended using Platinum® Taq DNA Polymerase 
High Fidelity (Invitrogen, Life Technologies, USA). 2 µL of 10 µM top strand oligo and 
2 µL of 10 µM bottom strand oligo were used as templates in a final reaction volume of 
50 µL. The cycling parameters used were: 98 °C for 2 minutes, 50 °C for 10 minutes, 72 
°C for 10 minutes and hold at 4 °C. Successful annealing was verified using agarose 
DNA gel electrophoresis. The annealed templates were then in vitro transcribed using 
HiScribe™ T7 Quick High Yield RNA Synthesis Kit (New England BioLabs Inc., UK) 
as per the manufacturer’s instructions. The synthesised sgRNAs were purified using 
RNA Clean & Concentrator kit (Zymo Research, USA). sgRNAs were eluted in 10 µL 
UltrapureTM water. Concentration and purity were determined using NanoDrop-1000. 
 
2.5.2 Synthesis of Cas9 mRNA 
Cas9 mRNA synthesis was carried out using a pME-Cas9-T2A-GFP plasmid purchased 
from Addgene (#63155). This plasmid contains a zebrafish-codon optimised Cas9 
mRNA sequence flanked by nuclear localisation signals. Plasmid DNA was linearised 
with Not1-High Fidelity restriction enzyme (New England BioLabs Inc., UK) at 37 °C 
for 2 hours. The linearised DNA was purified using phenol-chloroform extraction and in 
vitro transcribed using mMESSAGE mMACHINE™ T7 Transcription Kit (Ambion, 
Life Technologies, USA) as per the manufacturer’s instructions. Following this, a 
poly(A) tail was added to the synthesised mRNA using E. coli Poly(A) Polymerase (New 
England BioLabs Inc., UK) as per the manufacturer’s instructions to enhance stability. 
The Cas9 mRNA was then purified using the RNA Clean & Concentrator kit (Zymo 
Research, USA) and eluted in 10 µL UltrapureTM water. Concentration and purity were 
determined using NanoDrop-1000. 
 
2.5.3 Microinjection of CRISPR-Cas9 complexes 
For injections using Cas9 protein, stable ribonucleoprotein (RNP) complexes that are 
less-prone to degradation were generated based on established protocols (Burger et al., 
2016). RNPs were assembled by mixing sgRNA and Cas9 protein at concentrations of 
100 pg/embryo and 300 pg/embryo, respectively in 300 mM KCl. The final volume was 
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made up to 5 µL using UltrapureTM water. The RNPs were incubated at 37 °C for 5 
minutes and immediately injected into the cell of 1-cell stage zebrafish embryos. 
For injections using Cas9 mRNA, sgRNA was mixed with Cas9 mRNA at concentrations 
of 100 pg/embryo and 300 pg/embryo, respectively, in 300 mM KCl and immediately 
injected into the cell of 1-cell stage zebrafish embryos. Embryos injected with CRISPR-
Cas9 complexes were referred to as crispants. 
 
2.6 T7 Endonuclease I (T7E1) assay 
Genotyping using T7E1 assay was performed on genomic DNA obtained from individual 
zebrafish embryos at 24 - 48 hpf. Target regions were amplified using Platinum® Taq 
DNA Polymerase High Fidelity (Invitrogen, Life Technologies, USA) as per the 
manufacturer’s recommendations. 1 µL of undiluted genomic DNA was used in a final 
reaction volume of 20 µL. Primers were designed to span 50-100 bp on either side of the 
cut site and are listed under ‘genotyping primers’ in Appendix table 2. PCR products 
were verified using agarose DNA gel electrophoresis and purified using Agencourt® 
AMPure® PCR purification (Beckman Coulter, USA). Purified products were cleaved 
with T7E1, an enzyme that specifically recognizes and cleaves mismatched DNA 
(Guschin et al., 2010; Reyon et al., 2012). 100-200 ng of PCR product was denatured 
and reannealed in NEBuffer 2 (New England BioLabs Inc., UK) using the following 
programme: 95 °C for 5 minutes; ramp down to 85 °C at -2 °C/second; ramp down to 25 
°C at -0.1 °C/second and hold at 4 °C. Following this, 10 units of T7 Endonuclease I 
(New England BioLabs Inc., UK) was added and the mixture was incubated at 37 °C for 
15 minutes. The presence of mutations was observed as additional bands or a smear 
accompanied by a reduction in thickness of the primary band using agarose gel 
electrophoresis.   
 
2.7 High Resolution Melt Analysis (HRMA) 
Genotyping using HRMA was performed on genomic DNA obtained from individual 
zebrafish embryos at 24 – 48 hpf. Target regions were amplified using LightCycler® 480 
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High Resolution Melting Master (Roche Diagnostics, Germany) on a Roche 
LightCycler400 (Roche Life Science, USA). Primers used are listed under ‘genotyping 
primers’ in Appendix table 2. 1 µL of undiluted genomic DNA was mixed with 0.25 µM 
each of forward and reverse primers, 3 mM of MgCl2 and 5 µL of Master Mix and made 
up to a final reaction volume of 10 µL using UltrapureTM water. Cycling parameters used 
were: pre-incubation for 1 cycle 95 °C for 5 minutes; PCR for 40 cycles of 95 °C for 10 
seconds, 60 °C for 15 seconds and 72 °C for 20 seconds with single acquisitions; melting 
for 1 cycle of 95 °C for 1 minute, 40 °C for 1 minute, 65 °C for 1 second and ramp up to 
95 °C at a rate of 0.11 °C/second with 5 acquisitions per °C and hold at 37 °C.  
Analysis was carried out using the LightCycler® 480 Gene Scanning Software (Roche 
Diagnostics, Germany). The software identifies the presence of mutations by screening 
the generated melt curves for changes in shape. Raw melt curves are normalised to 
uniform pre-melt and post-melt signal values to account for differences in amplification 
level. Each normalised curve is then shifted to a temperature at which the dsDNA is 
entirely denatured. The final output is a difference plot where samples with similar melt 
curves cluster together and are plotted based on the degree of difference from a user-
specified reference curve. 
 
2.8 Deep sequencing 
As mutations in injected crispant embryos are mosaic in nature and cannot be detected 
using conventional Sanger sequencing, deep sequencing using the Ilumina MiSeq 
platform was performed. 
 
2.8.1 Library preparation 
Barcoded samples were generated using a two-step PCR approach. In the first PCR, 
target-specific primers containing universal adaptor extensions were used for 
amplification. Primers are listed in Appendix table 4. The universal adaptor sequences 




Forward: 5’-ACGACGCTCTTCCGATCT-primer sequence-3’ 
Reverse: 5’-CGTGTGCTCTTCCGATCT-primer sequence-3’ 
 
Target regions were amplified using Platinum® Taq DNA Polymerase High Fidelity 
(Invitrogen, Life Technologies, USA) as per the manufacturer’s recommendations. 0.2 
µL of undiluted genomic DNA was used in a final reaction volume of 20 µL. PCR 
products were verified using agarose DNA gel electrophoresis and purified using 
Agencourt® AMPure® PCR purification (Beckman Coulter, USA). Based on observed 
band intensities, 0.5-2 µL of the purified product was used as template in a second PCR 
using TruSeq® adaptors (Illumina, USA). The adaptor primers were kindly provided by 
Prof Ian Morison (Department of Pathology, University of Otago). These adaptors 
contain unique index sequences called barcodes and sequences complementary to the 
universal extensions introduced in the first round of PCR. Therefore, at the end of the 
second PCR all amplicons are indexed with a unique index assigned to each sample.  
Template DNA was mixed with 0.5 µM each of forward and reverse primers, 2 mM 
MgSO4, 0.2 mM dNTPs and 1.25 U of Platinum® Taq DNA Polymerase High Fidelity 
(Invitrogen, Life Technologies, USA). Cycling parameters used were: denaturation for 1 
cycle of 95 °C for 2 minutes; PCR for 10 cycles of 72 °C for 40 seconds and hold at 4 
°C. PCR products were verified using agarose DNA gel electrophoresis. 5 µL of each 
reaction was pooled to a single tube and purified using Agencourt® AMPure® PCR 
purification (Beckman Coulter, USA). DNA concentration of the purified library was 
estimated using Qubit® Fluorometer with the dsDNA High Sensitivity Assay kit 
(Molecular Probes, Life Technologies, USA). The average amplicon size was determined 
using the High Sensitivity DNA assay kit on the 2100 Bioanalyzer (Agilent, USA). 
Libraries were sequenced as 150 bp paired-end reads on IlluminaTM MiSeq by Dr Rob 




2.8.2 Analysis of reads 
Reads were processed using the open source, web-based platform, Galaxy. FastQC was 
used for quality control. MiSeq adaptor sequences were removed from the reads using 
Trim Galore. Reads were de-multiplexed using the Barcode Splitter tool with primer 
sequences serving as the split criteria. Reads were then mapped to the zebrafish reference 
genome GRCz10/danRer10 using Bowtie2. Mutational analysis was performed using the 
CrispRVariants R-package (Lindsay et al., 2016). Mutagenesis efficiencies were 
calculated and CrispRVariants plots were generated to visualise the spectrum of 
mutations generated.   
  
2.9 In situ hybridisation of adult zebrafish tissue sections 
Expression of stag2a in the zebrafish ovary was evaluated by colourimetric in situ 
hybridisation using the stag2a riboprobe. 
 
2.9.1 Histology 
Adult wild type zebrafish were euthanized in 0.02% Tricaine as per the Otago Zebrafish 
Facility Standard Operating Procedure and fixed in 4% PFA at 4 °C for a week. Fish 
were washed in 1xPBS to remove traces of fixative and decalcified in 0.5 M EDTA pH 
8.0 at room temperature for 10 days. Following washes in DEPC water to remove traces 
of EDTA, fish were dehydrated in ethanol series and infiltrated with xylene. Fish were 
then embedded in paraffin and cut into 5 µM transverse sections onto super-frost slides 
by the Otago Histology Services Unit (Department of Pathology, University of Otago).   
  
2.9.2 In situ hybridisation of tissue sections 
Slides were de-paraffinised and rehydrated in xylene-ethanol-1x PBS series. Tissue 
sections were then permeabilised by incubating in 0.2 M HCL for 10 minutes, 1 µg/mL 
Proteinase-K in 1x PBS for 10 minutes and 0.1 M Triethanolamine, pH 8.0/ 5 mM acetic 
anhydride for 20 minutes at room temperature to reduce background noise. Each of the 
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above steps were followed by 1xPBS-Tween washes. Sections were then pre-hybridised 
in hybridisation buffer at 68 °C for 1 hour in a hybridisation oven. Following this, the 
sections were incubated with 1.5 ng/µL of riboprobe overnight at 68 °C. Stringency 
washes were performed with a series of saline sodium citrate (SSC) buffers to remove 
unbound probe. Sections were then blocked using 2% Roche Blocking Buffer (Roche 
Diagnostics, Germany) for 1 hour at room temperature. Anti-DIG alkaline phosphatase 
antibody (Roche Diagnostics, Germany) was used for detection followed by visualisation 
with NBT/BCIP (Roche, Diagnostics, Germany). The staining solution was 
supplemented with 1 mM levamisole to block the activity of endogenous alkaline 
phosphatase. Slides were mounted and imaged using brightfield microscopy on a Nikon 
CS2 microscope (Nikon Corp, Japan). 
 
2.10 5hmC whole-mount immunofluorescence assay 
To determine the loss of Tet2 function in the zebrafish tet2nz203 mutant line generated, 
detection of 5hMC was carried out using whole-mount immunofluorescence assay based 
on established protocols (E. Gjini et al., 2015). Embryos were fixed in 4% PFA at 4 °C 
overnight, washed in 1x PBS-Tween followed by permeabilisation using 0.1% Triton in 
1x PBS for 30 minutes at room temperature. Embryos were then blocked in 2% foetal 
bovine serum (FBS) (Gibco, Life Technology, USA) in 1xPBS-Tween for 1 hour. 
Following this, embryos were incubated with 1:100 anti-5hMC primary antibody (Active 
Motif, USA) overnight at 4 °C. Embryos were washed with 1x PBS-Tween and incubated 
with 1:1000 Alexa Fluor 488 goat anti-rabbit secondary antibody for 1 hour at room 
temperature. Embryos were then washed in 1x PBS-Tween and mounted for imaging 
using Nikon C2 confocal microscope and NIS elements software (Nikon Corp, Tokyo, 
Japan NIS-Elements).     
 
2.11 Construction of tissue-specific vectors 
For tissue-specific mutagenesis, vectors were assembled to contain sgRNAs under the 
control of a ubiquitous promoter and Cas9 mRNA under desired tissue-specific 
promoters (Ablain et al., 2015). The tissue-specific Cas9 mRNA construct was 
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assembled using Gateway recombination and the CRISPR sgRNA was subsequently 
ligated through restriction digestion. 
 
2.11.1 Gateway recombination 
Tissue-specific CRISPR plasmids were constructed using the following components: 1) 
a 5’ entry vector containing a tissue-specific promoter (p5E-mfap4, Addgene plasmid 
#70052 or pENTR5'_ubi, Addgene plasmid #27320 or pCM293 drl plasmid, provided 
by Dr. Mosimann, IMLS Zurich), 2) a middle entry plasmid containing Cas9 mRNA 
tagged with EGFP (pME-Cas9-T2A-EGFP, Addgene plasmid #63155), 3) a 3’ entry 
vector containing a polyA sequence (p3E-polyA, Tol2-kit plasmid #302) (Kwan et al., 
2007) and 4) a destination vector containing the gRNA scaffold into which the target 
sgRNA is inserted (pDestTol2CG2-U6:gRNA, Addgene plasmid #63156). A schematic 
of the gateway reaction is shown in Figure 2.1. 
 
 
Figure 2.1. Schematic for multisite gateway reactions used to construct tissue-




Multisite gateway cloning was performed using Gateway® LR Clonase® Enzyme mix 
(Life Technologies, USA) as per the manufacturer’s recommendations using equimolar 
concentrations of the 5’entry, middle entry, 3’ entry and destination vectors. 4 µL of the 
gateway reaction was transformed into One Shot TOP10 chemically competent E. coli 
cells (Life Technologies, USA). Plasmid DNA was recovered from overnight cultures 
using Nucleospin® plasmid DNA purification kit (Macherey-Nagel, USA). 
Concentration and purity were determined using NanoDrop-1000. Successful 
recombination was verified by restriction digestion with EcoRI-High Fidelity enzyme 
(New England BioLabs Inc., UK) at 37 °C for 15 minutes.  
 
2.11.2 Ligation of sgRNA oligos 
A pair of oligos with overhangs for annealing were obtained for each sgRNA as shown 
below. 1 µL of each oligo was mixed with 8 µL of NEBuffer 2 (New England BioLabs 
Inc., UK) and annealed using the following cycling conditions: 95°C for 5 minutes and 
ramp down to 25 °C at -1 °C/minute.   
Forward: sgRNA sequence - GT 
Reverse: reverse complement of sgRNA sequence - GA 
 
The recombined plasmid vector described in Section 2.8.1 was linearised with BseRI 
restriction enzyme (New England BioLabs Inc., UK) at 37 °C for 1 hour. Linearised 
plasmid DNA was purified using phenol-chloroform extraction and ligated with the 
annealed oligos. Ligation was carried out using 0.5 µL of the oligo mix, 100 ng of 
linearised vector, 1x T4 DNA ligase buffer and 1U of T4 DNA ligase (Life Technologies) 
in a final reaction volume of 10 µL and  incubated overnight at 20 °C. 4 µL of the reaction 
was transformed into One Shot TOP10 chemically competent E. coli cells (Life 
Technologies, USA). Plasmid DNA was recovered from overnight cultures using 
Nucleospin® plasmid DNA purification kit (Macherey-Nagel, USA). Concentration and 
purity were determined using NanoDrop-1000. Successful ligation was verified by 
Sanger sequencing at the site of ligation. 
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2.11.3 Microinjection of tissue-specific CRISPR plasmids 
Tissue-specific plasmids were co-injected with Tol2 transposase mRNA to facilitate 
integration of the vector into the zebrafish genome. Tol2 mRNA was prepared from 
available pCS-TP plasmid (Kawakami, 2005). Plasmid DNA was linearised with NotI 
restriction enzyme (New England BioLabs Inc., UK) at 37 °C for 2 hours. The linearised 
DNA was purified using phenol-chloroform extraction and verified using agarose gel 
electrophoresis. In vitro transcription using mMESSAGE mMACHINE™ SP6 
Transcription Kit (Ambion, Life Technologies, USA) and lithium chloride precipitation 
were carried out as per the manufacturer’s instructions. Concentration and purity were 
determined using NanoDrop-1000.      
20 pg of tissue-specific plasmid was co-injected with 20 pg of Tol2 mRNA into the cell 
of 1-cell stage zebrafish embryos. Embryos were incubated at 28 °C and screened for 
fluorescence at different developmental stages using Leica M205FA epifluorescence 
(Leica Microsystems, Germany). 
 
2.12 Flow cytometry 
The protocol for isolation and dissociation of zebrafish whole kidney marrow (WKM) 
was adapted from existing protocols (LeBlanc et al., 2007). Adult zebrafish were 
euthanized by placing in ice-cold water as per the Otago Zebrafish Facility Standard 
Operating Procedure. Zebrafish were then transferred to a petri dish and a ventral midline 
incision was made from the gills to the anal fin. The abdominal walls were held open 
using forceps and the intestine, pancreas, spleen, swim bladder and reproductive tissue 
were removed. The WKM was found attached to the dorsal body wall as a black mass 
with a characteristic head-trunk-tail structure and finger-like projections. The projections 
were teased apart and the kidney was detached from the dorsal wall using forceps. 
The isolated WKM tissue was rinsed in PBS+ (ice-cold 0.9x PBS containing 5% FBS) 
and transferred to a plastic tube. The tissue was mechanically dissociated in 5 mL of fresh 
PBS+ using an 18.5 g syringe. The tube was filled with PBS+ and centrifuged at 1500 
rpm for 8 minutes. The supernatant was discarded and the cell pellet was re-suspended 
in 2 ml of PBS+. The solution was then passed through a 40 micron nylon mesh filter 
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into a clean tube and centrifuged at 1500 rpm for 8 minutes. The pellet was re-suspended 
in 1 mL of FBS+ and propidium iodide was added to a final concentration of 1 µg/mL. 
The mixture was incubated for 5 minutes at room temperature and subjected to flow 
cytometry using Beckman Coulter Gallios Flow Cytometer (Beckman Coulter, USA). 
Analysis was carried out using Kaluza Analysis Software (Beckman Coulter, USA) and 
plots were generated using GraphPad PRISM 7. Unpaired t-tests were used for estimating 
the statistical significance.  
 
2.13 Statistical methods 
GraphPad PRISM 7 was used for performing statistical analysis. Unpaired t-tests were 
used to estimate the statistical significance of RT-PCR and flow cytometry results. All 





3 Generation of stag1/2 zebrafish mutants using 
CRISPR-Cas9 
3.1 Background 
Somatic mutations in genes encoding the cohesin complex are recurrent in myeloid 
malignancies such as myelodysplastic syndrome (MDS) and acute myeloid leukaemia 
(AML) (Thol et al., 2014; Thota et al., 2014). Mutations in the subunits are mutually 
exclusive and dispersed along the length of the gene with no particular hotspots. While 
STAG2 and RAD21 mutations usually involve truncations or frameshift alterations, 
mutations in SMC1A and SMC3 are missense in nature (Thol et al., 2014; Thota et al., 
2014). Of all the cohesin genes, STAG2 is the most frequently mutated with mutation 
rates as high as 16% in AML (Papaemmanuil et al., 2016) and 17% in high-risk MDS 
(Haferlach et al., 2014; Thota et al., 2014). Mutations in STAG1 and STAG3 have been 
identified in only a small percentage of AML cases (Haferlach et al., 2014). 
In contrast, germline mutations in genes encoding the cohesin complex and its regulators 
lead to a group of developmental disorders called cohesinopathies. While dominant 
mutations in SMC1A, SMC3 and RAD21 lead to Cornelia de Lange syndrome (CdLS), 
mutations in STAG2 cause a spectrum of sex-specific phenotypes given its location on 
the X-chromosome. Severe neurodevelopmental and behavioural phenotypes have been 
reported in females with de novo STAG2 mutations (Mullegama et al., 2017) (Yuan et 
al., 2019) (Aoi et al., 2019). Males survive less pathogenic mutations and present with 
STAG2-related X-linked Intellectual Deficiency (Mullegama et al., 2019) (Soardi et al., 
2017). Patients carrying STAG1 variants show similar but milder CdLS-like phenotypes 
(Lehalle et al., 2017) (Yuan et al., 2019).  
Zebrafish have a total of four stag paralogues namely, stag1a, stag1b, stag2a and stag2b 
whose functions have not been previously characterised. In humans, cohesin-STAG1 and 
cohesin-STAG2 are reported to have unique functions in mitotic cell division, gene 
regulation and DNA repair (Cuadrado et al., 2019; Kojic et al., 2018; Mondal et al., 
2019; Remeseiro, Cuadrado, Carretero, et al., 2012; Remeseiro, Cuadrado, Gómez‐
López, et al., 2012). However, their distinct functions in transcriptional regulation are 
not completely understood. A third related STAG domain-containing protein called 
STAG3 is incorporated into the meiotic cohesin complex in vertebrates. In zebrafish, a 
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418 amino acid long Stag3 protein is annotated on the chromosome 14 with no previously 
known function.  
While the presence of four stag paralogues in zebrafish provides the opportunity to 
further dissect these tumour suppressor roles, it is crucial to first identify the true 
functional homologues. For this purpose, I sought to investigate the degree of 
evolutionary conservation and expression of the stag paralogues during zebrafish 
embryonic development. Paralogues that are highly conserved and/or robustly expressed 
were then targeted for mutagenesis using CRISPR-Cas9.  
CRISPR-Cas9 mutagenesis via the non-homologous end joining (NHEJ) repair pathway 
is now well-established in zebrafish. Various in silico tools are available for designing 
single guide RNAs (sgRNAs) with high on-target and low-to-no off-target efficiencies. 
Injection of the CRISPR components into 1-cell stage zebrafish embryos results in 
insertions or deletions with high but variable frequencies (Gagnon et al., 2014; Hwang 
et al., 2013). Injected embryos, referred to as “crispants” hereafter, acquire mutations in 
a mosaic fashion, including in cells of the germline. This allows for recovery of stable 
mutant zebrafish lines and due to preferential NHEJ repair, at least one predominantly 
recurring mutation should be generated at each target locus. Given that there are no 
hotspot regions for the STAG2 mutations in AML, most sgRNAs were designed to target 
early exons or the conserved STAG domain region. CRISPR mutagenesis of early exons 
can lead to truncated proteins and a degradation of mRNA by nonsense-mediated mRNA 
decay (NMRD). Mutagenesis of exons encoding functional domains can result in 
abnormal protein variants. It is expected that these mutants will be useful for 
characterising the roles of STAG1/2-mediated transcriptional regulation in zebrafish 
development in addition to elucidating pathogenic mechanisms in AML.  
 
3.2 Analysis of evolutionary conservation 
Zebrafish Stag1a and Stag1b proteins were found to share 87.8% similarity and Stag2a 
and Stag2b proteins, 78.6% similarity (accession identifiers are listed in Appendix table 
1). Differences in amino acids were localised to the N’ and C’ termini. All four zebrafish 
Stag proteins possess a conserved STAG domain (see Appendix Figures 1-4 for location). 
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Evolutionary analyses of protein sequences of the four paralogues was carried out using 
the PhyML algorithm (Guindon & Gascuel, 2003). Overall, Stag1 and Stag2 segregated 
into two distinct groups. Zebrafish Stag proteins were evolutionarily more divergent from 
their counterparts in other species. Between the two zebrafish Stag2 paralogues, Stag2b 
had a smaller number of substitutions and was more conserved compared to Stag2a. Both 
the zebrafish Stag1 paralogues showed nearly similar levels of conservation with the 
Stag1a being slightly less divergent than Stag1b (Figure 3.1). 
 
 
Figure 3.1. Evolutionary analysis of zebrafish Stag paralogues. Phylogenetic 
analysis was carried out using the PhyML algorithm using the maximum likelihood 
approach. All Stag1 and Stag2 homologues cluster into separate groups. The zebrafish 
Stag paralogues are evolutionarily more diverged from their counterparts. Bootstrap 
values shown at nodes indicate the probability or likelihood of seeing the same tree 
patterns. The scale denotes the number of substitutions per amino acid position. 
Species abbreviations: Hs, Homo sapiens; Mm, Mus musculus; Gg, Gallus gallus; Xt, 
Xenopus tropicalis; Dr, Danio rerio. See appendix table 1 for accession identifiers of the 
protein sequences used for this analysis.  
 
Syntenic analysis was performed using Genomicus PhyloView (Louis et al., 2013) using 
each zebrafish stag paralogue as a reference target. The corresponding paralogues of the 





Figure 3.2. Evolutionary conservation of zebrafish stag genes based on syntenic 
analyses. Analysis was carried out using Genomicus with each zebrafish stag 
paralogue used as input. Inputs are shown in the header rows of each alignment. 
Species chosen for analysis are shown on the right. The zebrafish species is listed twice 
in each alignment as the second row denotes the zebrafish stag paralogue that is 
syntenic with the input shown in the header. Taking stag1a (on chromosome 2) as an 
example, alignment with zebrafish stag1b on chromosome 24 is shown. Each gene in 
the input is represented by a uniquely coloured polygon. Homologues of a gene are 
represented with polygons of the same colour. Orthologues and paralogues are 
differentiated from each other by polygons with black outlines or white outlines 
respectively. Non-homologous genes are shaded out and not coloured. Gene 
57 
 
annotations have been indicated for genes that are conserved: orthologues are 
annotated in black, zebrafish paralogues in pink and non-zebrafish paralogues in purple. 
The presence of a double-headed blue arrow under some alignments indicates that 
these genes have been reversed relative to the canonical orientations.  
 
Zebrafish stag1a and stag1b are present on chromosomes 2 and 24 respectively and were 
found to share a highly conserved syntenic block of six genes but in opposite orientations. 
This indicated that a large segmental inverted duplication event gave rise to two stag1 
paralogues in zebrafish. Of the two paralogues, zebrafish stag1a had a higher 
conservation with STAG1 of other species compared to stag1b. On the contrary, zebrafish 
stag2a and stag2b, which are present on chromosomes 5 and 14 respectively, shared an 
equal level of conservation with their STAG2 counterparts (Figure 3.2).  
In summary, based on the combined results of the phylogenetic and syntenic analyses, 
stag1a and stag2b were found to be the more evolutionarily conserved of the zebrafish 
homologues. 
 
3.3 Expression of stag genes during zebrafish embryogenesis 
3.3.1 Quantification of stag paralogue mRNA by real-time PCR (RT-PCR) 
To determine the expression of the stag genes during zebrafish embryogenesis, RT-PCR 
was performed using primers unique to each paralogue (Appendix table 2). Locations of 
primers on the respective stag paralogues are depicted in Appendix figures 1-4. 
Expression was measured at intervals from 0.2 to 48 hours post-fertilisation (hpf) using 
mRNA extracted from pools of 30 embryos per time point. Early zebrafish development 
relies solely on maternal mRNA until about 3 hpf when the major wave of zygotic 
genome activation (ZGA) begins.  
All paralogues were found to be both maternally deposited and zygotically expressed 
(Figure 3.3). Across all developmental stages analysed, stag2b was found to be the most 
expressed paralogue, followed by stag1b. Expression of stag1a was at very low but at 





Figure 3.3. All four zebrafish stag paralogues are maternally inherited and 
zygotically expressed. Expression trends of stag paralogues during embryonic 
development is shown here.  
 
 
Figure 3.4. Expression of stag paralogues during early zebrafish development.  
Paralogue mRNA expression was determined at the indicated developmental time 
points. All paralogues are both maternally inherited and zygotically expressed. A) Low 
levels of expression are seen for stag1a mRNA throughout development. B) Compared 
to stag1a, stag1b mRNA shows robust expression. C) High maternal deposition followed 
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by significantly reduced zygotic expression is seen for stag2a mRNA. D) Robust 
expression relative to all other paralogues is seen throughout development for stag2b 
mRNA. At least three biological replicates comprising of pools of 30 embryos each were 
used per developmental time point. Expression levels were normalised to two reference 
genes namely, b-actin and rpl13a. Error bars are ± S.D.  
 
A unique expression profile was observed for stag2a with high maternal expression but 
very low zygotic expression. During the zygotic phase, stag2a is the least expressed of 
the four paralogues (Figure 3.4). Overall, stag1b and stag2b were found to be robustly 
expressed during both maternal and zygotic phases of development. Although relatively 
low, stag1a and stag2a mRNA were present at detectable levels, therefore they may have 
independent and non-redundant functions in embryonic development. 
 
3.3.2 Tissue distribution of stag paralogues during embryogenesis 
Whole-mount in situ hybridisation (WISH) was used to evaluate tissue-specific 
expression patterns of the stag paralogues. Paralogue-specific riboprobes were 
synthesised as follows. First, templates for the riboprobes were amplified from cDNA 
obtained from zebrafish embryos at 24 hpf (Figure 3.5A). Primers used for amplification 
are listed in Appendix table 2 and their locations in the respective paralogues are shown 
in Appendix figures 1-4. Amplicon sizes were 835 bp for stag1a, 993 bp for stag1b, 912 
bp for stag2a and 1096 bp for stag2b. The band intensities for the stag1a and stag2a 
amplicons were reduced but detectable, consistent with their lower expression relative to 
stag1b and stag2b. The resulting amplicons were ligated with commercial pGEM-T Easy 
plasmids (Figure 3.5B). For stag1a, stag2a and stag2b, plasmids were linearised with 
Spe1 (Figure 3.5C) and DIG-labelled riboprobes were generated by transcription using 
T7 RNA polymerase (Figure 3.5D). For stag1b, the template was linearized with ApaI 
and DIG-labelled riboprobe was generated by transcription using SP6 RNA polymerase.  
Hybridization of zebrafish embryos at 12 somites stage (12 ss) revealed a ubiquitous 
pattern of expression with no differences between the paralogues (Figure 3.6A-D). 





Figure 3.5. Synthesis of stag riboprobes. A) A 1% (wt/vol) DNA agarose gel showing 
amplified riboprobe templates for stag1a, stag1b, stag2a and stag2b in lanes 3-6, 
respectively, and the corresponding no template controls in lanes 7-10. B) Templates 
were ligated into the pGEM-T Easy vector backbone at the indicated restriction sites. C) 
A representative 0.8% (wt/vol) DNA agarose gel showing linearisation of ligated 
plasmids; lanes 2, 4 and 6 correspond to undigested plasmids versus lanes 3, 5 and 7 
to digested plasmids for stag1a, stag2a and stag2b, respectively. D) A representative 
1% (wt/vol) agarose gel showing synthesised riboprobes. Lanes 3 and 5 correspond to 
riboprobes for stag1a and stag1b, respectively. 1kb Plus ladder (L) was used; marker 
sizes in bp are indicated on the left side for all gels.  
 
Relatively strong expression was seen for stag1b and stag1a throughout the dorsal 
muscle and spinal cord tissue (Figures 3.6E-F) while stag2b and stag2a showed robust 
expression only in the posterior tail somites (Figure 3.6G-H). For all paralogues, higher 
expression was seen in the head than in other regions. This could simply reflect a higher 
cell density in the region or could indicate more complex and specialised functions in 
these cells (Monnich et al., 2009). Consistent with the RT-PCR data, expression of 
stag1a and stag2a was reduced compared to stag1b and stag2b. No major differences in 






Figure 3.6. The stag paralogues show ubiquitous expression in zebrafish 
embryogenesis. Lateral views of representative zebrafish embryos hybridised with 
probes for A) stag1a, B) stag1b, C) stag2a and D) stag2b, showing ubiquitous 
expression at 12 ss. Lateral views of representative zebrafish embryos hybridised with 
probes for E) stag1a, F) stag1b, G) stag2a and H) stag2b, showing ubiquitous 
expression at 24 hpf. Anterior is to the left. Numbers on the lower right hand corner 
indicate the number of embryos that had an expression pattern similar to the 
representative image. Scale bars are 10 µm for A-D and 50 µm for E-H.  
 
In summary, all four zebrafish stag paralogues may have functional roles in zebrafish 
embryonic development. Although stag1a is evolutionarily well-conserved based on 
shared synteny with human STAG1, it is expressed at very low levels compared to all 
other paralogues. On the other hand, while stag1b is expressed at high levels throughout 
development it is more evolutionarily diverged than stag1a. Among the stag2a and 
stag2b paralogues, stag2b may be the true homologue of human STAG2 based on both 
evolutionary and expression analysis. However, the surprisingly high levels of stag2a 
maternal mRNA may reflect overlapping or additional unique functions for stag2a. For 
example, Stag2a may be important for germ cell development but dispensable during 
later development. Furthermore, all paralogues were expressed during the critical 
embryonic haematopoiesis window from 12 hpf to 48 hpf. Therefore, all four stag 
paralogues were targeted for mutagenesis using CRISPR-Cas9. 
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3.4 CRISPR-Cas9 mutagenesis of stag paralogues 
In the following subsections, I describe the preliminary CRISPR-Cas9 workflow that was 
performed for all stag paralogues. This begins with the identification of efficient sgRNAs 
based on in silico analysis followed by synthesis and testing the in vivo editing efficiency 
by injecting zebrafish embryos. The subsequent recovery of germline mutants is 
described in individual sections dedicated to each paralogue thereafter. 
 
3.4.1 Design of single-guide RNAs (sgRNAs) 
The zebrafish GRCz10/danRer10 reference assembly was used for designing sgRNAs. 
Using the Pfam database (Finn et al., 2016) the functional STAG domain was found to 
be located on exons 6 and 7 in all stag paralogues. Dominant isoforms were used where 
multiple transcripts were present. Based on their location in early exons or STAG-domain 
encoding exons, a list of potential sgRNAs was identified for each paralogue using the 
CHOPCHOP database (Montague et al., 2014).  
For the stag2a paralogue, exon 19 was also targeted as it harboured conserved stretches 
of coding sequence for a frequent human AML mutation R614*. The sgRNA OC13 binds 
at the STAG domain on exon 6 of all four stag paralogues. OC13 was predicted to bind 
stag2a and stag2b as on-targets, and stag1a and stag1b as off-targets with a single 
mismatch each located away from the PAM (protospacer adjacent motif) site. The 
selected sgRNAs were ranked based on predicted CHOPCHOP mutagenesis efficiencies 
and further screened using two other in silico tools namely, CRISPRscan (M. A. Moreno-
Mateos et al., 2015) and Zebrafish Genomics (ZG) hub track on UCSC (Varshney et al., 
2015). Higher CRISPRscan scores indicated sgRNAs with high on-target editing 
efficiencies and minimal to no off-target activity. However, CRISPRscan cannot score 
sgRNAs that do not have two G nucleotides at the 5’ end. The 5’GG is required for 
transcription using the T7 RNA polymerase during sgRNA synthesis. This can, however, 
be added upstream of or in place of the first two nucleotides of the sgRNA with/without 
negative consequences (Varshney et al., 2015). The ZG hub also omitted sgRNAs 
without the 5’ GG and scores were assigned based on the number of predicted off-targets 




Figure 3.7. Summary of CRISPR-Cas9 editing strategies used. Exon diagrams of the 
four stag paralogues with locations of the sgRNAs indicated by triangles are shown here. 
Red triangles, sgRNAs that were selected for the generation of stable mutant lines; 
yellow triangles, sgRNAs that had low editing efficiencies; triangles with black outlines, 
sgRNAs injected in singleplex; triangles with purple outlines, sgRNAs injected in 
multiplex. Scale bars are 100 bases.  
 
As discrepancies in scoring were observed between the three tools, sgRNAs that scored 
well in at least two out of the three were preferred. All sgRNAs that were evaluated for 
in vivo editing efficiency are shown in Figure 3.7. Those that showed successful in vivo 
editing (discussed below) are listed in Table 3.1 along with their in silico prediction 
scores. Location of these sgRNAs at single-base resolution is depicted in Appendix 
figures 1-4. No off-targets were predicted for these sgRNAs (Table 1.1) by CRISPRScan. 
All off-target binding predicted by CHOPCHOP required the presence of a minimum of 
three mismatches often close to the PAM site and with the absence of inherent 5’GGs. 
All other sgRNAs are listed in Appendix table 3. Sequences for all sgRNAs are listed in 




Table 3.1. List of sgRNAs that showed successful in vivo editing. 






OC17 stag1a 3 49.5 55 636 
OC18 stag1b 3 54.11 Not found* Not found* 
OC14 stag2a 6 67.09 72 Not found 
OC16 stag2a 28 67.49 58 255 
OC22 stag2b.1 3 45.19 35 71 
*This sgRNA lacks 5’GG.  
 
The presence of polymorphisms at the 3’ end of sgRNA targets near the PAM site can 
adversely affect cutting efficiencies. As zebrafish lab strains are prone to acquiring 
polymorphisms over time with breeding, target regions of the selected sgRNAs were 
analysed by sequencing. Genomic DNA was extracted from individual wild type 
embryos, target regions were amplified and sequenced. No polymorphisms were 
observed close to the PAM site for any of the selected sgRNAs. However, 
polymorphisms were found in the region around the binding site for some sgRNAs. 
Although this may be disadvantageous for mutation screening that relies on detecting 
mismatched DNA, it can be resolved with sequencing. 
 
3.4.2 Synthesis of sgRNAs and Cas9 mRNA 
Synthesis of sgRNAs was carried out by a cloning-free oligo-based protocol as detailed 
in Chapter 2 (Varshney et al., 2016). Target-specific top strand oligos were annealed with 
universal bottom strand oligo (Figure 3.8A) and the resulting templates were transcribed 
using T7 polymerase to generate functional sgRNAs (Figure 3.8B). The synthesised 
sgRNAs were injected with either Cas9 protein (IDT) or Cas9 mRNA synthesised from 
the plasmid pME-Cas9-T2A-GFP obtained from Addgene. The plasmid was linearised 
with NotI restriction enzyme (Figure 3.8C) and transcribed using T7 polymerase (Figure 





Figure 3.8. Agarose gel electrophoreses of sgRNA and Cas9 mRNA synthesis. A) 
Assembly of sgRNA templates on a 2% (wt/vol) DNA agarose gel. Full-length templates 
containing both top and bottom strand shown in lanes 3-5 are larger than a top strand 
only control shown in lane 2. B) Successful in vitro transcription of sgRNAs on a 2% 
(wt/vol) DNA agarose gel. Lanes 3-5 show sgRNAs with the presence of two bands 
representing secondary structures seen with RNA. C) Restriction digestion of the pME-
Cas9-T2A-GFP plasmid using NotI on a 0.8% (wt/vol) DNA agarose gel. Undigested 
plasmid is shown lane 2 versus digested plasmid in lane 3. D) Successful in vitro 
transcription of Cas9 mRNA on a 1% (wt/vol) DNA agarose gel (lane 3). 1 kb Plus ladder 
(L) was used; marker sizes in bp are indicated on the left side for all gels.  
 
3.4.3 Microinjections and screening 
One-cell stage zebrafish embryos were injected with 100 pg of individual sgRNAs mixed 
with 100 pg Cas9 protein and in vivo editing was determined using either T7 
endonuclease 1 (T7E1) assay or high resolution melt analysis (HRMA) as detailed in 
Chapter 2. Singleplex injections with the sgRNAs OC6, OC7, OC8 and OC10 failed to 
generate mutations at the respective target loci. To recover mutations in any of the four 
paralogues and to save time, multiplex editing using combinations of sgRNAs was 
carried out in two sets (triangles with purple outlines in Figure 3.7). Set 1 comprised of 
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four sgRNAs: OC17, OC18, OC15 and OC13, targeting stag1a, stag1b, stag2a and all 
the four paralogues, respectively. Set 2 comprised of four sgRNAs OC14, OC15, OC16 
targeting stag2a and OC13. For each set, 50 pg per sgRNA was assembled with 300 pg 
of Cas9 protein to generate RNP complexes. For stag2a, no successful editing was 
observed with Cas9 protein with either singleplex or multiplex injections. To evaluate 
editing at later stages, singleplex injections were instead performed with 300 pg Cas9 
mRNA and 100 pg of either sgRNA OC14 or OC16.  
 
3.4.4 Evaluation of mutagenesis efficiencies using deep sequencing 
Mutations in crispants are mosaic in nature and appear as jumbled sequence with 
conventional Sanger sequencing. Therefore to determine the nature of mutations 
generated, deep sequencing using the Ilumina MiSeq platform was performed. Samples 
were prepared as described in Chapter 2. The MiSeq library comprised amplicons 
generated from four to six individual crispants for selected sgRNAs and three uninjected 
controls at 24-48 hpf. The average size of the sequencing library was estimated to be 361 
bp using Bioanalyser 2100 (Appendix figure 5). Deep sequencing yielded an average of 
2546 reads/sample. Reads were processed and aligned to the zebrafish reference genome 
GRCz10/danRer10 as described in Chapter 2. The analysis plots generated are shown in 
the paralogue-specific sections below.  
 
3.4.5 Multiplex editing with sgRNA OC13 
As detailed above, the OC13 sgRNA was used to target all four stag paralogues 
simultaneously (Figure 3.7). RNPs were injected at maximum concentrations of 286.7 
pg sgRNA and 640 pg Cas9 protein. Primer pairs specific to each stag paralogue were 
used for amplification of the OC13 target loci (see Appendix table 2 for primers). Mutant 
bands were observed in crispants at the stag1a and stag2a targets by T7E1 analysis 
(Figure 3.9B-C lanes 2 and 4 in both gels). However, no mutations were detected by 
conventional Sanger sequencing or deep sequencing using MiSeq. CrispRVariants plots 
for the crispants were similar to that of uninjected controls with only background 
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polymorphisms present (Appendix figure 6). Hence, the OC13 sgRNA was not evaluated 
any further.  
 
 
Figure 3.9. Analysis of multiplex editing using T7E1 assays. A) Representative 
T7E1 analysis of target regions in an uninjected control embryo at 48 hpf. Lanes 2-5 
correspond to OC13 target amplicons for stag1a, stag1b, stag2a and stag2b; lanes 6-
10 correspond to OC14, OC15, OC16, OC17 and OC18 target amplicons, respectively. 
B) Representative T7E1 analysis of a crispant injected with multiplex set-1 at 48 hpf. 
Lanes 2-5 correspond to OC13 target amplicons for stag1a, stag1b, stag2a and stag2b; 
lanes 6-8 correspond to OC17, OC18 and OC15 target amplicons, respectively. C) 
Representative T7E1 analysis of a crispant injected with multiplex set-2 at 48 hpf. Lanes 
2-5 correspond to OC13 target amplicons for stag1a, stag1b, stag2a and stag2b; lanes 
6-8 correspond to OC14, OC15 and OC16 target amplicons, respectively.  
 
3.5 The stag1anz204 germline zebrafish mutant line has a 38 bp 
insertion in exon 3 of stag1a 
Two sgRNAs, OC17 and OC19 targeting exon 3 and exon 1 respectively of stag1a, were 
used for editing. The OC17 sgRNA was injected in combination with other sgRNAs in 
multiplex set-1 as described above. Mutagenesis was assessed at the target loci of all the 
multiplexed sgRNAs by T7E1 analysis. The presence of mutant amplicons was 
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visualised as a smear (Figure 3.9B lane 6) in crispants and was not seen in uninjected 
control embryos (Figure 3.9A lane 9). An in vivo mutagenesis efficiency of 50% (n=2/4 
crispants) was determined for OC17 which was comparable to the predicted in silico 
efficiency. The secondary bands seen in the control samples (Figure 3.9A lanes 3, 7 and 
10) could be due to the presence of background polymorphisms in these amplicons.  
Mosaic editing was confirmed by Sanger sequencing and the remaining embryos in the 
pool were raised to constitute the F0 founder generation. The OC19 sgRNA which was 
injected in singleplex yielded a mutagenesis efficiency of 12% (Appendix table 3), as 
determined by HRMA. But no mosaic editing was observed upon sequencing. Hence this 
line was not evaluated any further. OC17-injected founder adults were outcrossed and 
the resulting embryos were screened using HRMA. Two out of nine founder fish screened 
exhibited high mutation efficiencies. The corresponding embryo pools were raised to 
constitute the F1 generation. Once adults, the F1 fish were genotyped by fin clipping. The 
different heterozygous mutations that were recovered are listed in Table 3.2.  
 
Table 3.2. List of heterozygous F1 mutations recovered for stag1a. 





Wild type 15 
Total screened 22 
Mutations, D-deletions, I-insertions are annotated based on distance from the cut site.  
 
Given that no predominant mutations were observed, the -8:38I mutation, a 38 bp 
insertion located 8 nucleotides upstream of the cut site was selected based on early 
premature truncation predicted for this mutation. The mutant allele was termed nz204. 
Mutant F1 fish were in-crossed and the F2 generation was genotyped using HRMA. 




Figure 3.10. Genotyping of the stag1a -8:38I mutation by HRMA. Representative 
melt profiles of the three genotypes are shown here.  
 
 
Figure 3.11. The stag1a nz204 mutation causes a frameshift in exon 3 resulting in 
a prematurely truncated protein variant. A) Chromatograms of representative wild 
type homozygous, heterozygous and mutant homozygous samples. Nucleotide 
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sequences are aligned to the target region in stag1a exon 3 on the reference genome. 
The 20 bp OC17 sgRNA with the PAM site is annotated in blue. B) Full-length wild type 
zebrafish Stag1a protein with a functional STAG domain. C) Truncated Stag1a protein 
variant generated by the nz204 mutation. Aberrant amino acids represented in red.  
 
Mutant homozygous amplicons had a lower melting temperature. Heterozygous and wild 
type homozygous amplicons had similar melting temperatures but could be identified by 
differences in the shape of the melt curve. Sanger sequencing was used to validate 
genotyping (Figure 3.11A). The nz204 mutation was predicted to lead to a frameshift 
resulting in a short stretch of 4 aberrant amino acids followed by a premature stop codon 
(Figure 3.11B-C). The mutant protein is predicted to be 67 amino acids long and does 
not contain a functional STAG domain. Distribution of genotypes in the F2 generation 
(n=34 fish) was found to be in the ratio: 32% wild type homozygotes, 47% heterozygotes 
and 21% mutant homozygotes. 
 
3.6 The stag1bnz205 germline zebrafish mutant line has a 13 bp 
deletion in exon 3 of stag1b 
For stag1b, two sgRNAs OC18 and OC21 targeting exon 3 and exon 28 respectively 
were used for editing. The OC18 sgRNA was injected in combination with other sgRNAs 
in multiplex set-1 as described above. Mutagenesis was assessed at the target loci of all 
the multiplexed sgRNAs by T7E1 analysis. Crispants (Figure 3.9B lane 7) had band 
patterns that were different from uninjected controls (Figure 3.9A lane 10). The in vivo 
editing efficiency using the T7E1 assay was found to be 50% (n=2/4 crispants) and was 
comparable to the predicted in silico efficiency. Further, mosaic editing was confirmed 
by Sanger sequencing.  
To evaluate the nature of mutations generated at the OC18 locus, deep sequencing using 
MiSeq was performed on four injected crispants and three uninjected controls. Output 
reads were analysed using CrispRVariants package. Analysis of the target region around 
the cut site revealed no mutations other than background SNPs in the uninjected controls 
(Figure 3.12A). The most frequently identified mutations in crispants were small 
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deletions, 5-14 bp in length. However, these variants were detected at low frequencies 




























































Figure 3.12. CrispRVariants plots of the stag1b OC18 target loci.  Analysis of deep 
sequencing is shown for A) three individual uninjected control embryos, C1-C3; and B) 
four individual injected crispants, CR1-CR4 is shown here. The reference strand is 
shown in the header row. The 20 bp sgRNA and 3 bp PAM are demarcated by boxes. 
The cut site is located 3 bp upstream of the PAM site and is denoted by a vertical line 
running through the plot. Pairwise alignments are shown for each variant in the left panel 





















































single nucleotide variant, D for deletion and I for insertion. Deletions are indicated by 
dashes and insertions by symbols above the respective alignments. The inserted 
sequences are shown in the legend at the bottom of the plot. The panel on the right 
shows the frequency of variants with the header row indicating the total number of reads 
per sample. Frequencies are colour coded based and the corresponding legend is 
shown on the far right.  
 
A second stag1b sgRNA, OC21, was injected in singleplex. However, mutations were 
repeatedly detected as faint bands with T7E1 assay. Therefore, only the OC18 crispants 
were evaluated further. As the sgRNAs OC17 and OC18 were multiplexed, the same F0 
founders were used to propagate mutations. Genotyping F1 adults revealed a single 
mutation, a 13 bp deletion located 9 nucleotides upstream of the cut site (-9:13D). Of 
note, this mutation was not detected in the F0 crispants by deep sequencing (Figure 
3.12B). Mutation rates in the F1 generation were low, with only 8/102 fish positive for 
the mutation.  
 
 
Figure 3.13. The stag1b nz205 mutation causes a frameshift in exon 3 resulting in 
a prematurely truncated protein variant.  A) HRMA genotyping of F2 embryos is 
visualised as a difference plot using the Gene Scanning software. Raw melt curves are 
normalised to have uniform pre- and post-melt values. Each normalised curve is then 
shifted to a temperature at which the dsDNA is entirely denatured. Finally, differences 
in melt curve shapes are shown after subtraction from a user-specified reference curve. 
B) Wild type full-length Stag1b protein containing the functional STAG domain. C) 
Truncated mutant Stag1b protein with aberrant amino acids represented in red.  
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Mutant F1 fish were in-crossed and the F2 generation was genotyped using HRMA. As 
the wild type and mutant homozygotes could not be differentiated based just on raw melt 
curves, Gene Scanning Software was used. The mutant homozygous and heterozygous 
samples clustered as separate groups when plotted as difference curves against a known 
wild type reference sample (Figure 3.13A). Genotyping was further validated by Sanger 
sequencing (Appendix Figure 7). The mutant allele was termed nz205. 
The nz205 mutation was predicted to lead to a frameshift resulting in a stretch of 46 
aberrant amino acids followed by a premature stop codon. The mutant protein is predicted 
to be 115 amino acids long and does not contain a functional STAG domain (Figure 
3.13B-C). The distribution of genotypes in the F2 generation (n=37 fish) was observed in 
a near-Mendelian ratio of 22% wild type homozygotes, 54% heterozygotes and 24% 
mutant homozygotes.  
 
3.7 No stag2a germline zebrafish mutant lines were recovered 
A total of nine sgRNAs targeting different regions of stag2a were tested through both 
singleplex and multiplex editing with Cas9 protein (Figure 3.7). No mutations were 
detected with six of the sgRNAs tested using T7E1 assays namely, OC6-OC10 and 
OC15. Mutations were detected in embryos injected with OC14 (Figure 3.9C lane 6 vs 
uninjected control in Figure 3.9A lane 6) and OC16 (Figure 3.9C lane 8 vs uninjected 
control in Figure 3.9A lane 8) using T7E1 assays. Mutations were also detected with the 
sgRNA OC20 using HRMA (not shown). However, none of these crispants showed proof 
of editing when sequenced. 
Embryos injected with sgRNAs OC14 or OC16 and Cas9 mRNA also showed no 
mutations upon sequencing but exhibited abnormal morphological phenotypes 
(discussed in chapter 4). Hence, deep sequencing was performed in these crispants. 
Mutations, predominantly small deletions were observed however at very low 
frequencies. The average mutagenesis efficiencies were found to be 4.9% and 0.65% for 
OC14 (Figure 3.14B) and OC16 (Appendix figure 8B), respectively. No mutations were 
detected at either of the targets in uninjected control embryos (Figure 3.14A for OC14 






























































Figure 3.14. CrispRVariants plots of the stag2a OC14 target loci. Analysis of deep 
sequencing is shown for A) three individual uninjected control embryos, C1-C3; and B) 
four individual crispants, CR1-CR4. The reference strand is shown in the header row. 
The 20 bp sgRNA and 3 bp PAM are demarcated by boxes. The cut site is located 3 bp 
upstream of the PAM site and is denoted by a vertical line running through the plot. 
Pairwise alignments are shown for each variant in the left panel and are listed by order 





















































D for deletion and I for insertion. Deletions are indicated by dashes and insertions by 
symbols above the respective alignments. The inserted sequences are shown in the 
legend at the bottom of the plot. The panel on the right shows the frequency of variants 
with the header row indicating the total number of reads per sample. Frequencies are 
colour coded based and the corresponding legend is shown on the far right.  
 
Both OC14-injected and OC16-injected crispant pools were raised. Once adults, these F0 
fish were outcrossed and the resulting embryos were screened for mutations. As before, 
no mutations were observed upon sequencing. OC14 and OC16 F0 founders were crossed 
together to generate double mosaic mutants. Analysis of embryos from this cross 
revealed low melt deflections by HRMA. However, no corresponding mutations could 
be detected using Sanger sequencing. In conclusion, no germline mutant lines could be 
established for the stag2a paralogue.  
 
3.8 The stag2bnz207 germline zebrafish mutant line has a 7 bp 
deletion in exon 3 of stag2b 
Two sgRNAs OC22 and OC23 targeting exons 3 and 12 of stag2b respectively, were 
tested individually and in duplex. Mutations were detected at the OC22 target site using 
HRMA (Figure 3.15) with a mutagenesis efficiency of 25% (n= 2/8). Mutant samples 
showed mosaic editing by sequencing. The OC23 target site proved difficult to optimize 
for HRMA analysis despite a total of three different primer pairs tested. However, mosaic 
editing of this target could also be confirmed through sequencing. Crispant pools injected 
with only OC22 or both OC22 and OC23 were raised to adulthood.  
Founders injected with single sgRNAs had lower mutagenesis efficiencies than their 
duplex counterparts at the OC22 target. Hence, F1 lines were established from the latter. 
A total of eight founders were screened and mutations were observed at both targets with 
up to 100% mutagenesis efficiencies. Mutations recovered in F1 adult fish are listed in 
Table 3.3. The most frequent mutation generated was -5:7D, a 7 bp deletion located 5 
nucleotides upstream of the cut site at the OC22 target site. No accompanying mutations 
were detected at the OC23 target site. The presence of a single predominant mutation 
suggested that microhomology-mediated end joining (MMEJ) repair may be prevalent at 
this locus. Analysis using an MMEJ-prediction tool, MENTHU (Microhomology-
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mediated End joining kNockout Target Heuristic Utility) (Ata et al., 2018), identified a 
strong microhomology sequence ‘AAGGG’ at the OC22 sgRNA binding site with a 
microhomology score of 1.71 (threshold ≥1.5).   
 
 
Figure 3.15. HRMA analysis of crispants injected with stag2b OC22 sgRNA. Melt 
curves for embryos carrying mosaic mutations cluster separately from wild type 
homozygous embryos.  
 
Table 3.3. List of heterozygous F1 mutations recovered at stag2b from duplex 
editing with sgRNAs OC22 and OC23. 




Mutation at OC23 target 
-5:7D 9 none 
unk:19D 3 compound heterozygous 




F1 adult fish carrying the -5:7D mutation were in-crossed and the resulting embryos were 
genotyped by HRMA (Figure 3.16A). Sanger sequencing was used to validate 
genotyping (Appendix figure 9). The mutant allele was termed nz207. The nz207 
mutation was predicted to lead to a frameshift resulting in a stretch of six aberrant amino 
acids followed by a premature stop codon. The mutant protein is predicted to be 60 amino 
acids long and does not contain a functional STAG domain (Figure 3.16B-C). Pools of 
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F2 embryos are presently being raised to adulthood. The viability of adult fish with 
mutant homozygous genotypes is yet to be determined. 
 
 
Figure 3.16. The stag2bnz207 mutation causes a frameshift in exon 3 resulting in a 
prematurely truncated protein variant. A) Genotyping of F2 embryos using HRMA is 
visualised as a difference plot using the Gene Scanning software. Further optimisation 
with additional samples is required to better segregate the genotype groups. B) Wild 
type full-length Stag2b protein containing the functional STAG domain. C) Truncated 
mutant Stag2b protein with aberrant amino acids represented in red.  
 
3.9 Discussion  
Characterisation of zebrafish wild type stag paralogues based on evolutionary 
conservation and expression during embryonic development identified all four 
paralogues to be functional. The zebrafish genome is characterised by the presence of 
duplicated genes owing to a whole-genome duplication event in common ancestor (of 
teleosts and mammals). Duplicated genes undertake one of the following fates: non-
functionalisation with the accumulation of deleterious mutations, sub-functionalisation 
with mutations resulting in shared expression and/or function or neofunctionalization 
with the accumulation of beneficial mutations (Moriyama & Koshiba-Takeuchi, 2018). 
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All four stag paralogues were ubiquitously expressed without major differences in 
expression patterns at 12 somites and 24 hpf suggesting no regulatory sub-
functionalisation. However, the temporal effects of such mechanisms need to be 
evaluated with time-course expression analysis.      
Conservation of the functional STAG domain in all four paralogues supports shared 
functions. Ubiquitous expression of all paralogues and especially robust expression in 
the head of zebrafish embryos at 24 hpf recapitulated the expression patterns for the other 
cohesin subunits rad21, smc1a, smc1b and smc3 (Monnich et al., 2009; B. Thisse & 
Thisse, 2004). While this is in line with an abundance of proliferating cells in the brain 
and the mandatory requirement of cohesin for cell division, Monnich et al. found that 
cohesin expression also extended to non-proliferating zones. Cohesin may have a non-
proliferative role such as in transcriptional regulation and therefore be required for the 
normal development of these structures. As detailed in Chapter 1, primitive embryonic 
haematopoiesis occurs between 12 and 24 hpf in zebrafish. This is followed by 
haematopoietic stem cell production beginning at 32 hpf and lasting up to 48 hpf. All 
four paralogues showed detectable levels of expression during this haematopoiesis 
window. This suggests that the four paralogues may be implicated directly or indirectly 
in embryonic haematopoiesis. 
Although numerous in silico tools are available for analysis of sgRNAs for CRISPR-
Cas9 mediated editing in zebrafish, their predicted efficiencies seldom overlap. This is 
evidently due to differences in the criteria used for scoring. Moreover, even sgRNAs that 
are predicted to have high mutagenesis efficiencies fail to perform in vivo. Only about 
50% of in silico-predicted sgRNAs are effective at generating mutations (Gagnon et al., 
2014; Hwang et al., 2013). A feature that could partly explain this discrepancy, both 
between tools and in vivo, is the presence of an inherent dinucleotide GG at the 5’ end of 
sgRNAs. Recently developed tools such as CRISPRscan and ZF hub filter out sgRNAs 
that fail to satisfy this criterion. The CHOPCHOP database, however, includes sgRNAs 
that have alternative nucleotides in the 5’ position and assigns efficiency scores based on 
specificity at the target of interest. It has been also reported previously that lack of the 
5’GG dinucleotide does not negatively impact sgRNA activity (Hwang et al., 2013). 
Among the different stag2a sgRNAs analysed here, the sgRNAs OC6-OC13 (Appendix 
table 3) do not contain a 5’GG. Consistent with more recent reports (Gagnon et al., 2014; 
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Varshney et al., 2015), these sgRNAs resulted in very low to nil in vivo editing. In 
conclusion, an inherent 5’GG in sgRNAs is required for efficient mutagenesis.  
Based on results from the different injection strategies tested, singleplex or duplex 
injections with Cas9 protein had the highest mutagenesis efficiencies. Compared to Cas9 
protein, mutagenesis mediated by Cas9 mRNA is slightly delayed (Y. Zhang et al., 2018) 
as it has to be first translated to Cas9 protein before binding the sgRNA at the target site. 
This delay is however not expected to affect editing efficiency (Hu et al., 2018). 
Multiplex editing is advantageous in that it is less labour-intensive and mutations in 
different genes can be propagated using the same founder fish. However, multiplexing 
requires careful selection of sgRNAs. Mutagenesis efficiencies have been shown to be 
independent of Cas9 binding affinities. sgRNAs with low mutagenesis efficiencies can 
still bind high levels of Cas9 making it unavailable to other more efficient sgRNAs. The 
use of multiple sgRNAs increases the number of potential off-targets. For the sgRNAs 
used in this study, no significant off-targets were predicted and mutant fish were out-
crossed at two generations (F0 and F1) before establishing stable mutants. Previous 
studies that characterised off-targets reported low mutation probability of 0.04% 
(Varshney et al., 2015) and poor mutagenesis efficiencies of 1.1-2.5% (Hruscha et al., 
2013). Sequencing at off-target loci in the stable mutants is required to ascertain the 
absence of any unintentional mutations.     
The T7E1 assay was initially used for identifying potential mutants as it is relatively 
inexpensive and relies on conventional PCR. However, this assay was found to have a 
high rate of false positives, possibly resulting from the presence of background 
polymorphisms around the sgRNA target regions. Hence for screening embryos injected 
with the newer sgRNAs OC22 and OC23, and embryos at ≥ F1 generation, a more reliable 
method in the form of HRMA was used. Although the presence of polymorphisms can 
influence melt curve profiles, establishing wild type reference curves allowed for easy 
identification of any new mutations generated.  
Deep sequencing using the Ilumina MiSeq platform was evaluated as a tool for detecting 
the nature of mutations generated. As mutagenesis efficiencies per injected embryo can 
be calculated deep sequencing may serve as a more accurate tool for screening potent 
sgRNAs. Although the number of reads obtained per sample was low, it was sufficient 
to reveal the predominant indels that were generated upon editing. However, these 
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predominant indels were not transmitted to subsequent generations. This could be 
explained by a preferential loss of deleterious mutations, i.e. embryos with these 
mutations may not be viable into adulthood. Deep sequencing analysis also identified 
numerous SNPs at all target sites in both injected and uninjected embryos. These were 
ruled out as artefacts as their frequencies were well below 50% and they were not 
previously identified with Sanger sequencing. In conclusion, deep sequencing for the 
identification of mosaic mutations may not necessarily be useful if the ultimate aim is to 
generate stable mutant zebrafish lines.  
Using CRISPR-Cas9, stable mutant lines were successfully established for both STAG1 
orthologues in zebrafish namely, stag1anz204 and stag1bnz205. Both mutations were 
homozygous viable, presumably due to functional compensation by the unaffected 
stag1/2 counterparts. However, fertility was considerably affected especially in the 
stag1anz204 line, with fewer fertilised embryos obtained in subsequent in-crosses. 
Although both stag1anz204 and stag1bnz205 mutant lines were recovered from the same 
founder fish, they were always found in isolation. It would be of interest to confirm this 
mutual exclusivity and to explore the degree of functional compensation through 
mutation combinations of the different paralogues.  
In zebrafish, wild type stag2a is maternally inherited but not expressed at high levels 
thereafter, raising the possibility of unique and critical roles in germ cell development 
and early embryogenesis. It is possible that any significant mutation load would have led 
to the production of incompetent oocytes or led to early embryonic lethality explaining 
why no mutations could be detected by conventional sequencing. Embryos derived from 
in-crossing F0 founders, from mutation-positive pools determined by deep sequencing, 
were used to evaluate stag2a loss and potential effects on morphological development.  
For stag2b, a predominant deletion mutation was recovered suggesting MMEJ as the 
preferred repair pathway at this locus. The germline inheritance of this mutation was 
determined but given time constraints, mutant embryos derived from in-crossing stag2b 
founder fish were used for characterisation. Due to MMEJ repair these F1 embryos are 
expected to represent a more homogenous mutant population and are hence suitable for 
phenotype-genotype correlation compared to embryos edited by NHEJ repair (Ata et al., 
2018). Transient knockout F1 embryos (Varshney et al., 2015), as well as F0 RNP-
injected crispants (Burger et al., 2016), have been previously shown to accurately predict 
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highly penetrant phenotypes. However, this approach has certain drawbacks; phenotypes 
with low penetrance can result in imprecise genotype-phenotype correlations and may be 
confounded by genetic compensation (El-Brolosy et al., 2019; A. Rossi et al., 2015). 
Germline mutant lines generated for stag1a and stag1b, and, F1 mutant embryos 
generated for stag2a and stag2b were characterised for morphological abnormalities and 





4 Characterisation of stag1/2 germline mutant 
zebrafish  
4.1 Background 
STAG1 and STAG2 have pleiotropic effects as evidenced by the plethora of 
developmental phenotypes associated with germline mutations in genes encoding the two 
subunits. Common phenotypes include microcephaly, intellectual disability, hearing loss, 
developmental delay and dysmorphic facial features (Aoi et al., 2019) (Mullegama et al., 
2019) (Soardi et al., 2017). These findings implicate STAG1 and STAG2 in 
neurodevelopment and human growth. In the context of AML, where somatic mutations 
in the STAG2 subunit occur later in life and are restricted to the haematopoietic 
compartment, cohesin haploinsufficiency leads to haematopoietic phenotypes. These 
include increased self-renewal capacity of haematopoietic stem and progenitor cells 
(HSPCs) and defective cell differentiation associated with myeloid skewing, as 
determined by various knockdown studies in human (Galeev et al., 2016; Mazumdar et 
al., 2015) and murine haematopoietic stem and progenitor cell lines (Fisher et al., 2016; 
Mullenders et al., 2015). Transcriptional input for such phenotypes comes from changes 
in chromatin accessibility at selective gene promoters. Cohesin subunits STAG1 and 
STAG2 have both unique and overlapping functions in regulating haematopoiesis 
(Cuadrado et al., 2019; Kojic et al., 2018; Aaron D. Viny et al., 2019).  
During early embryonic haematopoiesis spatiotemporal dysregulation of runx1+ 
haematopoietic precursors at 12 somite stage (ss) is seen in rad21 null zebrafish embryos. 
In addition, rad21 mutants show a downregulation of gata1a. Null mutants die by 35 
hours post-fertilisation (hpf) before embryonic haematopoiesis is complete (Horsfield et 
al., 2007). Given that the stag1a and stag1b mutants described in the previous chapter 
are mutant homozygous viable to adulthood, they provide the opportunity to study the 
effects of cohesin disruption during later stages of haematopoiesis.  
In this chapter, I describe the characterisation of stable zebrafish lines carrying mutations 
in the four stag paralogues generated as described in Chapter 3. Abnormalities in 
morphological development were assessed across embryonic and larval periods up to 10 
days post-fertilisation (dpf). Antisense morpholino oligonucleotides (MOs) that bind at 
the transcription start site of target mRNAs and block translation were used to validate 
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the aberrant phenotypes observed. Gene knockdown through mutagenesis may 
upregulate the expression of related genes with similar function as a means to overcome 
functional loss of the mutated gene (El-Brolosy et al., 2019; C. C. Rossi et al., 2009). 
The potential for genetic compensation was assessed using real-time PCR (RT-PCR). 
Expression analysis was performed in the stag1a and stag1b lines as mutant homozygous 
adults were available only for these. Lastly, defects in the two waves of embryonic 
haematopoiesis, namely primitive and definitive haematopoiesis were analysed using 
appropriate lineage-specific markers by whole-mount in situ hybridisation (WISH). 
Because no germline mutants were recovered for stag2a, the effect of stag2a loss on 
haematopoiesis was not analysed. The expression of wild type stag2a was evaluated in 
ovary sections to determine if mutation in this subunit was likely to affect fertility and 
mutation transmission through the germline.  
 
4.2 Morphological characterisation of stag1/2 mutant lines 
To determine the impact of stag1/2 loss on growth and development, morphological 
analysis was carried out in clutches of embryos obtained from in-crosses of F1 
heterozygous fish carrying germline mutations in individual stag paralogues. 
Representative embryos with morphological abnormalities were genotyped and the 
distribution of abnormal phenotypes was determined in each cross. Wild type embryos 
injected with individual stag MOs termed ‘morphants’ hereafter, were used for validating 
mutant phenotypes. A MO dose of 0.5 mM was selected after testing two concentrations 
of 0.25 mM and 0.5 mM to evaluate off-target toxicity. For expression analysis using 
RT-PCR, pairs of mutant homozygous adults were in-crossed and resulting embryo pools 
were used for RNA extraction. Each biological replicate comprised 30 individual 
embryos. Pools of uninjected wild type embryos were used as controls.  
 
4.2.1 stag1a nz204 mutants have normal morphology 
No significant morphological abnormalities were observed in stag1anz204 mutants during 
embryonic development. At 24 hpf, all embryos derived from stag1anz204/+ heterozygous 
in-crosses had normal morphology (Figure 4.1B) and were indistinguishable from wild 
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type controls (Figure 4.1A). In contrast, the majority of morphants injected with 0.5 mM 
stag1a MO exhibited severe defects in anteroposterior (A/P) patterning (Figure 4.1C). 
Morphants exhibited a partial to complete loss of anterior structures. These defects were 
first observed during gastrulation and became prominent by 12 hpf, when the head of the 
embryo can be differentiated as a distinct entity. Embryos with complete loss of anterior 
structures died prematurely at 72 hpf while the remaining showed varying levels of 
recovery. 
At the later stage of 7 dpf, the majority of embryos from the heterozygous crosses 
continued to show normal development and were indistinguishable from wild type 
controls (Figure 4.2A). Only a small percentage of embryos were developmentally 
delayed and characterised by defects in craniofacial and gut development and/or delayed 
swim bladder inflation (Figure 4.2B).  
 
 
Figure 4.1. stag1anz204 mutants have normal morphology at 24 hpf. Lateral views of 
a representative A) wild type control with normal morphology, B) stag1anz204 mutant 
homozygous embryo with normal morphology and C) stag1a morphant with 
anteroposterior patterning defects, at 24 hpf. Anterior is to the left. All scale bars are 100 
µm.  
 
These defects were not subsequently observed in embryos (n=18) obtained from in-cross 
of a single mutant homozygous pair. However, this finding needs to be replicated with 
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more pairs. In older breeding adults, fertilisation rates were severely impacted in both 
stag1anz204/+ heterozygous and stag1anz204 mutant homozygous fish with lower numbers 
of fertilised eggs obtained in subsequent crosses. In contrast, stag1a morphants exhibited 
severe developmental abnormalities at 7 dpf. Embryos were characterised by progressive 
oedema leading to death (Figure 4.2C).  
 
 
Figure 4.2. stag1anz204 mutants show mild morphological abnormalities at 7 dpf.  
Lateral views of a representative A) wild type control with normal morphology, B) 
stag1anz204 mutant homozygous embryo with delayed swim bladder inflation (red arrow) 
and C) stag1a morphant with severe oedema, at 7 dpf. Anterior is to the left. All scale 
bars are 100 µm. 
 
A quantitative representation of the various phenotypes observed in stag1a mutants and 





Figure 4.3. Summary of morphological abnormalities observed in stag1a mutants 
and morphants. A) Percentage distribution of phenotypes observed in embryos 
obtained with two individual crosses of stag1anz204 heterozygous fish at 7 dpf. Embryos 
with craniofacial defects also show defective or delayed swim bladder inflation, leading 
to abnormalities in the gut region. The total number of embryos screened in each cross 
is shown above the respective columns. B) Percentage distribution of phenotypes in 
morphants injected with 0.5 mM stag1a MO. The majority of the morphants are abnormal 
with defects in anteroposterior (A/P) patterning at 24 hpf and oedema at 7 dpf. The total 
number of embryos screened independently at each time point is indicated above the 
respective columns.  
 
Expression of the four stag paralogues in stag1anz204 mutants was quantified using RT-
PCR. RNA was extracted from pools of embryos at 48 hpf, with known wild type or 
mutant homozygous genotype and expression was normalised to two reference genes 
namely, β-actin and rpl13a. A significant downregulation in the expression of stag1a 
mRNA was observed in the mutants compared to wild type (Figure 4.4A). 
Downregulation of stag1a mRNA was accompanied by a moderate but significant 
decrease in the mRNA of the remaining three paralogues (Figure 4.4B-D). 
In summary, stag1anz204 mutants exhibited normal morphological development despite 
significant loss of stag1a mRNA. The small percentage of swim bladder and craniofacial 
defects seen may have resulted from the accompanying loss of expression in the other 
stag paralogues. However, absence of mutations at the stag1a locus in a significant 




Figure 4.4. stag1a mRNA expression is significantly downregulated in stag1anz204 
mutants at 48 hpf. Expression of A) stag1a is significantly reduced in mutants 
compared to wild type embryos. Residual mRNA may reflect that targeted for nonsense-
mediated degradation. Moderate but significant reductions in mRNA expression levels 
of B) stag1b, C) stag2a and D) stag2b is also seen in mutants compared to wild type 
embryos. Five biological replicates each for mutants and wild type controls were tested. 
A pool of 30 embryos at 48 hpf with known mutant or wild type genotype comprised a 
single biological replicate. Error bars are ± standard deviation (S.D.). Statistical 
significance was determined using t-tests. Asterisks indicate significance: **** p 
<0.0001; * p=0.0139, p=0.0431, and p=0.0225 in order.  
 
In stag1a morphants, phenotypes seen were severe at both developmental stages analysed 
compared to mutants. Similar phenotypes were also observed in morphants injected with 
a lower dose of 0.25 mM MO. The severity of phenotypes can be attributed to the early 
activity of MOs in targeting maternal stag1a mRNA and the inherently low expression 
of zygotic stag1a mRNA itself (described in Chapter 3). Lastly, genetic compensation 
was not identified for stag1anz204 mutants because a decrease in expression of the 




4.2.2 stag1bnz205 mutants show craniofacial and pigmentation anomalies 
Morphological analysis of stag1bnz205 mutants exhibited abnormalities in embryonic 
development which were first observed at 36 hpf. Significant developmental delay 
together with microcephaly and a reduction in overall pigmentation was seen in both 
heterozygous (n=6 genotyped) and mutant homozygous (n=1 genotyped) embryos 
(Figure 4.5B, compared to wild type control in 4.5A). Some heterozygous embryos 
exhibited normal morphology (n=2 genotyped) indicating potential differences in 
pathogenicity conferred by the two parental alleles. At 36 hpf, morphants injected with 
doses of 0.25 mM or 0.5 mM stag1b MO phenocopied abnormalities seen in the mutants. 
Both microcephaly and pigmentation defects were more severe and additional 
abnormalities in the development of the yolk extension (YE) were seen (Figure 4.5C). 
 
 
Figure 4.5. stag1bnz205 mutants exhibit developmental abnormalities at 36 hpf. 
Lateral views of a representative A) wild type control with normal morphology, B) 
stag1bnz205 mutant homozygous embryo with microcephaly (black arrow) and ubiquitous 
pigment reduction and C) stag1b morphant with microcephaly (black arrow), ubiquitous 
pigment reduction and additional yolk extension defects (red arrow), at 36 hpf. Anterior 




Embryos obtained from out-crossing mutant homozygous males either showed normal 
morphology (n=53/132) similar to wild type siblings (Figure 4.6A-A’) or exhibited a 
range of developmental defects at 4 dpf. The most prominent was the presence of 
abnormal pigmentation in the caudal tail fin region (n=79/132) that first appeared at 54 
hpf (Figure 4.6B-B’). Both melanocytes and iridophores were misplaced in the caudal 




Figure 4.6. stag1bnz205 mutants show craniofacial defects and displaced pigment 
cells at 4 dpf. Lateral views of a representative A), A’) wild type homozygous embryo 
with normal morphology, B, B’) stag1bnz205/+ heterozygous embryo with abnormal caudal 
fin pigments (blue arrow heads in B’), C), C’) stag1bnz205 mutant homozygous embryo 
with abnormal lateral line pigments (red arrow) and craniofacial defects (black arrow) 
and D), D’) stag1b morphant with severe abnormal pigmentation in the caudal fin (blue 
arrow heads in D’), abnormal pigments in the gut region (blue arrow) and craniofacial 
defects (black arrow), at 4 dpf. Anterior is to the left. Scale bars are 100 µm.  
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In mutant homozygous embryos at 4 dpf, while pigmentation defects along the lateral 
line were observed, only few ectopic pigments were seen in the caudal fin (n=1 
genotyped). However, these embryos also exhibited abnormal pigments in the cardiac 
region, and in addition, showed craniofacial defects characterised by a smaller head and 
protrusion of the upper jaw (Figure 4.6C-C’). The pigmentation and craniofacial defects 
seen in stag1b mutants were phenocopied in stag1b morphants at 4 dpf. Abnormal 




Figure 4.7. Summary of morphological abnormalities observed in stag1b mutants 
and morphants.  Percentage distribution of phenotypes in embryos obtained from 
individual crosses of stag1bnz205/+ heterozygous fish A) at 36 hpf and B) at 4 dpf. Some 
embryos with craniofacial defects also had abnormal pigments in the caudal fin. 
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Embryos were independently screened at each stage. The total number of embryos 
screened per cross is shown above the respective columns. C) Percentage distribution 
of phenotypes in morphants injected with 0.5 mM stag1b MO. The total number of 
embryos screened independently at 36 hpf and 4 dpf is indicated above the respective 
columns. 
 
By 8 dpf, heterozygous embryos acquired defects in the notochord (n=17/74) along with 
other abnormalities such as defects in swim bladder inflation (n=55/74), or craniofacial 
development (n=2/74). By 8 dpf, mutant homozygous embryos (n=3 genotyped) acquired 
bent notochords with severe swim bladder defects leading to additional abnormalities in 
the gut region and exhibited severe craniofacial defects characterised by a ventrally-
drooping jaw (Appendix figure 10). This suggests possible defects in the development of 
the Meckel’s cartilage and requires further characterisation using techniques such as 
Alcian Blue staining.  
As in mutants, delayed or defective swim bladder inflation leading to abnormal gut 
development was also seen in morphants (Figure 4.6D-D’). A small percentage of 
embryos also showed cardiac oedema. A quantitative representation of the various 
phenotypes observed in stag1b mutants and morphants is shown in Figure 4.7. Further 
evaluation using larger numbers of embryos with known genotypes is required to make 
conclusive genotype-phenotype correlations. The observed phenotypes may be transient 
or may not impact survival as stag1bnz205 mutant homozygotes were recovered in 
adulthood. 
Expression levels of the four stag paralogues were determined in stag1b mutants using 
RT-PCR. RNA was extracted from pools of embryos with known wild type or mutant 
homozygous genotype at 48 hpf. Expression was normalised to two reference genes 
namely, β-actin and rpl13a. A significant downregulation in the expression of stag1b 
mRNA was observed in the stag1bnz205 mutants compared to wild type (Figure 4.8B). 
This was accompanied by a moderate but significant increase in stag2a mRNA (Figure 
4.8C). Although a trend towards increase in stag1a mRNA (Figure 4.8A) and a trend 






Figure 4.8. stag1b mRNA expression is significantly reduced in stag1bnz205 
mutants at 48 dpf. A) No significant change in stag1a mRNA is seen. B) stag1b mRNA 
is significantly reduced in mutants, indicative of nonsense-mediated degradation. C) 
stag2a mRNA is significantly increased in mutants compared to wild type. D) No 
significant change in stag2b mRNA is seen. Five biological replicates for wild type 
controls and three biological replicates for mutants were tested. A pool of 30 embryos 
at 48 hpf with known wild type or mutant genotype comprised a single biological 
replicate. Error bars are ± S.D. Statistical significance was determined using t-tests. 
Asterisks indicate significance: ** p=0.0017; * p=0.0247, and ns=nonsignificant.  
 
In summary, stag1bnz205 mutants exhibited defects in the development of craniofacial 
structures and pigmentation, both of which are derived from the multipotent neural crest 
cell population. Abnormal phenotypes were seen in heterozygous embryos consistent 
with haploinsufficiency and were evident from as early as 36 hpf. Additional defects in 
swim bladder and notochord development were observed at later stages. All 
abnormalities were phenocopied in stag1b morphants. Lastly, stag1bnz205 mutants 
showed a significant downregulation in stag1b mRNA with possible compensatory 
expression from stag2a.   
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4.2.3 stag2a F1 mutants show infrequent developmental abnormalities  
As described in Chapter 3, no detectable mutations were recovered at the stag2a locus. 
However, abnormal phenotypes were identified in both crispants and subsequent out-
crosses. To evaluate the type of abnormalities that could be generated by stag2a loss, F1 
embryos obtained from crossing injected founder fish were used. These fish carried 
mosaic mutations at low frequencies as evidenced by deep sequencing analysis described 
in Chapter 3. As expected, the majority of F1 mutant embryos showed normal 
development at 36 hpf (Figure 4.9A). A small percentage of embryos exhibited defects 
in yolk extension development (Figure 4.9B). Yolk extension abnormalities were 
phenocopied in morphants injected with doses of 0.25 mM or 0.5 mM stag2a MO (Figure 
4.9C). In addition, overall pigmentation was reduced in morphants.  
 
 
Figure 4.9. stag2a F1 mutant embryos exhibit transient abnormalities at 36 hpf. 
Lateral views of a representative A) stag2a F1 embryo with normal morphology, B) 
stag2a F1 embryo with abnormalities in yolk extension development (black arrow) and 
C) stag2a morphant with defects in yolk extension development (black arrow). Pigments 





At the later stage of 6 dpf, most stag2a F1 embryos continued to show normal 
development similar to wild type controls (Figure 4.10A). A small percentage showed 
defects in notochord development accompanied by abnormal pigmentation along the 
lateral line (Figure 4.10B-C). Additionally, some embryos also presented with defects in 
swim bladder inflation leading to gut abnormalities (Figure 4.10C). 
 
 
Figure 4.10. stag2a F1 mutant embryos show transient abnormalities at 6 dpf. 
Lateral views of a representative A) wild type embryo with normal morphology, B) stag2a 
F1 embryo with a bent notochord and abnormal pigmentation along the lateral line (red 
arrow), C) stag2a F1 embryo with defective swim bladder inflation (blue arrow) and the 
presence of discontinuous pigmentation along the lateral line (red arrow). D) stag2a 
morphant with developmental delay characterised by craniofacial defects (black arrow), 
defective swim bladder inflation (blue arrow) and loss of pigments along the lateral line 
97 
 
(red arrow). Anterior is to the left. Scale bars are 100 µm for A, C and D, and 50 µm for 
B.  
 
At 6 dpf, stag2a morphants exhibited severe developmental delay characterised by 
craniofacial and swim bladder defects as seen in mutants. A striking loss of pigments 
along the lateral line and a corresponding increase in pigments in the pericardial cavity 
and yolk region were observed (Figure 4.10D). A quantitative representation of the 
various phenotypes observed in stag2a mutants and morphants is shown in Figure 4.11.  
 
 
Figure 4.11. Summary of morphological abnormalities observed in stag2a mutants 
and morphants. Percentage distribution of phenotypes observed in embryos obtained 
from individual crosses of stag2a mosaic F0 founders. Embryos were screened 
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independently at A) 36 hpf and B) 6 dpf.  The total number of embryos screened in each 
cross is shown above the respective columns. At 6 dpf, some embryos with craniofacial 
defects also had defects in pigmentation and/or swim bladder inflation and notochord 
development. C) Percentage distribution of phenotypes in morphants injected with 0.5 
mM stag2a MO. The total number of embryos screened independently at 36 hpf and 5 
dpf is indicated above the respective columns. At 6 dpf, some embryos with craniofacial 
defects also had defects in pigmentation and/or swim bladder inflation. All embryos 
showed developmental delay.  
 
Given the inherently low expression of stag2a at late developmental stages, whether the 
observed abnormalities are consequences of stag2a loss in early development or non-
specific developmental anomalies requires further clarification.  
As the observed abnormalities were seen at low frequencies with no detectable mutations 
and that stag2a showed high maternal and low zygotic expression, it was hypothesised 
that stag2a may be implicated in gamete formation. As preliminary evidence for this 
hypothesis, in situ hybridisation was performed using stag2a riboprobe on ovary sections 
from a wild type adult female. Probe synthesis was carried out as described in Chapter 2. 
Marked expression of stag2a was seen in the ovary compared to the surrounding tissue 
(Figure 4.12).  
 
 
Figure 4.12. Wild type stag2a is expressed in ovary of adult zebrafish. In situ 
hybridisation of stag2a probe on a transverse wild type ovary section. Expression of 
stag2a is visualised as purple staining in the oocytes (black arrows). ov- ovary, sb- swim 
bladder and aw- abdominal wall. 
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The sections used predominantly contained immature and developing oocytes. Hence, 
further characterisation using sections containing oocytes at different stages and from 
multiple fish is required. However, this finding suggests a potential role for stag2a in 
germ cell development which may explain the absence of germline mutations. In 
summary, defects in the development and pigmentation defects were seen in stag2a F1 
mutants, although at low frequencies. These abnormalities were also phenocopied in 
stag2a morphants suggesting a direct or indirect role for stag2a in embryonic 
development. In addition, expression in developing oocytes implicated stag2a in germ 
cell development and a maternally-derived role in early embryogenesis. 
 
4.2.4 stag2bnz207 mutants show abnormal pigment cell distribution and 
patterning defects  
Morphological analysis of stag2bnz207 mutants revealed no major abnormalities during 
early embryonic development up to 24 hpf (Figure 4.13B compared to wild type control 
in 4.13A). On the contrary, the majority of morphants injected with 0.5 mM stag2b MO 
developed necrosis visualised as grey cells by 18 hpf (Figure 4.13C). Morphants with 
severe necrosis progressed to develop cardiac oedema and died by 4 dpf while in the 
remaining embryos, necrosis was transient. Other abnormalities that developed at later 
stages are described below. At 48 hpf, abnormal pigmentation in the caudal fin was seen 
in both stag2bnz207/+ heterozygous (n=11 genotyped) and stag2bnz207 mutant homozygous 
(n=6 genotyped) embryos. During normal embryonic development at 72 hpf, 
melanocytes in the tail primordium occur as two rows of cells at the boundary of the tail 
and fin fold. While the dorsal row is continuous, the ventral row normally has a small 
gap in pigment cells. Both heterozygous (n=2 genotyped) and mutant homozygous 
embryos (n=4 genotyped) showed aberrant or completely absent pigment gaps. 
At 6 dpf, abnormalities in craniofacial and swim bladder development were seen. The 
upper jaw was flattened rather than curved as in wildtype (Appendix figure 11) possibly 
due to mild defects in the development of the ethmoid plate and the palatoquadrate 
cartilage. These phenotypes were more common in mutant homozygous embryos (n=6 
genotyped) compared to heterozygous embryos (n=3 genotyped). The presence of 
pigments in the caudal fin and abnormal pigmentation along the lateral line was observed 
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in both heterozygous (n=2 genotyped) (Figure 4.14C) and mutant homozygous embryos 
(n=2 genotyped) (Figure 4.14D). The caudal fin pigments seen were relatively more 
severe in mutant homozygous embryos (Figure 4.14D’ compared to 4.14C’). All mutant 




Figure 4.13. stag2bnz207 mutants have normal morphology at 24 hpf. Lateral views 
of a representative A) wild type control with normal morphology, B) stag2bnz207 mutant 
embryo with normal morphology and C) stag2b morphant with severe necrosis 
phenotype, at 24 hpf. Anterior is to the left. All scale bars are 100 µm.  
 
As with stag1b, some heterozygous embryos (n=2 genotyped) also had relatively normal 
morphology (Figure 4.14B-B’). At all developmental stages analysed, wild type siblings 
(n=11 genotyped) showed normal development. Abnormalities in craniofacial and gut 
development and lateral line pigment defects were phenocopied in the stag2b morphants 
at 6 dpf (Figure 4.14E-E’). Surprisingly, no pigments were observed in the caudal fin but 
a small percentage of morphants showed defects in the length and morphology of the fin 
fold. Morphants also exhibited severe developmental delay, cardiac oedema and pigment 
accumulation in the pericardial cavity and gut region. A quantitative representation of 





Figure 4.14. stag2bnz207 mutants show craniofacial defects and pigment cell 
displacement at 6 dpf. Lateral views of a representative A), A’) wild type control with 
normal morphology and B), B’) stag2bnz207/+ heterozygous embryo with wild type-like 
morphology, at 6 dpf.  C), C’) Lateral views of a representative stag2bnz207/+ heterozygous 
embryo at 6 dpf with developmental delay characterised by a small head and under-
formed jaw (black arrow) and delayed swim bladder inflation (blue arrow). A single 
ectopic pigment is seen in the caudal tail fin (blue arrowhead in C’). D), D’) Lateral views 
of a representative stag2bnz207 mutant homozygous embryo at 6 dpf with developmental 
delay characterised by craniofacial defects (black arrow) and delayed swim bladder 
inflation (blue arrow). Pigment cell displacement caudal tail fin is seen (blue arrowheads 
in D’). E), E’) Lateral views of a stag2b morphant at 6dpf with developmental delay, 
craniofacial defects in jaw development (black arrows),swim bladder defects (blue 
arrow) and cardiac oedema (grey arrow). Pigment accumulation in the pericardial cavity 
and gut region and abnormal pigmentation along the lateral line (red arrow) are seen. 





Figure 4.15. Summary of morphological abnormalities observed in stag2b 
mutants and morphants. A) Percentage distribution of phenotypes observed at 6 dpf 
in embryos obtained from two individual crosses of stag2bnz207 heterozygous fish. The 
majority of the embryos with caudal fin pigment cell displacement also had defects or 
delay in swim bladder inflation. The majority of embryos with craniofacial defects also 
had displaced pigment cells in the caudal fin. The total number of embryos screened in 
each cross is shown above the respective columns. B) Percentage distribution of 
phenotypes in morphants injected with 0.5 mM stag2b MO. The total number of embryos 
screened independently at 24 hpf and 6 dpf is shown above the respective columns. 
 
Although the nature of phenotypes conferred by stag2b loss is clear, further evaluation 
using larger numbers of embryos with known genotypes is required to make conclusive 
genotype-phenotype correlations. Further, follow-up characterisation using Alcian Blue 
staining can help clarify what underlying craniofacial structural elements are affected. 
Striking late-stage phenotypes indicating disruption of the dorsoventral body axis were 
observed in stag2b F0 crispants. These included the presence of dorsal or ventral 
secondary tails made up of un-patterned tissue (Figure 4.16B) or patterned secondary fins 
with an additional notochord (Figure 4.16C). Secondary tails developed even in the 
presence of a reduced primary tail fin mesoderm (Figure 4.16D). These phenotypes 
occurred at a low frequency of 3% (n=7/241) and embryos were not viable beyond early 
larval stages. Although these abnormalities were not seen in subsequent generations, they 




Figure 4.16. stag2bnz207 crispants show disrupted dorsoventral patterning at >7 
dpf. Lateral views of a representative A) uninjected embryo with normal morphology at 
9 dpf, B) stag2b crispant with a secondary ventral tail (black arrow) at 11 dpf, C) stag2b 
crispant with a secondary dorsal fin (black arrow) at 7 dpf, D) stag2b crispant with a 
secondary ventral fin (black arrow) and a compromised primary tail fin (blue arrow) at 
11 dpf. Anterior is to the left. All scale bars are 100 µm.  
 
In summary, the abnormalities in dorsoventral body axis patterning and defects in the 
development of craniofacial structures and the location of pigment cells seen in 
stag2bnz207 mutants are suggestive of a larger role for stag2b in regulating cell fate 
determination. Early embryonic development was normal in mutants, consistent with the 
high load of maternally-inherited stag2b mRNA. Abnormalities were seen in 
heterozygous embryos consistent with haploinsufficiency and were evident from 48 hpf. 
Compared to stag1bnz205 mutants, the caudal fin pigment phenotypes were more 
pronounced in stag2bnz207 mutants but were not phenocopied in stag2b morphants. 
However, other defects in craniofacial and swim bladder development were 
phenocopied. As the F2 generation is currently being raised, neither the level of stag2b 
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mRNA loss and its impact on the levels of the other paralogues, nor whether the mutation 
is homozygous-viable could be evaluated. 
In conclusion, among the four paralogues, only the stag1anz204 mutants were 
asymptomatic. All other stag mutants presented with defects in abnormal pigmentation 
and notochord development. A striking abnormal positioning of melanocytes was 
observed in the caudal fins of stag1bnz205 and stag2bnz207 mutants but not in stag2a mosaic 
mutants. The displaced pigment cells were also observed to include one or two 
iridophores in some embryos. Melanocytes present in other regions including the lateral 
line, the ventral CHT region and the yolk region were disrupted in all three mutant lines. 
Defects in lateral line pigments may be associated with malformed notochords in some 
of these embryos. Of note, dorsal melanocytes in the head and along the length of the 
embryo showed no major changes in any mutants. While abnormal pigmentation in the 
caudal fin was phenocopied only in stag1b morphants, abnormal pigmentation in the 
other regions were phenocopied in all three morphants. 
 
4.2.5 Preliminary analyses of stag1/2 combination mutants   
To decipher the interdependent roles of the stag paralogues, mutant combinations were 
generated by in-crossing fish carrying individual stag1/2 mutations (Figure 4.17). A cross 
with stag1anz204/+ and stag1bnz205/+ heterozygous fish resulted in 28% of embryos with 
abnormal caudal fin pigments and an additional 4% with accompanying craniofacial 
abnormalities, at 5 dpf. This ratio is in concordance with the haploinsufficiency 
phenotypes conferred by the nz205 allele described above. No new phenotypes or 
increase in severity of existing phenotypes were seen. Surprisingly, no abnormalities 
were observed with crossing a stag1anz204 mutant homozygous fish with a stag1bnz205 
mutant homozygous fish where all the resulting embryos double heterozygotes. Lastly, 
embryos obtained from a cross with stag1anz204 mutant homozygous and stag2bnz207 
heterozygous fish showed abnormal caudal fin pigments at 5 dpf. Abnormalities were 
observed in 41% of embryos indicating an association with the haploinsufficient nz207 
allele. While from the above crosses it was clear that the stag1a nz204 allele does not 
increase pathogenicity in combination with other stag mutations, compensatory effects 
in the levels of other paralogues may confound observations. Furthermore, the observed 
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phenotypes in crosses involving heterozygous parents may be influenced by the direction 
of the cross. Future analyses with double mutant homozygous embryos for the different 
paralogues may help clarify these discrepancies. 
 
 
Figure 4.17. Summary of morphological abnormalities seen in stag1/2 
combination mutants. Percentage distribution of phenotypes observed in embryos at 
5 dpf obtained from individual crosses of stag1/2 mutant fish, as indicated. The total 
number of embryos screened in each cross is shown above the respective columns.  
 
4.3 Characterisation of primitive embryonic haematopoiesis 
Defects in primitive embryonic haematopoiesis were evaluated by WISH using 
riboprobes detecting the expression of lineage-specific haematopoietic markers. Primers 
used for WISH probe synthesis are listed in Appendix table 2. 
 
4.3.1 runx1 expression in the PLM is expanded in stag1anz204 mutants and 
reduced in stag2a and stag2b mutants at 12 somites 
Expression of runx1 was found to be upregulated at all regions of expression in 
stag1anz204 heterozygous (Figure 4.18B) and mutant homozygous embryos (Figure 
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4.18C) compared to wild type (Figure 4.18A-A’) at 12 somites. Enhanced expansion was 
observed in the bilateral stripes which may indicate an increase in haematopoietic 
progenitors in mutant homozygous embryos (Figure 4.18C’). This expansion was 
relatively mild in heterozygous embryos (Figure 4.18B’). In comparison, only a small 
fraction of stag1a morphants (n=5/51) showed a similar upregulation of runx1 expression 




Figure 4.18. Increased runx1 expression is seen in the PLM of stag1anz204 mutants 
at 12 somites. Lateral views of a representative A, A’) wild type homozygous embryo 
with normal runx1 expression, B, B’) stag1anz204/+ heterozygous embryo with moderately 
increased runx1 expression in the PLM (black arrow), C, C’) stag1anz204 mutant 
homozygous embryo with increased runx1 expression in the PLM (black arrows) and D, 
D’) stag1a morphant showing normal runx1 expression, at 12 somites. Numbers on the 
lower right hand corner indicate the number of embryos that had an expression pattern 




Surprisingly, no changes in runx1 expression were seen in either stag1bnz205 heterozygous 
(Figure 4.19B-B’) or mutant homozygous embryos (Figure 4.19C-C’) compared to wild 
type (Figure 4.19A-A’) at 12 somites. Normal runx1 expression in the ALM, PLM and 
RBN was present in all stag1b morphants screened (Figure 4.19D-D’). In a small fraction 
of morphants (n=8/39), ectopic runx1 expression was seen in the region posterior to the 
ALM (Figure 4.19F, arrows compared to 4.19E). In addition, the ALM of these embryos 
showed mild signs of unconstrained or diffuse runx1 expression.  
 
 
Figure 4.19. No changes in runx1 expression is seen in stag1bnz205 mutants at 12 
somites. Lateral views of a representative A) wild type homozygous embryo, B) 
stag1bnz205/+ heterozygous embryo, C) stag1bnz205 mutant homozygous embryo and D) 
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stag1b morphants, all with normal runx1 expression at 12 somites. Anterior is to the left. 
A’-D’) Posterior views of PLM runx1 expression in corresponding embryos. E, F) Ventral 
views of stag1b morphants with normal or ectopic runx1 expression (indicated by 
arrows). Numbers on the lower right-hand corner indicate the number of embryos that 
had an expression pattern similar to the representative image. Scale bars are 100 µm 
for A-E and 50 µm for F.  
 
As mentioned in Chapter 3, a single predominant mutation was recovered at the stag2b 
locus possibly due to MMEJ-mediated repair. Therefore, F1 embryos obtained from 
crossing fish carrying mosaic mutations in stag2b expected to predominantly carry the 
same mutation were used for evaluation of haematopoietic phenotypes. In contrast to 
stag1anz204 mutants and similar to rad21nz171 mutants (see Section 1.3.3), runx1 




Figure 4.20. A reduction in runx1 expression is seen in the PLM of stag2b F1 
mutants at 12 somites. Lateral views of a representative A) wild type control with 
normal runx1 expression, B) stag2b F1 mutant embryo with reduced runx1 expression 
in the PLM (arrow) and C) stag2b morphant with mild reduction in runx1 expression at 
all regions (arrows), at 12 somites. Anterior is to the left. A’-C’) Posterior views of PLM 
runx1 expression in corresponding embryos. Numbers on the lower right-hand corner 
indicate the number of embryos that had an expression pattern similar to the 
representative image. All scale bars are 100 µm.  
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Among the pool of F1 embryos evaluated, n=12/28 embryos were mutant and n=9/12 
mutant embryos showed significant downregulation of runx1 in the PLM (Figure 4.20B-
B’, arrows) compared to wild type controls (Figure 4.20A-A’). Expression in the RBN 
was also mildly reduced in these embryos. Loss of runx1 expression in the PLM was 
recapitulated in stag2b morphants, but with additional loss in the RBN and ALM (Figure 
4.20C-C’, arrows). 
In summary, loss of stag1/2 had the strongest impact on runx1 expression in the PLM at 
12 somites. While stag1anz204 mutants were characterised by an increase in runx1 
expression, the opposite was seen in stag2b F1 mutants. The increased runx1 mRNA seen 
in stag1a mutants was however not recapitulated in stag1a morphants. In contrast, in 
stag2b morphants, reduced runx1 expression was extended to the RBN and the ALM. 
Interestingly, of the four paralogues, stag1b was found to have no role in regulating runx1 
expression in both mutants and morphants.  
 
4.3.2 Primitive myeloid skewing is seen in stag1anz204 and stag2b F1 
mutants at 24 hpf 
At 24 hpf, gata1a expression which marks primitive erythroid cells in the ICM, was 
significantly downregulated in stag1anz204 mutant homozygous embryos (Figure 4.21C) 
compared to wild type siblings (Figure 4.21A). Among stag1anz204/+ heterozygous 
embryos screened, gata1a expression was reduced in 50% of embryos while the 
remaining showed normal expression. In contrast, pu.1 expression which marks myeloid 
cells, was increased in both stag1anz204/+ heterozygous (Figure 4.21E) and stag1anz204 
mutant homozygous embryos (Figure 4.21F) compared to wild type siblings (Figure 
4.21D). An increase in the number of pu.1+ cells in the yolk (Figure 4.21E’ and 4.21F’ 
compared to 4.21D’) to a milder extent in the RBI (Figure 4.21F, arrow) was observed. 
Both stag1bnz205/+ heterozygotes and stag1bnz205 mutant homozygotes exhibited no 
change in gata1a expression at 24 hpf (Figure 4.22A-C). For unknown technical reasons, 
WISH for pu.1 expression was unsuccessful in the stag1b line (Figures 4.22D-F’). Two 
different batches of pu.1 probe and a total of three biological replicates were tested. 
Although further evaluation is required, it is expected that pu.1 expression would not be 
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affected in the mutants given that loss of stag1b did not have any impact on the 
expression of the other primitive haematopoietic markers evaluated. 
 
 
Figure 4.21. A myeloid bias is seen in stag1anz204 mutants during primitive 
haematopoiesis at 24 hpf. Lateral views of a representative A) stag1a+ wild type 
homozygous embryo with normal gata1a expression, B) stag1anz204/+ heterozygous 
embryo with moderate reduction in gata1a expression in the ICM (arrow) and C) 
stag1anz204 mutant homozygous embryo with a significant reduction in gata1a expression 
in the ICM (arrow), at 24 hpf. Lateral views of a representative D) wild type homozygous 
embryo with normal pu.1 expression, E) stag1anz204/+ heterozygous embryo with 
increased pu.1 expression in the yolk and F) stag1anz204 mutant homozygous embryo 
with increased pu.1 expression in the yolk and RBI (arrow), at 24 hpf. Anterior is to the 
left. D’-F’) Corresponding ventral views of pu.1 expression in the yolk. Numbers on the 
lower right-hand corner indicate the number of embryos that had an expression pattern 
similar to the representative image. Scale bar is 500 µm for A and 100 µm for the rest. 
 
As mentioned earlier, F1 embryos were used for the evaluation of stag2b loss on 
haematopoiesis. Among the pool of F1 embryos evaluated, n=10/19 were mutant and of 
these mutant embryos n=6/10 showed reduced gata1a expression in the ICM at 24 hpf 
(Figure 4.23B). Among the wildtype embryos in the pool, n=8/9 showed normal gata1a 





Figure 4.22. Primitive erythropoiesis is normal in stag1bnz205 mutants at 24 hpf. 
Lateral views of a representative A) stag1b+ wild type homozygous embryo, B) 
stag1bnz205/+ heterozygous embryo and C) stag1bnz205 mutant homozygous embryo with 
normal gata1a expression in the ICM, at 24 hpf. Lateral views of representative D) 
stag1b+ wild type homozygous embryo, E) stag1bnz205/+ heterozygous embryo and F) 
stag1bnz205 mutant homozygous embryos showing unsuccessful pu.1 WISH staining. C’-
F’) Corresponding ventral views of pu.1 expression in the yolk. Anterior is to the left. 
Numbers on the lower right-hand corner indicate the number of embryos that had an 
expression pattern similar to the representative image. Scale bars are 500 µm for A, B 
and C and 100 µm for D, E and F.  
 
Among the pool of F1 embryos used for evaluation of pu.1 expression, n=15/22 embryos 
were mutant and of these mutant embryos n=10/15 showed relatively increased pu.1 
expression in the yolk (Figure 4.23D’) and ectopic expression in the ICM (Figure 4.23D, 
arrow). Amon the wildtype embryos in the pool, n=5/7 showed normal pu.1 expression 
(Figure 4.23C-C’).  
In summary, both stag1anz204 and stag2b F1 mutants showed defects in primitive 
haematopoiesis at 24 hpf. Loss of stag1a or stag2b led to an increase in myeloid cells at 
the expense of the erythroid lineage. As F1 embryos were used for evaluation of stag2b 
loss, the defects seen may not have been fully penetrant. Although ectopic pu.1 
expression was seen in a significant number of stag2b mutants, the penetrance of this 
phenotype is yet to be evaluated in germline mutants. Loss of stag1b had no effect on 




Figure 4.23. A moderate myeloid bias is seen in stag2b F1 embryos during 
primitive haematopoiesis at 24 hpf. Lateral views of a representative A) wildtype 
embryo with normal gata1a expression and B) stag2b F1 embryo with reduced gata1a 
expression (arrow) in the ICM at 24 hpf. Lateral views of a representative C) wildtype 
embryo with normal pu.1 expression and D) stag2b F1 embryo with moderately 
increased pu.1 expression in the yolk and ectopic expression in the ICM (arrow), at 24 
hpf. Anterior is to the left. C’, D’) Corresponding ventral views of pu.1 expression in the 
yolk. Numbers on the lower right-hand corner indicate the number of embryos that had 
an expression pattern similar to the representative image. All scale bars are 100 µm.  
 
4.4 Characterisation of definitive embryonic haematopoiesis  
Defects in definitive haematopoiesis were evaluated using WISH for two markers 
namely, runx1 and cmyb that are expressed in haematopoietic stem and progenitor cells 
(HSPCs) at 36 hpf. During embryonic development, HSPCs arise from the ventral wall 
of the dorsal aorta (VDA) where they express both runx1 and cmyb. Post-emergence, 
HSPC seeding in the CHT region is predominantly characterised by cmyb expression. 
Primers used for WISH probe synthesis are listed in Appendix table 2.  
 
4.4.1 HSPCs are downregulated in stag1anz204 mutants and unaffected in 
stag1bnz205 and stag2b F1 mutants at 36 hpf 
At 36 hpf, runx1 expression was significantly downregulated in the VDA of stag1anz204 
mutant homozygous embryos (Figure 4.24C-C’), compared to wild type siblings (Figures 
4.24A-A’). Among stag1anz204/+ heterozygous embryos, a similar reduction in runx1 




Figure 4.24. Definitive HSPCs are reduced in stag1anz204 mutants at 36 hpf. Lateral 
views of a representative A, A’) stag1a+ wild type homozygous embryo with normal 
runx1 expression, B, B’) stag1anz204/+ heterozygous embryo with reduced runx1 
expression in the VDA and C, C’) stag1anz204 mutant homozygous embryo with reduced 
runx1 expression in the VDA, at 36 hpf. The VDA region is magnified and reduced 
expression is indicated by arrows. Lateral views of a representative D, D’) stag1a+ wild 
type homozygous embryo with normal cmyb expression, E, E’) stag1anz204/+ 
heterozygous embryo with moderately reduced cmyb expression in the VDA (arrow) and 
CHT and F, F’) stag1anz204 mutant homozygous embryo with moderately reduced cmyb 
expression in the VDA (arrow) and CHT, at 36 hpf. The CHT region is magnified and 
reduced expression is indicated by arrows. Anterior is to the left. Numbers on the lower 
right-hand corner indicate the number of embryos that had an expression pattern similar 
to the representative image. All scale bars are 100 µm.  
 
The stag1anz204/+ heterozygous embryos remaining showed expression comparable to 
wild type. Expression of cmyb expression was found to be moderately reduced in both 
the VDA and CHT of stag1anz204 mutant homozygous embryos (Figure 4.24F-F’), 
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compared to wild type siblings (Figure 4.24D-D’) at 36 hpf. A similar reduction in cmyb 
expression was seen in the majority of stag1anz204/+ heterozygous embryos (n=13/20) 
(Figure 4.24E-E’) at 36 hpf. Overall, HSPC production was found to be compromised in 
stag1anz204 mutants. No changes in runx1 expression were seen in the VDA of 
stag1bnz205/+ heterozygous (Figure 4.25B-B’) and stag1bnz205 mutant homozygous (Figure 
4.25C-C’) embryos, compared to wild type siblings (Figure 4.25A-A’) at 36 hpf. 
Similarly, cmyb expression was also normal in the VDA and CHT of both heterozygous 
(Figure 4.25E-E’) and mutant homozygous embryos (Figure 4.25F-F’), compared to wild 
type siblings (Figure 4.25 D-D’).  
 
 
Figure 4.25. Definitive HSPCs are not affected in stag1bnz205 mutants at 36 hpf. 
Lateral views of a representative A, A’) stag1b+ wild type homozygous embryo, B, B’) 
stag1bnz205/+ heterozygous embryo and C, C’) stag1bnz205 mutant homozygous embryo, 
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showing normal runx1 expression in the VDA at 36 hpf. Lateral views of a representative 
D, D’) stag1b+ wild type homozygous embryo and E, E’) stag1bnz205/+ heterozygous 
embryos and F, F’) stag1bnz205 mutant homozygous embryo, showing normal cmyb 
expression in the CHT at 36 hpf. Numbers on the lower right-hand corner indicate the 
number of embryos that had an expression pattern similar to the representative image. 
Anterior is to the left. All scale bars are 100 µm.  
 
Among the stag2b F1 mutants evaluated, n=13/31 were mutants and the majority of these 
mutant embryos (n=9/13) showed normal runx1 expression in the VDA at 36 hpf (Figure 
4.26A-A’). As a sufficient number of F1 embryos could not be obtained, stag2b 
morphants were used as proxy to determine cmyb expression at 36 hpf. However, the 
posterior tissue in the majority of these embryos (n=39/46) was damaged by staining. 
The remaining embryos (n=7/46) showed wild type-like cmyb expression (Figure 4.26 




Figure 4.26. runx1+ HSPCs are not affected in stag2b F1 mutants at 36 hpf. Lateral 
views of a representative A) stag2b F1 mutant embryo with normal runx1 expression in 
the VDA and B) stag2b morphant with normal cmyb expression in the VDA and CHT, at 
36 hpf. Anterior is to the left. Numbers on the lower right hand corner indicate the fraction 
of embryos that had an expression pattern similar to the representative image. All scale 
bars are 100 µm.  
 
In summary, definitive haematopoiesis was affected in stag1anz204 mutants. The number 
of HSPCs expressing runx1 and cmyb was reduced in the VDA and the CHT of mutants 
at 36 hpf. Of note, no concurrent loss of expression was seen in anterior regions of 
embryos. As with primitive haematopoiesis, stag1bnz205 mutants showed no changes in 
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definitive haematopoiesis. While it was evident that runx1 expression in the VDA of 
stag2b F1 mutants was not affected, the effect of stag2b loss on cmyb expression in the 
CHT is unknown.  
In conclusion, in contrast to the common theme of developmental abnormalities seen, 
stag1/2 mutant lines showed significant differences in embryonic haematopoiesis. Loss 
of stag1a resulted in increased runx1 expression and later primitive myeloid skewing. 
On the other hand, stag2b loss led to a selective reduction of runx1 expression in the 
PLM , a phenotype similar to that seen in rad21nz171 mutants (Horsfield et al., 2007). 
Later, stag2b F1 mutants showed reduced primitive gata1a expression and ectopic pu.1 
expression. During definitive haematopoiesis, HSPC numbers were reduced in 
stag1anz204 mutants compared to wild type siblings and unchanged at least in the VDA of 
stag2b F1 mutants. 
 
4.5 Preliminary characterisation of defects in the specification 
of tailbud progenitors in stag1bnz205 mutants 
The predominant morphological abnormalities seen in the stag1/2 mutants involved 
pigment cell displacement, notochord development, and body axis patterning. Although 
these defects were observed in both the stag1bnz205 and stag2bnz207 mutant lines, 
embryonic haematopoiesis was affected only in the latter. To evaluate if stag1b is 
required for non-haematopoietic processes, I evaluated the expression of markers that 
label tailbud progenitors that are involved in notochord formation and axis patterning in 
stag1bnz205 mutant embryos. 
Neuromesodermal progenitors (NMPs) and midline progenitor cells (MPCs) which are 
specified during gastrulation reside in the tailbud. NMPs give rise to the spinal cord and 
somites while MPCs give rise to the midline structures namely, floor plate, notochord, 
and hypochord. These midline structures provide support for patterning the body axis 
and are marked by col2a1 expression. A second marker sox2 is expressed in the 
hypochord and in the neural plate or presumptive spinal cord. The expression of sox2 in 
NMPs drives neural fates at the expense of mesoderm formation. Given its expression in 
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the neural plate border, sox2 is also implicated in neural crest induction. WISH was 
performed using probes for col2a1 and sox2 on stag1bnz205 mutants at 14 ss. 
Expression of col2a1 in both stag1bnz205/+ heterozygous (n=11 genotyped) (Figure 4.27B) 
and stag1bnz205 mutant homozygous embryos (n=4 genotyped) (Figure 4.27C) was 
similar to wild type siblings (n=1 genotyped) (Figure 4.27A), at 14 somites of 
development. However, the notochord was characterised by kinks (arrows) in the mutants 
which may be predictive of future ossification defects.  
 
 
Figure 4.27. Characterisation of tailbud progenitor specification in stag1bnz205 
mutants at 14 somites. Lateral views of a representative A) stag1b+ wild type sibling, 
B) stag1bnz205/+ heterozygous embryo and C) stag1bnz205 mutant homozygous embryo, 
all with normal col2a1 expression at 14 somites. Arrows indicate notochord kinks in 
mutants. Lateral views of a representative D) stag1b+ wild type sibling with normal sox2 
expression, E) stag1bnz205/+ heterozygous embryo and F) stag1bnz205 mutant 
homozygous embryo with normal sox2 expression in the brain, hypochord, and spinal 
cord, at 14 somites. Expansion of sox2 expression into the tailbud mesoderm is 
indicated by arrows. Anterior is to the left. b, brain, sc, spinal cord, hy, hypochord. Scale 
bars are 100 µm.  
 
Expression of sox2 was normal in the brain, anterior regions of the presumptive spinal 
cord and hypochord of stag1bnz205/+ heterozygous (n=2 genotyped) and stag1bnz205 
mutant homozygous (n=4 genotyped) compared to wild type siblings (n=1 genotyped). 
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However, expression of sox2 in the posterior spinal cord was diffuse, and expanded into 
the nearby mesoderm of mutants (Figure 4.27E-F, arrows) compared to wild type (Figure 
4.27D). These preliminary observations require further investigation with more embryos 
and at different developmental stages. 
 
Table 4.1. Summary of stag1/2 mutant phenotypes. 
 stag1a stag1b stag2a stag2b 
Mutation type Germline Germline None 
recovered 
Germline (F1 
used for WISH) 







role in early 
embryogenesis 
























tic stem and 
precursor cells 
No defects No defects 
 
The effects of stag1/2 loss on embryonic development and haematopoiesis are 
summarised in Table 4.1. In summary, stag1a loss was asymptomatic while stag1b and 
stag2b loss resulted in developmental delay accompanied by craniofacial and 
pigmentation defects. While the loss of stag1a affected both primitive and definitive 
embryonic haematopoiesis, the loss of stag2b in F1 mutants only affected primitive 
haematopoiesis. In contrast, loss of stag1b did not affect haematopoiesis and preliminary 
evidence suggests a regulatory role in non-haematopoietic cell types. High maternal and 
ovary expression of stag2a suggest a possible role for stag2a in germ cell development 
and early embryogenesis. Thus, both unique and overlapping roles were identified for 
119 
 
the four stag paralogues in embryonic development and/or haematopoiesis suggesting 
sub-functionalisation in zebrafish. 
 
4.6 Discussion 
Characterisation of the cohesin stag1/2 zebrafish mutant lines revealed distinct functions 
for the four stag paralogues in embryonic development and haematopoiesis. Although 
developmental delay was seen, unlike rad21 mutants, loss of stag1/2 did not cause 
embryonic arrest and mutants were viable to adulthood. This is expected given the 
overlapping requirements of the stag paralogues in mitotic division. The necrosis 
phenotype seen in stag2b mutants may be caused by a transient mitotic arrest and may 
reflect a delay in switching between the paralogues. Differences in the number of mitotic 
cells can be detected using an anti-phosphohistone H3 antibody and Giemsa staining can 
be used to detect chromosomal abnormalities. Specific morphological abnormalities seen 
with stag1/2 loss were mild defects in jaw development and ectopic caudal fin 
pigmentation. Zebrafish models of cohesinopathies characterised by craniofacial 
dysmorphia and neurodevelopmental anomalies are associated with loss of both cohesin 
subunits such as rad21 (Schuster et al., 2015) and cohesin-regulatory factors like nipbl 
(Muto et al., 2011) and esco2 (Monnich et al., 2011). Early defects in cranial 
development were seen only in stag1bnz205 mutants, in the form of microcephaly at 36 
hpf. Loss of function variants in cohesin subunits have been associated with incomplete 
division of embryonic forebrain in humans and have been reported to be particularly 
severe in patients with mutations in STAG2 (Kruszka et al., 2019). In addition, STAG2 
mutant cases are associated with a higher incidence of spinal anomalies.    
Both craniofacial and pigment cell types are derived from the transient population of 
multipotent neural crest cells. These cells are induced from the neural plate border (NPB) 
and migrate dorsally between the epidermis and somites or medially through the somites 
to reach various regions in the embryo. Pigment cells migrate via the dorsal pathway (M. 
W. Klymkowsky et al., 2010). As no abnormalities were seen in somitogenesis in 
mutants and as pigment cells reached the caudal end of embryos, loss of stag1/2 may not 
affect dorsal neural crest cell migration. Defects in neural crest derivatives seen in these 
mutants may be due to earlier defects in neural crest cell induction and later specification 
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influenced by signals from surrounding tissue. For example, active Wnt signalling in the 
NPB is required for neural crest induction and later secreted Wnt signals serve as 
regulators of cell fate determination (Lewis et al., 2004). Characterisation of runx1 
expression at 12 somites showed no significant changes in RBN neurons in the stag1/2 
mutants. This is of importance as both the RBN and neural crest cells are specified from 
the NPB and may share common developmental regulators (C. C. Rossi et al., 2009).  
Defects in swim bladder inflation co-existing with gut anomalies were also seen in all 
four mutant lines but at low frequencies. The gut is derived from the endoderm and has 
been previously implicated alongside cardiac patterning defects in nipbl morphants 
(Muto et al., 2011). While stag1/2 mutants showed normal cardiac morphogenesis, 
cardiac oedema was frequently seen in stag2a and stag2b morphants. However, cardiac 
oedema is a non-specific phenotype commonly seen with the use of morpholinos (Eve et 
al., 2017). Although cardiac patterning was unaffected, mutants presented with 
patterning defects in other tissues. The most striking was the dorsal and ventral secondary 
tails observed in stag2b crispants. The presence of ventral secondary tails has been 
previously associated with loss of BMP signalling, a known lateralising factor in 
zebrafish development (Y. Yang & Thorpe, 2011). However, no previous dorsal tail 
phenotypes have been reported in zebrafish. During the establishment of the mediolateral 
axis in zebrafish embryos, FGF and Wnt serve as medialising factors and oppose the 
action of BMP (Goto et al., 2017; Polevoy et al., 2019; Row et al., 2018). Hence it is 
possible that stag2b could function in balancing signal outputs from these three networks.  
While stag1anz204 mutants were asymptomatic, depletion of stag1a by MO led to severe 
anteroposterior patterning defects. This raises two possibilities: either the stag1anz204 
mutants are not null mutants or the phenotypes seen in morphants are due to off-target 
effects. Injecting the stag1a MO into stag1anz204 mutants can help clarify these issues. If 
the stag1anz204 mutants are less sensitive to MO depletion than wildtype controls, they 
are null mutants and the MO phenotype is not due to off-target effects. On the other hand, 
if the stag1anz204 mutants are more sensitive to MO depletion, then the mutation may only 
have led to a partial loss of function of stag1a. If the mutant and wildtype phenotypes are 
similar, then the MO phenotypes are due to off-target activity. 
As previously reported with mutations in cohesin components, heterozygous loss of 
stag1/2 was associated with haploinsufficiency. However, some heterozygous embryos 
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also presented with normal phenotypes in both the stag1bnz205 and stag2bnz207 mutant 
lines. This could be due to a difference in the severity of phenotypes conferred by the 
maternal and paternal alleles. Analysis of mRNA expression in stag1anz204 and stag1bnz205 
mutant homozygous embryos revealed that expression levels of stag paralogues other 
than the one targeted are also altered. In stag1anz204 mutants, all other stag paralogues 
were significantly downregulated. In contrast, in stag1bnz205 mutants, stag2a was 
significantly upregulated. Given similarities in mutant phenotypes and the 
interconnectedness of mRNA expression levels, it is difficult to ascertain the function of 
individual stag paralogues in embryonic development.   
Differences in the transcriptional regulation of key haematopoietic markers were 
observed in the stag1anz204 and stag2b F1 mutants. In the PLM, runx1 expression 
appeared de-constrained with stag1a loss and in contrast, reduced with stag2b loss at 12 
ss. These results support recent reports of a preferential interaction of STAG1 with 
insulators and STAG2 with enhancers (Cuadrado et al., 2012; Kojic et al., 2018; Aaron 
D. Viny et al., 2019). Reduction of gata1a expression seen in both mutants is consistent 
with loss of erythroid differentiation reported upon cohesin depletion in murine HSPCs 
(Mullenders et al., 2015; Sasca et al., 2019) and upon overexpression of mutant cohesin 
in human cord blood-derived CD34+ cells (Mazumdar et al., 2015). Cross-antagonism 
between the gata1a erythroid and pu.1 myeloid lineages was observed in the form of 
increased pu.1+ cells in stag1anz205 mutants and increased and ectopic pu.1+ cells in 
stag2b F1 mutants at 24 hpf. Spatial differences in pu.1 expression further suggest that 
specification of mature myeloid cell types may be altered in these mutants. This can be 
clarified using WISH analysis with lineage markers such as macrophage-specific mpeg 
and granulocyte-specific lyz and mpx. As myeloid expansion is frequently accompanied 
by downregulation of the lymphoid lineage, it is of interest to evaluate the expression of 
the T-cell marker rag1 in the thymus. In summary, the myeloid skewing phenotypes 
observed in stag1/2 mutants are indicative of MPN-like disease and the incidence and 
latency of this phenotype in the adult kidney marrow remains to be evaluated. 
The effect of cohesin loss could not be previously studied using zebrafish as the existing 
rad21nz171 mutants die before definitive blood development is complete (Horsfield et al., 
2007). Loss of both HSPC markers in stag1anz204 mutants indicates a role for cohesin in 
HSPC specification. These results are however in contrast to previous studies where 
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cohesin depletion resulted in increased self-renewal of HSPCs (Galeev et al., 2016; 
Mazumdar et al., 2015; Mullenders et al., 2015; Aaron D. Viny et al., 2019). In addition, 
increased cohesin expression is required during differentiation to facilitate dynamic 
changes in gene expression whereas it has little role in maintaining steady-state gene 
expression (Sasca et al., 2019). Therefore, the HSPC defects seen with stag1a loss may 
not be related to HSPC maintenance but rather an impairment of HSPC specification. 
A recent study reported an increase in HSPC-derived pu.1 myeloid compartment with 
nipblb loss in zebrafish embryos. This phenotype was caused by hyperactivation of 
canonical Wnt pathway (Mazzola et al., 2019a). In a previous study by the same authors, 
nipblb loss was reported to downregulate Wnt signalling at <48 hpf and affect neuronal 
development (Pistocchi et al., 2013). Loss of function mutants for nipblb and stag 
paralogues in zebrafish share several common phenotypes including body axis 
patterning, and endoderm specification. It is possible that the stag paralogues may also 
have similar Wnt modulatory functions in zebrafish development. Dysregulation of the 
Wnt signalling pathway has been reported in AML by several groups (Staal et al., 2016).  
While stag1b loss affected neither primitive embryonic haematopoiesis nor HSPC 
production, it led to ectopic expression of runx1 in the yolk and of sox2 in the tailbud 
mesoderm. Whether such ectopic expression is a consequence of disrupting cohesin 
STAG1-associated insulator activity or simply a non-specific phenotype needs further 
evaluation. Furthermore, expression of sox2 in MPCs is regulated by canonical Wnt 
signalling (Row et al., 2018). Evaluation of MPC-derived midline structures 
characterised by col2a1 labelling showed no major changes. Kinks seen in the notochord 
could be an early indicator of future notochord defects in mutants (Gray et al., 2014).  
Collectively, the zebrafish stag1/2 mutants described here recapitulate the mild spectrum 
of craniofacial and neurodevelopmental phenotypes seen in STAG2 mutant 
cohesinopathy patients and provide an opportunity to uncover the biological pathways 
implicated in these disorders. The haematopoietic phenotypes imparted by stag1a and 
stag2b mutations indicate non-redundant roles for the two subunits in transcriptional 





5 Modelling acute myeloid leukaemia in zebrafish 
5.1 Background 
Acute myeloid leukaemia (AML) is characterised by combinatorial mutations which are 
necessary for malignant transformation. While the loss of function of the cohesin 
complex can perturb haematopoiesis, cohesin mutations alone are not sufficient to cause 
leukaemia. Among the genes that are most frequently co-mutated with cohesin subunit 
STAG2 is the epigenetic regulator TET2. In a recent study analysing a cohort of 1540 
AML patients, 16% had mutations in the STAG2 subunit of which 14% had an additional 
mutation in the TET2 gene (Papaemmanuil et al., 2016). Mutations in TET2 are non-
pathogenic on their own and occur mostly as initiating events in the hierarchy of AML 
mutations. This is based on two major findings in multiple studies: (1) TET2 mutations 
are found in asymptomatic elderly individuals with clonal haematopoiesis (Busque et al., 
2012; Young et al., 2016) and, (2) mutations occur with high variant allele frequencies 
in AML cases including in AML with myelodysplasia (Hirsch et al., 2018; T. L. Lin et 
al., 2014).  
Zebrafish have well-conserved orthologues of all three human TET family genes TET1, 
TET2, and TET3. The two catalytic domains critical for enzymatic activity namely, 
cysteine (Cys)-rich region and a double-stranded β-helix (DSBH) or 2-oxoglutarate-Fe 
(II) dependent dioxygenase domain are well conserved in all three zebrafish TET 
proteins. While zebrafish tet1 is expressed in the anterior head structures, tet2 and tet3 
are expressed in embryonic haematopoietic tissue, in the intermediate cell mass (ICM) at 
22 hpf and ventral wall of the dorsal aorta (VDA) 36 hpf  (Ge et al., 2014).  
The effects of tet2 loss in zebrafish haematopoiesis were previously studied by different 
groups, with inconsistent haematopoietic findings however. In tet2 mutants generated by 
zinc finger nuclease (ZFN) (E. Gjini et al., 2015) or TAL effector nuclease (TALEN) 
based editing (C. Li et al., 2015), no defects are seen in either primitive or definitive 
embryonic haematopoiesis. Double mutants for tet2 and tet3 using TALENs also show 
normal primitive haematopoiesis but have significant downregulation of haematopoietic 
stem and progenitor cells (HSPC) markers. It was hence speculated that tet3 could replace 
tet2 to some extent in embryonic haematopoiesis. In contrast, a recent study found that 
maternal-zygotic loss of tet2 generated by CRISPR mutagenesis causes downregulation 
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of all primitive haematopoietic lineages with no change in definitive HSPC-derived 
lineages (Rajan et al., 2018). Lastly, a study that assessed morpholino-mediated tet2 
knockdown observed significant reductions in the primitive erythroid lineage and in 
HSPCs characterised by cmyb expression (Ge et al., 2014).  
Discrepancies between these studies could be due to differences in specificity of the 
editing methods used and the region on the tet2 gene that was targeted. Both ZFN and 
TALEN editing targeted exons 7 and 8 respectively, which encode the functional DSBH 
domain, while CRISPR editing targeted early exon 2. To evaluate the effect of 
combinatorial loss of cohesin with tet2, I generated a highly specific loss of function tet2 
mutant by using CRISPR-Cas9 to target the region around the oxygenase domain of tet2. 
In sections 5.2 and 5.3, I describe the generation and characterisation of a tet2 zebrafish 
mutant line: tet2nz203. 
Mutations in cohesin subunit genes are frequently seen in core-binding factor AML 
(CBF-AML), an AML subtype that is characterised by chromosomal alterations in the 
CBF complex namely t(8;21)(q22;q22) and inv(16)(p13q22). These alterations result in 
the fusion proteins, RUNX1-RUNX1T1 and CBFB-MYH11, respectively. Mutations in 
cohesin co-occur with t(8;21)(q22;q22) but never in patients with inv(16)(p13q22) 
(Duployez et al., 2016; R. Sood et al., 2016). We obtained a transgenic zebrafish line, 
Tg(runx1+23:runx1-runx1t1:polyA), from Dr. Andrew Wood, University of Auckland. 
This line expresses RUNX1-RUNX1T1 fusion protein under the control of the +23 runx1 
enhancer, an enhancer identified in mouse that is also active in zebrafish haematopoiesis 
(Marsman et al., 2017; Ng et al., 2010). The RUNX1-RUNX1T1 fusion was expressed in 
the background of cohesin mutations in rad21 or stag1/2 to analyse combinatorial effects. 
The characterisation of combinatorial mutants generated by crossing cohesin mutants 
rad21nz171 and stag1/2 to the Tg(runx1+23:runx1-runx1t1:polyA) is described in Section 
5.4. 
Germline mutations in genes that are essential for embryonic development lead to early 
embryonic lethality, such as in rad21nz171 mutants (Horsfield et al., 2007), or cause strong 
developmental phenotypes that may mask other aberrations, such as in stag1/2 mutants 
(described in Chapter 4). Importantly, mutations seen in AML are somatic in nature and 
are restricted to the haematopoietic compartment. Existing animal models of AML are 
characterised by germline mutations and do not recapitulate these features. I created 
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zebrafish mutant lines that continually generate de novo mutations that can be restricted 
to haematopoietic cells using tissue-specific promoters. CRISPR guides previously 
identified for stag1/2 and tet2 were used. I describe the creation of these lines in section 
5.5. In section 5.6, the use of flow cytometry was tested as a readout for diagnosing 
haematopoietic alterations in whole kidney marrow (WKM) of adult zebrafish mutants.  
 
5.2 Development of the tet2nz203 zebrafish mutant line 
5.2.1 Identification of efficient tet2 sgRNAs 
A total of three sgRNAs were evaluated for the tet2 gene. Two sgRNAs OC1 and OC2 
were selected based on in silico analysis for high on-target editing efficiency at the 
functional oxygenase domain and predicted low off-target activity. The sequence for the 
sgRNA OC3 was provided by the Goll lab based on their previous TALEN mutagenesis 
study (C. Li et al., 2015). In silico efficiencies were determined using three different 
tools, as described in Chapter 3. Efficiencies for the tet2 sgRNAs are listed in Table 5.1 
and their locations on the tet2 gene are shown in Figure 5.1A. Sequences for sgRNAs are 
shown in Appendix table 4. The sgRNA OC1 was designed to target exon 6, cutting 
within the cysteine-rich domain and upstream of the oxygenase domain. OC1 had the 
highest predicted efficiency on two out of three tools. The sgRNAs OC2 and OC3 
targeted exons 9 and 8, respectively, cutting within the oxygenase domain. No significant 
off-targets were predicted for any of the sgRNAs. No polymorphisms were detected at 
the target sites of uninjected controls by sequencing. 
 
Table 5.1. In silico analysis of tet2 sgRNAs. 






OC1 6 65.2 51 445 
OC2 9 52.69 Not found* 715 
OC3 8 57.78 32 132 




Following in silico screening, one-cell stage wild type zebrafish embryos were injected 
with RNPs comprising of 50 pg sgRNA and 160 pg Cas9 protein. T7E1 endonuclease 
assays were performed on seven embryos per injected batch to confirm editing. In vivo 
editing efficiencies were found to be 71% for both OC1 and OC2 (n=5/7 crispants), and 
82% (n=6/7 crispants) for OC3. Representative mutant band patterns generated by each 
sgRNA upon T7E1 analysis are shown in Figure 5.1B. Distinct band patterns were seen 
for each sgRNA (lanes 2, 4 and 6). No mutant bands were seen in corresponding 
uninjected controls (lanes 1, 3 and 5).  
 
 
Figure 5.1. CRISPR editing strategy used to generate loss of function tet2 
zebrafish mutants. A) Exon diagram of the tet2 gene with locations of three sgRNAs 
used for editing. The OC1 sgRNA that was selected to establish stable lines is denoted 
by a red triangle. The other two sgRNAs OC2 and OC3 are denoted by yellow triangles. 
The cysteine-rich functional domain present on exon 6 is highlighted in orange. The 
DSBH dioxygenase domain spans exon 7 to 10 and is highlighted in green. Scale bar 
indicates 100 bases. B) Representative T7E1 analysis on a 2% (wt/vol) DNA agarose 
gel. Lanes 1 and 2 correspond to OC1 target amplicons in an uninjected control and in 
an injected crispant, respectively. Lanes 3 and 4 correspond to OC3 target amplicons in 
an uninjected control and in an injected crispant, respectively. Lanes 5 and 6 correspond 
to OC2 target amplicons in an uninjected control and in an injected crispant, 
respectively. Lane 8 corresponds to 1kb Plus ladder with marker sizes in bp shown on 




































































































































































































































































































Figure 5.2. Deep sequencing analysis of mutations generated in tet2 crispants. 
Ten crispants (CR1 to CR10) were analysed per sgRNA. Controls included six 
uninjected embryos (C1-C6) and two embryos injected with Cas9 protein (CA1 and 
CA2). CrispRVariants plots of the A) OC1 target locus in controls, B) OC1 target locus 
in crispants, C) OC2 target locus in controls, D) OC2 target locus in crispants, E) OC3 
target locus in controls and F) OC3 target locus in crispants. The reference strand is 






















































cut site is located 3 bp upstream of the PAM site and is denoted by a vertical line on the 
plot. Pairwise alignments are shown for each variant in the left panel and are listed by 
order of location from the cut site. Variants are denoted as SNV, single nucleotide 
variant; D, deletion; I, insertion. Deletions are indicated by dashes ‘-‘ and insertions by 
symbols above the respective alignments. The inserted sequences are shown in the 
legend at the bottom of the plot. The right panel shows the frequency of variants with 
the header row indicating the total number of reads per sample. Frequencies are colour 
coded based and the corresponding legend is shown on the right.  
 
To determine the nature of mutations generated, deep sequencing using MiSeq was 
performed. The MiSeq libraries were constructed from the gDNA of ten crispants per 
sgRNA. Six uninjected embryos and two embryos injected with Cas9 protein only were 
used as controls. The predominant mutation generated by the OC1 sgRNA was -3:4D, a 
tetra-nucleotide deletion located 3 nucleotides upstream of the cut site (Figure 5.2B). Of 
note, this mutation showed a significantly higher frequency compared to all other 
mutations present within the same embryo. The average mutagenesis efficiency was 
found to be 31% for OC1. Of the three sgRNAs, OC2 generated the lowest frequency of 
indels and an average mutagenesis efficiency of 20% possibly due to an absence of 5’GG 
(Figure 5.2D). This sgRNA was not evaluated further. The sgRNA OC3 generated two 
predominant mutations namely, -3:4D and -1:3D (Figure 5.2F) and was characterised by 
an average mutagenesis efficiency of 52%. No significant mutations were detected in 
controls at all target sites (Figures 5.2A, 5.2C, and 5.2E). Crispants injected with OC1 or 
OC3 were raised to constitute the F0 generation. 
 
5.2.2 Recovery of stable tet2 mutants 
F0 fish were outcrossed and the resulting F1 embryos were analysed using T7E1 assays. 
Mutation patterns observed were similar to those observed in F0 crispants for the 
respective sgRNAs. Among the OC1 founders analysed, six out of eight had high 
mutagenesis efficiencies ranging from 50% to 77%. Among the OC3 founders analysed, 
four out of five had high mutagenesis efficiencies ranging from 33% to 66%. The most 
predominant mutation generated was -3:4D but a small percentage of fish also showed 
the presence of a second mutation, 13:4D. As these fish proved difficult to genotype they 
were not evaluated further. OC1 founders were used to establish the F1 generation.  
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Lines were raised from four different OC1 founder outcrosses. Once adults, the F1 fish 
were genotyped by fin clipping. The list of mutations recovered is shown in Table 5.2. 
Of note, the -3:4D mutation that was detected in the injected crispants by deep 
sequencing was also recovered. However, this mutation was only found in male fish and 
could not be propagated. The most predominant mutation generated was -2:3I, a non-
truncating missense mutation. Therefore a more pathogenic mutation in the form of -7:8I 
mutation was selected for propagation. 
Fish heterozygous for the -7:8I mutation were in-crossed and the resulting F2 embryos 
were genotyped using HRMA. Analysis using the Gene Scanning software revealed that 
heterozygotes could be readily identified based on their unique melt profiles (Figure 
5.3A). Wild type and mutant homozygous samples clustered together but could be 
separated by spiking a small amount of wild type DNA in a second HRMA assay. Post-
spiking, the mutant homozygotes acquired melt profiles similar to heterozygotes 
differentiating them from wild type homozygotes that showed no change (Figure 5.3B). 
Genotyping was further validated by Sanger sequencing (Appendix figure 15). The 
mutant allele was termed nz203. 
 
Table 5.2. List of heterozygous mutations recovered for tet2 with the OC1 sgRNA. 









Wild type 20 
Total screened 42 






Figure 5.3. The tet2nz203 mutation leads to a prematurely truncated protein with 
complete loss of the functional dioxygenase domain. A) Genotyping of F2 embryos 
using HRMA visualised as a difference plot using the Gene Scanning software. 
Heterozygous samples group separately. Wild type and mutant homozygous samples 
cannot be differentiated. B) Post-spiking with wild type DNA, wild type and mutant 
homozygous samples group separately. C) Wild type full-length protein containing the 
cysteine-rich (orange) and dioxygenase DSBH (green) functional domains. Positions of 
the catalytically important iron (blue stars) and 2-oxyglutarate residues (purple star) are 
also shown. D) Truncated tet2 mutant protein with partial loss of the cysteine domain 




The nz203 mutation was predicted to lead to a frameshift resulting in a stretch of 17 
aberrant amino acids followed by a premature stop codon. The mutant protein is 
characterised by a partial loss of the cysteine domain and a complete loss of the 
dioxygenase domain (Figure 5.3C-D). The mutation was homozygous viable and 
distribution of genotypes in the F2 generation (n=21 fish) was observed in the ratio of 
33% wild type homozygotes, 38% heterozygotes and 28% mutant homozygotes. 
 
5.3 Characterisation of tet2nz203 germline mutants 
5.3.1 tet2nz203 mutants have normal morphology 
The effect of the nz203 mutation on embryonic development was evaluated by 
morphological assessment of embryos obtained from in-crossing heterozygous fish. 
Subtle abnormalities were seen in a small percentage of embryos such as the presence of 
modestly curved trunks at 48 hpf and deflated swim bladders at 7 dpf.  
 
 
Figure 5.4. tet2nz203 mutation does not significantly affect development. Lateral 
views of a representative A) wild type control with normal morphology, B) mutant 
homozygous embryo with normal morphology and C) mutant homozygous embryo with 
modest trunk curvature, at 48 hpf. Anterior is to the left. Numbers on the lower right 
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corners indicate the number of embryos that had a morphology similar to the 
representative image. Scale bars are 100 µm.  
 
Representative embryos were genotyped and were found to be either heterozygous (n=3 
embryos) or mutant homozygous (n=6 embryos). Examination of subsequent generations 
of mutant homozygous embryos at 48 hpf, also showed similar bent trunk phenotype 
(Figure 5.4). Expression levels of tet2 mRNA were measured using RT-PCR on pools of 
embryos with known wild type or mutant homozygous genotype. Expression was 
normalised to two reference genes, β-actin and rpl13a. A significant downregulation in 
tet2 mRNA expression was observed in tet2nz203 mutants compared to wild type at 48 hpf 




Figure 5.5. tet2 mRNA expression is significantly downregulated in tet2nz203 
mutants at 48 hpf. Quantification of tet2 mRNA levels using RT-PCR in tet2nz203 
mutants compared to wild type. Three biological replicates were used for each group 
and each biological replicate comprised a pool of 30 embryos. The reference genes β-
actin and rpl13a were used for normalisation. Error bars are ± standard deviation (S.D.). 
Statistical significance was determined using t-test: ** p=0.0084.  
 
The nz203 mutation affects critical catalytic domains, therefore the enzymatic role of tet2 
in converting 5-methylcytosine (5mC) to 5-hydroxy methylcytosine (5hMC) should be 
compromised. Preliminary analysis using whole-mount immunofluorescence with an 
anti-5hMC antibody was carried out in zebrafish embryos at 48 hpf (Appendix figure 
16). A modest reduction in 5hMC expression was observed in heterozygous (n=3 
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embryos) and mutant homozygous embryos (n=4 embryos) compared to wild type (n=1 
embryo). This assay however needs further optimisation and the results obtained will 
need to be validated using the gold standard dot blot assay to quantify any reduction of 
5hMC levels in the tet2nz203 mutants. 
In summary, tet2nz203 mutants did not exhibit any major morphological abnormalities 
during embryonic development. Expression of tet2 mRNA was significantly 
downregulated in mutants and may lead to reduced 5hMC levels.  
 
5.3.2 Primitive erythropoiesis is downregulated in tet2nz203 mutants 
Primitive haematopoiesis was evaluated using WISH for the markers gata1a and pu.1 
that mark the erythroid and myeloid lineages respectively.  
 
 
Figure 5.6. Primitive erythropoiesis is downregulated in tet2nz203 mutants at 24 hpf. 
Lateral views of a representative A) tet2+ wild type embryo showing normal gata1a 
expression, B) tet2nz203/+ heterozygous embryo showing slightly reduced gata1a 
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expression and C) tet2nz203 mutant homozygous embryo showing reduced gata1a 
expression at 24 hpf. Lateral views of a representative D) tet2+ wild type embryo, E) 
tet2nz203/+ heterozygous embryo and F) tet2nz203 mutant homozygous embryo, all showing 
normal pu.1 expression at 22 hpf. Anterior is to the left. Numbers on the lower right 
corners indicate the number of embryos that had expression patterns similar to the 
representative image. Scale bars are 100 µm for A-C and 50 µm for D-F.  
 
At 24 hpf, tet2nz203/+ heterozygous embryos (Figure 5.6B) showed a mild reduction in 
gata1a expression in the ICM compared to wild type siblings (Figure 5.6A). In contrast, 
a drastic reduction in gata1a expression was observed in tet2nz203 mutant homozygous 
embryos (Figure 5.6C).  
Quantification of gata1a mRNA expression using RT-PCR of cDNA obtained from 
whole embryos also showed reduced expression of gata1a in mutants compared to wild 
type (Figure 5.7). However this difference was not statistically significant. No change in 
pu.1 expression was seen in either tet2nz203/+ heterozygous (Figure 5.6E) or tet2nz203 
mutant homozygous embryos (Figure 5.6F) compared to wild type siblings (Figure 
5.6D), at 22 hpf. 
 
 
Figure 5.7. gata1a mRNA expression is reduced in tet2nz203 mutants at 48 hpf. 
Quantification of gata1a mRNA levels using RT-PCR in tet2nz203 mutants compared to 
wild type. Three biological replicates were used per group and each biological replicate 
comprised a pool of 30 embryos. The reference genes β-actin and rpl13a were used for 
normalisation. Error bars are ± S.D. and statistical significance was determined using t-




5.3.3 HSPC production is compromised in tet2nz203 mutants 
Definitive haematopoiesis was evaluated using WISH for two HSPC markers runx1 and 
cmyb at 36 hpf. A dramatic reduction in runx1 expression was observed in the VDA of 
tet2nz203 mutants (Figure 5.8B) compared to wild type (Figure 5.8A) at 36 hpf, while 
expression in other regions was largely unaffected. Expression of the cmyb marker was 
also reduced in tet2nz203 mutants (Figure 5.8D) compared to wild type (Figure 5.8C) at 
36 hpf. While expression was reduced throughout the embryo, differences were 
especially pronounced in the caudal haematopoietic tissue (CHT) region. Thus, the 
number of HSPCs expressing runx1 and cmyb is reduced in tet2nz203 mutants.  
 
 
Figure 5.8. HSPC production is affected in tet2nz203 mutants at 36 hpf. Lateral views 
of a representative A), A’) tet2+ wild type embryo showing normal runx1 expression and 
B), B’) tet2nz203 mutant homozygous embryo showing reduced runx1 expression in the 
VDA (insets) at 36 hpf. Lateral views of a representative C), C’) tet2+ wild type embryo 
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showing normal cmyb expression and D), D’) tet2nz203 mutant homozygous embryo 
showing reduced cmyb expression in the CHT (insets) at 36 hpf. Anterior is to the left. 
Numbers on the lower right corners indicate the number of embryos that had expression 
patterns similar to the representative image. Scale bars are 100 µm for A and C, and 50 
µm for B and D.  
 
In summary, both primitive and definitive embryonic haematopoiesis were affected in 
tet2nz203 mutants. Downregulation of gata1a expression suggests that primitive 
erythropoiesis was downregulated, while no change in pu.1 expression suggests that 
myelopoiesis was intact at 24 hpf. The number of HSPCs was reduced in the VDA and 
CHT, marked by reduction of runx1 and cymb expression at 36 hpf. 
 
5.4 Characterising combinatorial AML mutations in zebrafish 
To evaluate the consequences of co-occurrence of cohesin mutations with other AML, 
combinatorial mutant zebrafish were generated. Heterozygous adult fish carrying single 
mutations were crossed and the resulting embryos were characterised. Combinatorial loss 
of the cohesin subunit mutations with tet2 or the runx1-runx1t1 translocation were 
evaluated. No significant developmental phenotypes were seen with heterozygous loss of 
tet2 in combination with heterozygous loss of cohesin subunits rad21 or stag1b. Given 
time constraints and low stock numbers, combinations with other cohesin subunits stag1a 
and stag2b could not be evaluated. 
 
5.4.1 The Tg(runx1+23:runx1-runx1t1:polyA) transgenic line 
The Tg(runx1+23:runx1-runx1t1:polyA) transgenic line expresses a human RUNX1-
RUNX1T1 fusion under the control of a mouse Runx1+23 enhancer, which actively 
drives expression of the fusion gene in zebrafish haematopoietic tissue. Expression is 
seen in the rostral blood island (RBI) and ICM at 24-28 hpf. The line also carries an 
EGFP transgenesis marker under the control of the zebrafish heart-specific promoter, 
cmlc2 within the same construct. The presence of the fusion can be determined by EGFP 
expression in the heart beginning from 28 hpf. Alternatively, genotyping can be 
performed by conventional PCR using primers that amplify a 448 bp region across the 
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fusion (Figure 5.9C). PCR products are electrophoresed on an agarose gel. A positive 
PCR reaction indicates the presence of the fusion. 
 
 
Figure 5.9. Characteristics of Tg(runx1+23:runx1-runx1t1:polyA) transgenic line. 
A) A schematic of the vector construct used to generate the Tg(runx1+23:runx1-
runx1t1:polyA) transgenic line. B) A schematic of a 28 hpf zebrafish embryo showing 
the sites of runx1+23 expression in orange and expression of the heart-specific cmlc2 
EGFP transgenesis marker in green. C) Representative fin-clip genotyping PCR of the 
fusion region on a 1% (wt/vol) DNA agarose gel. Lanes 2-4 and 6-7 correspond to 
zebrafish positive for the fusion gene and lane 5 corresponds to zebrafish negative for 
the fusion. Lane 1 corresponds to 1kb Plus ladder with marker sizes in bp shown on the 
right. ICM, intermediate cell mass; RBI, rostral blood island.  
 
5.4.2 Mutations in the cohesin complex cooperate with runx1-runx1t1 to 
cause transient haematopoietic phenotypes 
The Tg(runx1+23:runx1-runx1t1:polyA) line was crossed to cohesin mutants with 
heterozygous loss of rad21 or stag1a. Because mutants were still being recovered for 
stag2b, combinatorial loss was instead evaluated by injecting the runx1-runx1t1 line with 
the OC22 stag2b sgRNA. The runx1-runx1t1 translocation in isolation, and in 
combination with rad21 loss, showed no phenotype at 36 hpf. In contrast, combinations 
with stag1a or stag2b loss led to a transient proliferative phenotype in the RBI. The RBI 
of embryos from these crosses had an overall abnormal morphology and appeared 
expanded. Abnormalities were more severe with stag1a (Figure 5.10C-C’) with some 
embryos further showing a transient accumulation of slow circulating cells in the CHT 
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at 36 hpf (Figure 5.10F-F’). While blood circulation was not completely disrupted, 
clumping of circulating cells leading to a slower rate of circulation than normal was 
observed (Appendix figure 17). In addition, anterior cardiac pooling of blood was 
observed in some embryos. In contrast, stag2b crispants with the translocation showed 
milder RBI phenotypes and the necrosis phenotype previously reported for stag2bnz207 
mutants was also seen in the majority of the injected embryos screened (Figure 5.10D-
D’). Follow-up characterisation using techniques such as EdU-incorporation is required 
to ascertain the number of proliferative cells in the RBI region. 
 
 
Figure 5.10. stag1a or stag2b loss in combination with runx1-runx1t1 expression 
leads to expansion of the RBI and CHT during zebrafish embryogenesis. Lateral 
views of a representative A), A’) wild type control with normal morphology, B), B’) runx1-
runx1t1+ embryo with normal morphology, C), C’) embryo from runx1-runx1t1 and 
stag1anz204/+ cross with abnormal RBI cell proliferation phenotype (red arrow), D), D’) 
runx1-runx1t1+ embryo injected with stag2b sgRNA showing mild RBI cell proliferation 
(red arrow) and necrosis (black arrow), at 24 hpf. Lateral views of a representative E), 
E’) wild type control with normal morphology and F, F’) embryo from a runx1-runx1t1 
and stag1anz204/+ cross with blood cell accumulation in the RBI and ICM (inset), at 36 
hpf. Anterior is to the left. Numbers on the lower right corners indicate the number of 
embryos that had a morphology similar to the representative image. Scale bar is 50 µm 
for C and 100 µm for the rest.  
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Embryos carrying the runx1-runx1t1 translocation in isolation or in combination with 
stag2b or rad21 loss presented with craniofacial and pigmentation defects at 4 dpf. While 
runx1-runx1t1+ embryos had ectopic pigments in the ventral trunk region (Figure 5.11B), 
this phenotype was not seen in combination with cohesin loss. Instead stag2b loss led to 
disruption of pigments along the lateral line as seen previously in stag2bnz207 mutants 
(Figure 5.11C). Embryos also developed cardiac oedema. While no striking 
abnormalities in pigmentation were seen with rad21 loss, defects in jaw development 
and residual hatching gland cells were seen at 4 dpf (Figure 5.11D). 
 
 
Figure 5.11. stag2b or rad21 loss in combination with runx1-runx1t1 expression 
amplifies craniofacial and pigmentation defects at 4 dpf. Lateral views of a 
representative A) wild type control with normal morphology, B) runx1-runx1t1+ embryo 
with a deformed jaw (black arrow) and ectopic ventral trunk pigments (red arrow), C) 
runx1-runx1t1+ embryo injected with stag2b sgRNA with a small head and deformed jaw, 
cardiac oedema (blue arrow), residual hatching gland cells (grey arrow) and reduced 
pigmentation along the lateral line (red arrow) and D) embryo from a runx1-runx1t1 and 
rad21nz171/+ cross with under-formed jaw (black arrow) and residual hatching gland cells 
(grey arrow), at 4 dpf. Anterior is to the left. Numbers on the lower right corners indicate 
the number of embryos that had a morphology similar to the representative image. Scale 
bars are100 µm.  
 
I then characterised erythro-myelopoiesis in runx1-runx1t1 and rad21nz171/+ combination 
mutants using WISH for gata1a and pu.1 markers at 24 hpf. Reduced gata1a expression 
was seen in the ICM of embryos carrying runx1-runx1t1 in isolation (n= 5 genotyped) 
(Figure 5.12B) and in combination with rad21nz171/+ (n= 3 genotyped) (Figure 5.12C), 
compared to wild type (Figure 5.12A) at 24 hpf. In contrast, aberrant pu.1 expression 
was seen in embryos carrying runx1-runx1t1 in isolation and in combination with 
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rad21nz171/+. Accumulation of pu.1+ cells was seen in the posterior ICM of both runx1t1-
runx1t1 only (n= 4 genotyped) (Figure 5.12E-E’) and runx1t1-runx1t1 in combination 
with rad21nz171/+ embryos (n= 4 genotyped) (Figure 5.12F-F’) compared to wild type 
(Figure 5.12D-D’) at 24 hpf.  
 
 
Figure 5.12. rad21 loss cooperates with runx1-runx1t1 to maintain reduced 
primitive erythropoiesis and dysregulated primitive myelopoiesis at 24 hpf. Lateral 
views of a representative A) wild type control with normal gata1a expression, B) runx1-
runx1t1 embryo with reduced gata1a expression in the ICM and C) runx1-
runx1t1/rad21nz171/+ embryo with reduced gata1a expression in the ICM at 24 hpf. Lateral 
views of a representative D), D’) wild type control with normal pu.1 expression, E), E’) 
runx1-runx1t1 embryo with ectopic pu.1 expression in the ICM and F), F’) runx1-
runx1t1/rad21nz171/+ embryo with ectopic pu.1 expression in the ICM, at 24 hpf. Anterior 
is to the left. Scale bars are 100 µm.  
 
In summary, cohesin mutations in combination with the runx1-runx1t1 translocation led 
to expansion of the RBI and CHT during early embryogenesis. Abnormalities at later 
stages included craniofacial and pigmentation defects. Preliminary characterisation of 
erythro-myelopoiesis in rad21/runx1-runx1t1 combinatorial mutants showed reduced 
primitive erythropoiesis accompanied by ectopic pu.1 expression in the ICM.  
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5.5 Creation and characterisation of tissue-specific mutations 
in zebrafish 
Mutations in AML arise in HSCs and multipotent progenitors and are propagated in a 
haematopoiesis lineage-restricted manner. To recapitulate this cell-autonomous property, 
zebrafish lines carrying tissue-specific mutations were created. Plasmids containing a 
target sgRNA under the control of a ubiquitous u6 promoter and a zebrafish codon-
optimised Cas9 mRNA tagged with EGFP under the control of a lineage-specific 
promoter were constructed. These plasmids also contained a heart-specific EGFP 
transgenesis marker driven by the cmlc2 promoter and Tol2 sites which allow for 
genomic integration of all the above-mentioned components (Ablain et al., 2015). The 
presence of both the sgRNA and Cas9 mRNA in the same construct would cause 
continual generation of de novo mutations governed by the spatiotemporal nature of the 
tissue-specific promoter used to drive Cas9 expression. Three different promoters were 
used to drive Cas9 expression, as listed below. 
(i) A ubiquitin (ubi) promoter was used to drive Cas9 expression in all tissues. 
Ubiquitous tet2 and stag2b mutant lines were generated using the previously identified 
sgRNAs OC1 and OC22. These lines were used as proof-of-principle for the vector 
system used here. 
(ii) A microfibril-associated protein 4 (mfap4) promoter was used to drive Cas9 
expression selectively in macrophages (Walton et al., 2015). Macrophage-specific tet2 
mutant lines were generated using the sgRNA OC1. 
(iii) A draculin (drl) promoter was used to drive Cas9 expression in mesendodermal 
progenitors. Early drl expression is seen both mesoderm and endoderm progenitors 
during gastrulation at 6 hpf and later becomes restricted to cardiovascular lineages 
including HSC precursors (Henninger et al., 2017; Mosimann et al., 2015; Prummel et 
al., 2019). drl-specific stag2b mutant lines were generated using the sgRNA OC22. 
In addition, three ‘no-sgRNA’ control lines were generated for each of the above 
promoters. These lines carry all components except the sgRNA insert. An overview of 




Figure 5.13. Outline of approaches adopted to generate tissue-specific mutants. 
The plasmid constructs that were injected into 1-cell zebrafish embryos and the resulting 
EGFP expression patterns at 24 hpf are shown for different tissue-specific mutants. 
Stable transgenic mutants were recovered and are to be used to generate an array of 
combinatorial mutants. Whole kidney marrow (WKM) analysis is to be used as an 
endpoint to determine disease induction. Processes shown in the grey panel have been 
completed and are discussed in this chapter.  
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One-cell stage zebrafish embryos are injected with respective plasmids and 
spatiotemporal expression of EGFP driven by the lineage-specific promoters is 
monitored during embryogenesis. Embryos were raised to adulthood and outcrossed to 
wild type WIKs. Successful transgenesis was determined by the presence of heart-
specific EGFP in the F1 generation. F1 adult fish with successful transgenesis are 
expected to carry an increased load of somatic mutations leading to a more penetrant 
disease phenotype which can be assessed by methods such as flow cytometry of the 
WKM. The tissue-specific mutants can further be crossed to previously generated 
germline mutant lines to determine the effects of tissue-specific gene loss in the 
background of a pre-existing mutation. Inter-crosses between tissue-specific mutants can 
accurately reveal cell type-specific disease mechanisms. For example, the introduction 
of cohesin mutations in the background of pre-existing tet2 mutation could delineate the 
processes involved in the evolution of clonal haematopoiesis to myeloid malignancies. 
Processes shown in grey in Figure 5.13 have been completed and are discussed in the 
subsequent subsections. 
 
5.5.1 Construction of tissue-specific CRISPR-Cas9 plasmids  
Multisite gateway cloning was performed to generate tissue-specific Cas9 mRNA 
construct. Individual components namely, 5’ entry tissue-specific promoter, middle entry 
Cas9-EGFP and 3’ entry polyA were cloned into a destination vector as detailed in 
Chapter 2. The destination vector was then linearised with BseRI and sgRNAs were 
ligated.  
A different approach was adopted for plasmids containing the mfap4 promoter, as the 
promoter sequence contained a BseR1 restriction site. The sgRNA was first inserted into 
the destination vector (Figure 5.14A) followed by the Gateway recombination. 
Successful sgRNA insertion was determined by sequencing upstream of the scaffold 
region (Figure 5.14B). Multisite recombination was verified by restriction digestion with 
EcoR1 to confirm the presence of all components (Figure 5.14C). 
Following this, 20 pg of the tissue-specific plasmid was mixed with 20 pg of Tol2 mRNA 
and injected into one-cell stage zebrafish embryos. The final plasmid maps and 




Figure 5.14. Construction of injectable tissue-specific CRISPR-Cas9 plasmids. A) 
Restriction digestion of #63156 pDestTol2CG2-U6:gRNA destination vector using 
BseR1 enzyme on a 0.8% (wt/vol) DNA agarose gel. Digested vector is shown in lane 3 
versus undigested in lane 2. B) Chromatogram showing insertion of tet2 sgRNA OC1 
upstream of the scaffold in the destination vector. C) Verification of successful 
recombination using restriction digestion with EcoR1 on a 0.8% (wt/vol) DNA agarose 
gel. Lanes showing successful recombination reactions are marked by an asterisk. 
Lanes 2-5 represent the cmlc2:EGFP;ubi:cas9-EGFP plasmid. Lanes 6-10 represent the 
cmlc2:EGFP;drl:cas9-GFP plasmid. Lanes 11-12 represent the cmlc2:EGFP;u6:OC1; 
mfap4:cas9-GFP plasmid. 1kb Plus ladder was used; marker sizes in bp are indicated 
on the left side for all gels.  
 
5.5.2 Development of stable transgenic tet2 mutant zebrafish lines 
Immune dysregulation resulting from TET2 loss is increasingly being recognised as a 
critical contributor to myeloid malignancies (Banerjee et al., 2019; Cull et al., 2018; Cull 
et al., 2017). While the effects of TET2 loss in HSPCs have been extensively studied, 
effects in differentiated cells remain underexplored. Here, I describe the generation of 
stable transgenic zebrafish mutant lines with ubiquitous or macrophage-specific tet2 loss. 
Tg(cmlc2:EGFP;u6:OC1;ubi:cas9-EGFP:polyA) ubiquitous embryos hereafter referred 
to as Tg(ubi:tet2) embryos and Tg(cmlc2:EGFP;u6:OC1;mfap4:cas9-EGFP:polyA) 
macrophage-restricted embryos hereafter referred to as Tg(mfap4:tet2) were generated. 
Tg(cmlc2:GFP;ubi:cas9-EGFP:polyA) hereafter referred to as Tg(ubi) and 
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Tg(cmlc2:GFP;mfap4:cas9-EGFP:polyA) hereafter referred to as Tg(mfap4) embryos 
that do not carry any sgRNAs served as background controls. 
 
5.5.2.1 Ubiquitous tet2 mutant lines 
Both Tg(ubi) and Tg(ubi:tet2) embryos showed ubiquitous EGFP expression in the 
somites, heart and head at 42 hpf (Figure 5.15). Unlike the early expression reported from 
4 hpf for the ubi promoter, expression was only observed beginning from 18 hpf. 
Expression of the heart-specific transgenesis marker was seen from 28 hpf. No major 
morphological abnormalities were seen. A small percentage of transgenic embryos 
showed a mild bent trunk phenotype [n= 7/19 for Tg(ubi) and n= 7/30 for Tg(ubi:tet2)].  
 
 
Figure 5.15. EGFP expression in Tg(ubi) and Tg(ubi:tet2) embryos at 42 hpf. Lateral 
representative A) brightfield, A’) EGFP fluorescence and A’’) merged images of a 
Tg(ubi) control embryo at 42 hpf. Lateral representative B) brightfield, B’) EGFP 
fluorescence and B’’) merged images of a Tg(ubi:tet2)  embryo at 42 hpf. EGFP 
expression is observed throughout the body of the embryos. Anterior is to the left. Scale 
bars are 100 µm.  
 
EGFP+ injected embryos were raised to adulthood and outcrossed. The resulting F1 
embryos showed cmlc2-driven but not ubi-driven EGFP expression. All embryos had 
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normal morphology. The presence of mutations in the F1 embryos was determined by 
T7E1 analysis (Figure 5.16). 
 
 
Figure 5.16. Mutations are seen in F1 embryos ubiquitously targeted for tet2 using 
the tissue-specific CRISPR system. T7E1 analysis of Tg(ubi:tet2) F1 embryos on a 
2% (wt/vol) DNA agarose gel. Lane 2 corresponds to a wild type control and lanes 3-6 
correspond to transgenic tet2 F1 embryos. 1kb Plus ladder was used; marker sizes in bp 
are indicated on the left.  
 
5.5.2.2 Macrophage-specific tet2 mutant lines 
Injection of the macrophage-specific vectors led to EGFP expression as early as 5.3 hpf 
in the yolk macrophages. By 24 hpf, expression was restricted to the RBI, anterior yolk 
and in regions of the brain, consistent with the previously reported presence of 
macrophages at these sites (Bennett et al., 2001). No circulating EGFP+ cells were seen. 
Post-36 hpf, only cmlc2-driven EGFP expression was observed. Some embryos showed 
background fluorescence in the somites at ~48 hpf even in the absence of the cmlc2-
driven EGFP.  
Both Tg(mfap4) and Tg(mfap4:tet2) embryos showed robust EGFP expression in the RBI 
(arrow), anterior yolk and head (Figure 5.17). No major morphological abnormalities 
were seen. Injection-associated bent trunk phenotypes were seen as before in a small 
percentage of transgenic embryos [n= 4/94 for Tg(mfap4) and  n=9/51 for 
Tg(mfap4:tet2)]. EGFP+ injected embryos were raised to adulthood and outcrossed. 
Embryos from one out of three founder fish showed EGFP expression and again only 
cmlc2-driven expression was observed. All embryos had normal morphology. 
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Genotyping these lines involves the extraction of genomic DNA from blood or flow-
sorted macrophages. Given time constraints mutagenesis could not be evaluated. 
 
 
Figure 5.17. EGFP expression in Tg(mfap4) and Tg(mfap4:tet2) embryos at 28 hpf. 
Lateral representative A) brightfield, A’) EGFP fluorescence and A’’) merged images of 
a Tg(mfap4) control embryo at 28 hpf. EGFP expression is seen in macrophages 
resident in the RBI region (white arrow), yolk sac and in the head. Lateral representative 
B) brightfield, B’) EGFP fluorescence and B’’) merged images of a Tg(mfap4:tet2) 
embryo injected at 28 hpf. EGFP expression is seen in macrophages resident in the RBI 
region (white arrow), yolk sac and in the head. In addition, vector-driven background 
EGFP expression is seen in some somites. Anterior is to the left. Scale bars are 100 
µm.  
 
In summary, transgenic zebrafish lines with ubiquitous and macrophage-restricted 
targeting of tet2 were successfully generated. Stable transgenesis was confirmed by 
cmlc2 expression in F1 embryos from both lines and additionally, by the presence of 
mutations in the Tg(ubi:tet2) line. Morphological development was normal in embryos 
from both lines consistent with that seen in tet2nz203 mutants. The bent trunk phenotypes 
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seen in some embryos could be due to stress or mild toxicity from injecting large vector 
constructs. 
 
5.5.3 Development of stable transgenic drl-specific stag2b mutant lines 
As described in Chapter 4, a wide range of phenotypical abnormalities was seen in 
stag2bnz207 mutants consistent with the multifaceted roles of the cohesin complex. To 
uncouple the haematopoiesis-specific effects, a mesendoderm-specific draculin 
promoter was used to restrict stag2b loss to all LPM derivatives which includes 
haematopoietic and cardiovascular lineages. Here, I describe the generation of stable 
transgenic zebrafish mutant lines with ubiquitous or draculin-specific stag2b loss. 
Tg(cmlc2:EGFP;u6:OC22;ubi:cas9-EGFP:polyA) ubiquitous embryos hereafter 
referred to as Tg(ubi:stag2b) embryos and Tg(cmlc2:EGFP;u6:OC22;drl:cas9-
EGFP:polyA)  draculin-restricted embryos hereafter referred to as Tg(drl:stag2b) were 
generated. Tg(cmlc2:GFP;drl:cas9-EGFP:polyA) hereafter referred to as Tg(drl) 
embryos that do not carry any sgRNAs served as background control. 
Although the reported expression for the drl promoter is from 9 hpf, EGFP expression 
in drl-injected embryos was observed only beginning from ~16 hpf. During early stages, 
drl expression is restricted to the lateral plate mesoderm and hence could be obscured by 
autofluorescence from the yolk. Tg(drl) control embryos showed weak EGFP expression 
in the dorsal aorta, heart, ICM and RBI, detectable up to 24 hpf (Figure 5.18A-A’’). In 
contrast, robust EGFP expression was seen in Tg(drl:stag2b) embryos with additional 
expression in some somite cells (Figure 5.18C-C’’). Tg(ubi:stag2b) embryos showed 
robust ubiquitous EGFP expression (Figure 5.18B-B’’). As with the mfap4 plasmids, drl-
driven EGFP expression in the somites was seen even in the absence of cmlc2 
transgenesis marker in some embryos.  
While Tg(drl) control embryos had normal morphology, Tg(ubi:stag2b) embryos (n= 
14/90) and Tg(drl:stag2b) embryos (n= 37/72) showed transient necrosis and a 
proliferative ICM at 24 hpf (Figure 5.18). A small percentage of non-fluorescent 
Tg(drl:stag2b) embryos also showed necrosis (n= 5/33). A quantitative representation of 
EGFP expression and necrosis phenotype observed at 24 hpf is shown in Figure 5.18C. 
At a later stage of 4 dpf, Tg(drl:stag2b) embryos showed abnormal caudal fin 
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pigmentation (n= 16/31), again independent of EGFP expression (EGFP+ and abnormal 




Figure 5.18. EGFP expression in embryos with ubiquitous and draculin-specific 
targeting of stag2b at 24 hpf. Lateral representative A) brightfield, A’) EGFP 
fluorescence and A’’) merged images of a Tg(drl) embryo with normal morphology at 24 
hpf. EGFP expression is seen in the ICM and heart. Lateral representative B) brightfield, 
B’) EGFP fluorescence and B’’) merged images of a Tg(ubi:stag2b) embryo showing 
necrosis and a proliferative ICM at 24 hpf. EGFP expression is seen in the ICM, RBI and 
heart in addition to expression in some somites. Lateral representative C) brightfield, C’) 
EGFP fluorescence and C’’) merged images of a Tg(drl:stag2b) embryo showing 
necrosis and a proliferative ICM at 24 hpf. EGFP expression is seen in the ICM, RBI and 
heart. Anterior is to the left. D) The distribution of GFP expression and morphological 
phenotypes at 24 hpf is shown. The number of embryos screened per line is shown 
above the columns. Scale bars are 100 µm.  
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Tg(ubi:stag2b) EGFP+ embryos were raised to adulthood and outcrossed. The resulting 
F1 embryos showed cmlc2-driven but not ubi-driven EGFP expression. As before, 
transient necrosis was observed in F1 embryos at 24 hpf. Beginning from 4 dpf, the 
presence of abnormal pigments and/or craniofacial defects were seen in F1 embryos (n= 
86/262) (Figure 5.19). Abnormalities were seen irrespective of EGFP expression. The 
presence of mutations was evaluated by HRMA (Figure 5.20). Representative embryos 
were validated by Sanger sequencing. 
 
 
Figure 5.19. Morphological abnormalities are seen in Tg(ubi:stag2b) F1 embryos 
at 10 dpf. Lateral views of a representative A) wild type control with normal morphology 
and B) Tg(ubi:stag2b) F1 embryo with pigmentation and craniofacial abnormalities, at 10 
dpf. Anterior is to the left. Scale bars are 500 µm.  
 
 
Figure 5.20. Mutations are seen in F1 embryos ubiquitously targeted for stag2b 
using the tissue-specific CRISPR system. HRMA analysis of Tg(ubi:stag2b) F1 
embryos. Melt curves of mutant embryos (red) cluster away from reference wild type 




In summary, transgenic zebrafish lines with ubiquitous and draculin-restricted targeting 
of stag2b were successfully generated. Stable transgenesis was confirmed by cmlc2-
driven EGFP expression in F1 embryos from both lines and additionally, by the presence 
of mutations in the Tg(ubi:stag2b) line. Abnormal morphological development with 
phenotypes similar to that seen in stag2bnz207 mutants was observed in both 
Tg(ubi:stag2b) and Tg(drl:stag2b) embryos. 
 
5.6 Characterisation of haematopoiesis in adult mutants 
Whole kidney marrow (WKM) is the primary site of HSPC-derived haematopoiesis in 
adult zebrafish. The WKM consists of four major subpopulations namely, erythrocytes, 
lymphocytes, myelomonocytes and immature precursors of all lineages. These 
subpopulations can be resolved based on their light scatter properties using flow 
cytometry (Traver et al., 2003). In myeloid malignancies, the relative proportions of 
haematopoietic subpopulations in the kidney are disrupted with skewing towards the 
myeloid lineage. Here, I evaluated the use of flow cytometry as a diagnostic tool to 
examine the WKM profile of rad21nz171/+ heterozygous mutants.  
 
5.6.1 Characterisation of WKM in rad21nz171/+ mutants by flow cytometry 
WKM was isolated from rad21nz171/+ heterozygous (n=3) and wild type (n=3) fish at 24 
months of age. Single-cell suspensions were prepared as described in Chapter 2 and 
subjected to flow cytometry. The four WKM populations were resolved using forward 
scatter (FSC) and side scatter (SSC). There was no statistically significant difference in 
the proportion of WKM subpopulations in rad21nz171/+ mutants compared to wild type 
(Figure 5.21). However, an increase in the precursor population was observed in 
rad21nz171/+ mutants compared to wild type with a mean composition of 9.9% in mutants 
compared to 6.6% in wild type. A decrease in the myelomonocyte population was 
observed in rad21nz171/+ mutants compared to wild type with a mean composition of 




Figure 5.21. WKM profiles of rad21nz171/+ mutant and wild type zebrafish 
assessed by flow cytometry. Representative scatter plots for WKM of A) a wild type 
fish and B) rad21nz171/+ heterozygous mutant, at 24 months of age. C) A comparison of 
the WKM subpopulations in rad21nz171/+ versus wild type fish is shown. Subpopulations 
are represented as % of the total cells gated. Error bars are ± S.D.  
 
Although these results point towards an increase in immature precursors accompanied a 
decrease in myeloid differentiation in rad21nz171/+ mutants, the flow cytometry protocol 
clearly requires further optimisation. While the overall distribution was similar to that 
previously reported by others (Traver et al., 2003), the haematopoietic subpopulations 
were more scattered making it difficult to gate. Moreover, a group of cells with higher 
side scatter properties were also seen. These could potentially be non-haematopoietic 




Mutations in AML are combinatorial in nature and occur as clonal events restricted to 
the haematopoietic lineage. While the presence of a mutational hierarchy in AML has 
become clear with recent whole-exome sequencing studies of AML patients (Benton et 
al., 2016; Greif et al., 2018), determining the significance of mutation ordering and which 
mutation combinations are the most relevant to pathogenesis remains challenging. 
Cohesin mutations are recognised as founding or initiating events that co-operate with 
other mutations such as in RUNX1, SRSF2, TET2 and DNMT3A or translocations such 
as RUNX1-RUNX1T1 to cause AML. Cohesin mutations are part of the underexplored 
spectrum of AML mutations and animal models that recapitulate the cohesin mutant 
AML phenotype are lacking. In contrast, although epigenetic regulators are well-studied 
and multiple mutant animal models have been developed, these are predominantly based 
on temporally inducible ubiquitous germline mutations (Celik et al., 2015; Meyer et al., 
2016; L. Yang et al., 2016). Hence they fail to recapitulate the somatic and 
haematopoiesis-restricted nature of mutations seen in AML. 
Another challenge that remains is determining the disease mechanisms behind clonal 
haematopoiesis evolution to malignancy. In a first comprehensive study to address this, 
Loberg et al. showed that the induction of Npm1 mutations after the development 
Dnmt3a-mediated clonal haematopoiesis in mice led to myeloproliferative disorders 
accompanied by mutations in Ras-MAPK pathway genes. Subsequent bone-marrow 
transplantation lead to AML in recipient mice accompanied by mutations in additional 
signalling pathways such as Ptpn11 and Flt3 (Loberg et al., 2019). 
Here, combinatorial zebrafish cohesin mutants carrying mutations in cohesin and in tet2 
or the runx1-runx1t1 translocation were generated. To clarify the inconsistencies seen 
with existing tet2 zebrafish mutant models, CRISPR-Cas9 was used to generate the 
zebrafish mutant line, tet2nz203. Consistent with previous studies (E. Gjini et al., 2015; C. 
Li et al., 2015), loss of tet2 did not affect morphological development during 
embryogenesis. In zebrafish, tet2 is not maternally deposited and 5hMC levels are only 
detectable from the start of segmentation indicating that it may not be required for early 
embryogenesis (Almeida et al., 2012). As the tet2nz203 mutants were homozygous viable 
to adulthood and fertile, tet2 is dispensable for overall development.  
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Primitive erythropoiesis but not myelopoiesis was affected in tet2 mutants consistent 
with tet2 depletion leading to reduced erythroid differentiation. As both orthologues tet2 
and tet3 are expressed in the ICM of wild type zebrafish embryos at 24 hpf (Ge et al., 
2014), tet2 may have a selective nonredundant role in primitive erythropoiesis. Similar 
defects in zebrafish were seen upon morpholino-induced depletion of tet2 (Ge et al., 
2014), and in a reverse genetic screen identifying chromatin regulators of haematopoiesis 
(Huang et al., 2013).  
During definitive haematopoiesis at 36 hpf, both HSPC markers runx1 and cmyb were 
downregulated in the tet2 mutants, a phenotype previously reported only in tet2/tet3 
double mutants (C. Li et al., 2015). The study by Li et al. further identified a combined 
requirement for tet2 and tet3 in Notch signalling-mediated HSPC production. The 
discrepancy in HSPC phenotype seen may be due to downregulation of tet3 expression 
in the mutants and could be investigated in future. 
Multiple in vitro and in vivo studies using mice and human cell lines showed that tet2 
loss leads to increased self-renewal in HSPCs and subsequently results in myeloid 
expansion with skewing towards the monocytic lineage (Ko et al., 2011; Z. Li et al., 
2011; Moran-Crusio et al., 2011; Pronier et al., 2011). Although tet2 mutations do not 
impact embryonic and larval haematopoiesis in zebrafish, they lead to increased 
progenitors and myelomonocytes resulting in myelodysplastic syndrome (MDS) by 24 
months of age (E. Gjini et al., 2015). These findings in various model systems are 
consistent with the high incidence of tet2 mutations in chronic myelomonocytic 
leukaemia (CMML) (Patel et al., 2017; Patnaik et al., 2016).  
A mechanistic role for tet2 in regulating the differentiation-associated anterior 
homeobox-A (hox) gene cluster has been established (Bocker et al., 2012), providing an 
explanation for the self-renewal phenotypes seen with tet2 mutations. A similar 
mechanism has been identified in Rad21-depleted murine HSPCs where increased self-
renewal was conferred by de-repression of Hoxa9 (Fisher et al., 2016). While tet2 mutant 
models develop CMML/MDS, they never progress to AML. With the additional loss of 
cohesin, common pathways such as those regulating self-renewal of HSPCs may be 
further impacted causing transformation to AML. Combinatorial mutants generated by 
crossing tet2nz203 and rad21nz171/+ or stag1bnz205  fish may present with severely impaired 
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erythroid differentiation and defective HSPC specification based on the similar 
phenotypes seen in single mutants for these haematopoietic lineages.  
Cohesin loss in combination with the runx1-runx1t1 translocation expressed under the 
+23 runx1 enhancer led to expanded RBI phenotypes with stag1a or stag2b at 24 hpf. 
On the other hand, runx1-runx1t1 in isolation or in combination with rad21 did not show 
significant changes. In contrast, previous studies showed that global expression of runx1-
runx1t1 in zebrafish embryos leads to an accumulation of non-circulating haematopoietic 
cells in the RBI and ICM regions (Kalev-Zylinska et al., 2002; Yeh et al., 2008). Upon 
characterisation, the accumulated cells were found to be myeloblasts and a myeloid 
sarcoma-like phenotype was suggested. Although embryos from the stag1anz204/runx1-
runx1t1 mutation combination showed accumulation of cells in the ICM and RBI at 36 
hpf, circulation was not disrupted. Discrepancies in morphological phenotypes seen 
could be because the Tg(runx1+23:runx1-runx1t1:polyA) line used here expresses the 
fusion protein in a lineage-restricted manner and hence may not recapitulate the strong 
phenotypes seen with global expression. WISH on runx1-runx1t1 mutants in isolation 
and in combination with rad21nz171 showed downregulation of primitive erythroid cells 
and aberrant myeloid cells in the ICM. These findings are consistent with the 
aforementioned models. Moreover, runx1-runx1t1 has previously been shown to 
negatively impact erythropoiesis by blocking gata1a acetylation (Choi et al., 2006). 
Mutations in AML are restricted to the haematopoietic compartment, first arising as 
clonal mutations in HSPCs and subsequently expanding to cause full-blown leukaemia 
(Jan et al., 2012; Shlush et al., 2014). Existing zebrafish models of myeloid malignancies 
were generated to carry germline mutations (see Chapter 1 for examples) and hence do 
not accurately recapitulate the nature of de novo mutations seen in AML. In the tissue-
specific mutant lines generated here, de novo mutations are continually generated as both 
the sgRNA and Cas9 mRNA are present in the same vector leading to highly penetrant 
tissue-restricted gene loss. Moreover, as mutations in AML are frequently seen in global 
regulators that function in multiple developmental processes including haematopoiesis, 
restriction of gene loss may be useful to dissect haematopoiesis-specific functions.  
Transgenic zebrafish lines with mfap4-restricted tet2 loss and draculin-restricted stag2b 
loss were generated. The normal morphological development seen in tet2nz203 mutants 
was phenocopied in embryos with macrophage-specific tet2 loss. Endogenous mfap4 is 
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expressed in zebrafish macrophages beginning during the embryogenesis at 19 hpf up 
until the early larval stages. The mfap4 promoter has been shown to faithfully recapitulate 
this endogenous expression and is stable even during larval stages (Walton et al., 2015). 
Generating mutations in early macrophages may be useful for delineating specific 
regulatory mechanisms and may generate a myeloid malignancy model with shorter 
latency.  
Loss of Tet2 expression in murine macrophages increased the expression of 
inflammatory genes including Arginase1 (Arg1) while differentiation remained 
unaffected (Cull et al., 2017). ARG1 was also seen to be overexpressed in bone marrow 
myelomonocytes of TET2 mutant lower-grade MDS and CMML patients (Cull et al., 
2018). An emerging hypothesis is that TET2 loss creates a hyperinflammatory 
environment in the bone marrow where mutant clones but not normal haematopoietic 
cells are equipped to survive. The macrophage-specific tet2 zebrafish mutant line 
generated here may be useful to further delineate the biological mechanisms involved in 
this process. It will also be interesting to examine how other mutations including cohesin 
mutations perform in a hyperinflammatory environment. To this end, combinatorial 
transgenic mutant lines will be generated and characterised. 
The necrosis and abnormal pigmentation phenotypes seen in stag2bnz207 mutants were 
also observed with drl-specific stag2b loss. This observation suggests a probable role for 
stag2b in early mesoderm-haematopoietic fate specification warranting further 
investigation. Expression of the cmlc2 transgenesis marker was stable across generations 
in all transgenic lines generated but expression of promoter driven GFP expression was 
lost. As both markers are within the same Tol2 construct, differences in promoter strength 
and the nature of the site of integration may account for differences in expression seen.  
To diagnose AML in the different mutant lines generated, flow cytometry on the WKM 
will be performed. Preliminary lineage analysis in rad21nz171/+ heterozygous mutant fish 
showed increased precursors and decreased myelomonocytes in the WKM at 24 months 
of age. Although these changes were statistically insignificant, the overall trend observed 
is in line with previous reports on cohesin loss resulting in increased HSPCs in murine 
models (Fisher et al., 2016; Mullenders et al., 2015). Increased HSPCs may be associated 




In conclusion, two important characteristics of AML namely, the presence of 
combinatorial mutations and the haematopoiesis tissue-specific nature of mutations 
present can be successfully modelled using zebrafish allowing for reliable 






Transcriptional dysregulation is increasingly being recognised as the causative 
mechanism in cohesinopathies and in cohesin-mutant AML. Mutations in cohesin 
subunits fall under the chromatin-spliceosome genomic AML category, a group that is 
associated with variable clinical outcomes given the heterogeneity of its members. To 
predict prognosis and stratify treatment groups, it is necessary to understand which 
mutation combinations and what biological pathways are key to AML progression. 
Although STAG2 is the most frequently mutated of the cohesin subunits, its functions in 
normal development and the effects of its loss in carcinogenesis are not fully known. 
Here, zebrafish were used to delineate the specific roles of the STAG1 and STAG2 
paralogues in transcriptional regulation of embryonic development and haematopoiesis. 
These mutant lines can help understand the etiology of multigenic traits observed in 
cohesinopathies. In addition, zebrafish were used to model aberrations in two other 
members of the chromatin-spliceosome subgroup namely TET2 and RUNX1 taking into 
account the combinatorial and haematopoiesis-restricted nature of AML mutations. 
These models are expected to develop AML with high penetrance and short latency 
periods. They can inform on the significance of mutation ordering and the synergistic 
disease mechanisms and disease prognosis associated with different mutation 
combinations. Importantly zebrafish mutants are a cheap alternative to mice for drug 
screens given their high fecundity and low maintenance costs. As a starting point, drugs 
that affect enhancer stabilisation such as bromodomain inhibitors or Wnt inhibitors can 
be trialled in these mutants. The hypothesis of my study was that the cohesin subunits 
STAG1 and STAG2 play non-redundant roles in the transcriptional regulation of cell fate 
determination. Using loss of function zebrafish mutants, I found that the Stag paralogues 
had distinct roles during zebrafish embryogenesis which I discuss below.  
 
6.1 Specific contributions of Stag paralogues to zebrafish 
embryogenesis 
Recent reports in humans and mice show that cohesin-STAG1 preferentially interacts 
with CTCF in the establishment of topological associating domains (TADs) while 
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cohesin-STAG2 is crucial for short-range tissue-specific interactions (Cuadrado et al., 
2019; Kojic et al., 2018; Aaron D. Viny et al., 2019). In zebrafish, the two Stag1 
paralogues showed further subfunctionalisation. Depletion of stag1a and stag1b in 
zebrafish embryos affected different processes, namely haematopoiesis and 
pigmentation, respectively. As evident from zebrafish models of cohesinopathy, small 
changes in gene dosage can significantly disrupt cohesin function (Muto et al., 2011) 
(Schuster et al., 2015). In this regard, stag1a may be dispensable for gross embryonic 
development. The high levels of stag1b relative to stag1a may further reflect a unique 
temporal requirement for stag1b in early embryogenesis.  
Human cohesin-STAG2 preferentially binds non-CTCF enhancer sites in the genome and 
cannot be replaced by cohesin-STAG1 when depleted. On the other hand, cohesin-
STAG2 can replace cohesin-STAG1 at CTCF insulator sites however this leads to weaker 
insulation at some sites (Kojic et al., 2018) (Cuadrado et al., 2019). Therefore, the 
similarity of craniofacial and pigmentation phenotypes seen in stag1b and stag2b mutants 
suggest a loss of insulation at specific developmental genes. As discussed in Section 4.6, 
both craniofacial and pigment cells are derived from neural crest precursors. Hence, 
regulators of neural crest cell induction and specification may be among genes that are 
dysregulated in these mutants. 
Further evidence for stag1b as a preferential regulator of gene insulation comes from the 
observation that sox2 is expanded in the tailbud of stag1b mutants. While this phenotype 
requires further investigation, an expansion of sox2 expression in this region indicates a 
switch from mesodermal to neural cell fate. Bipotent progenitor cells in the posterior 
tailbud are specified into mesoderm in the presence of Wnt and into neural tissue in the 
presence of sox2; Wnt signalling represses sox2 expression (Row et al., 2018). Similar 
dysregulation of posterior signals could explain the ectopic tails observed in the stag2b 
crispants. 
Based on findings from siRNA-mediated depletion of STAG1 or STAG2 in primed mouse 
embryonic stem cells, STAG2 but not STAG1 was shown to be important for establishing 
polycomb domains and long-range spatial Hox clusters in association with the polycomb 
repressor complex, PRC1 (Cuadrado et al., 2019). Loss of STAG1 was shown to increase 
contacts between the Hox spatial clusters and downregulate pathways such as 
dorsoventral axis function, Wnt signalling and melanogenesis. Loss of STAG2 was 
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shown to decrease Hox spatial contacts and upregulate pathways including apoptosis, 
cancer and cardiac defects. Some parallels can be drawn here with regard to the 
disruption of melanocytes and body axis patterning observed in the stag1b and stag2b 
zebrafish mutants.   
 
6.2 Stag loss dysregulates embryonic haematopoiesis 
Based on the opposing effects of stag1a and stag2a/2b loss on runx1+ haematopoietic 
precursors in the zebrafish PLM, these paralogues may differentially regulate runx1 
expression. Transcription of runx1 occurs from two promoters, P1 and P2, producing 
different isoforms that have non-redundant functions in haematopoiesis. P2 isoforms are 
predominantly present at the onset of primitive and definitive haematopoiesis while P1 
isoforms are present after the onset of definitive haematopoiesis and function in 
maintenance and differentiation (Mevel et al., 2019; Sroczynska et al., 2009). In 
zebrafish, the two promoters are separated by a 91 kb intron containing cohesin binding 
sites that may act as enhancers and/or insulators if additionally bound by CTCF 
(Marsman et al., 2014). Marsman et al. found that CTCF depletion led to ectopic runx1 
expression in the tailbud of zebrafish embryos, implying that CTCF and cohesin could 
cooperate to constrain the spatiotemporal expression of certain developmental genes 
(Marsman et al., 2014). 
Given that accurate spatiotemporal expression of runx1 is required throughout 
haematopoiesis, a complex regulatory environment may exist at its locus. In line with 
this, the stag paralogues could be involved in differentially looping regulatory elements 
with the two runx1 promoters at different time points (Figure 6.1). Cohesin-Stag1 may 
constrain runx1 expression by mediating connections with insulator elements such as the 
previously identified +89 insulator, through interactions with CTCF (Marsman et al., 
2014). In contrast, cohesin-Stag2 may activate runx1 transcription by mediating 
connections with enhancer elements such as the previously identified +39 enhancer 
(Marsman et al., 2014).  
At 12 somites, runx1 expression from the P2 promoter could be activated by looping of 
the +39 enhancer with the P2 promoter by cohesin-Stag2. In addition, runx1 expression 
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from the P2 promoter may be repressed by local interactions with the +89 insulator 
mediated by cohesin-Stag1. Hence upon stag1a loss, runx1 expression increased in the 
PLM, whereas upon stag2a or stag2b loss, runx1 expression reduced in the PLM of 
mutants compared to wild type.  
 
 
Figure 6.1. A hypothetical model for differential regulation of runx1 expression 
during embryonic haematopoiesis in zebrafish. A) At 12 somites, runx1 is 
predominantly expressed from the P2 promoter in the lateral plate mesoderm. Cohesin-
Stag2 may activate transcription by looping a +39 enhancer with the P2 promoter. 
Cohesin-Stag1 with CTCF may constrain runx1 expression by looping a +89 insulator 
with the P2 promoter. B) At 36 hpf, runx1 is predominantly expressed from P1 promoter 
in haematopoietic stem and progenitor cells arising from the haemogenic endothelium. 
Cohesin-Stag2 may activate transcription by looping a +39 enhancer with the P1 
promoter. Cohesin-Stag1 with CTCF may shield the +39 enhancer from the P2 promoter 




At 36 hpf, cohesin-Stag2 switches looping of the +39 enhancer from the P2 promoter to 
the P1 promoter. To enable this switch, cohesin-Stag1 may serve to shield the +39 
enhancer from the P2 promoter thereby repressing runx1 transcription from the P2 
promoter (Figure 6.1). 
Dysregulation of runx1 expression in the bilateral mesoderm or PLM at 12 somites raises 
the possibility that other cell lineages that are specified here may also be affected. The 
earliest cells of the PLM express pax2a and pax8 and are committed to a renal fate. 
Subsequently, a subset of these cells called haemangioblasts turn on scl expression, 
acquiring an endothelial or a haematopoietic fate. Haematopoietic commitment is then 
initiated with expression of gata1a. Haemangioblasts also initiate runx1 expression 
beginning from the 5 somite stage (Davidson & Zon, 2004) (Warga et al., 2013). Based 
on the observations that runx1 expression is dysregulated and gata1a expression is 
downregulated in the zebrafish stag mutants, it can be speculated that commitment to the 
endothelial lineage may be affected. Expression analysis using endothelial cell markers 
such as fli1a and erg could clarify this.  
Two recent studies have uncovered roles for STAG2 in maintaining the balance between 
HSC self-renewal and differentiation via regulating the chromatin context at 
haematopoietic differentiation factors. Viny et al. showed that loss of Stag2 decreased 
chromatin accessibility at Pu.1 target genes which include lymphoid-lineage specifying 
factors resulting in B-cell aplasia, erythroid dysplasia and myeloid skewing. Block in 
differentiation could be rescued by Stag2 restoration but not Pu.1 overexpression, 
signifying the importance of chromatin context in differentiation (Aaron D. Viny et al., 
2019). Sasca et al. showed that Stag2 was required to evict the Etv6 repressor from 
erythroid lineage-commitment genes to facilitate erythroid differentiation (Sasca et al., 
2019). These findings provide a mechanistic explanation to the myeloid skewing and 
erythroid dysplasia phenotypes seen with stag1a and stag2b loss. But given that both 
stag1a and stag2b are required for embryonic haematopoiesis, a further division of labour 
in organising the chromatin of different cell types may exist in zebrafish. 
Regulation of Hox genes by PRC is a well-conserved mechanism in both invertebrates 
and vertebrates (Bantignies et al., 2011; Mallo & Alonso, 2013; Schoenfelder et al., 
2015; Soshnikova & Duboule, 2009). Both PRC complex members (Chrispijn et al., 
2018; Le Faou et al., 2011) and Hox gene clusters (Amores et al., 1998; Bruce et al., 
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2001) are duplicated in zebrafish and the functions of some group members are not yet 
known. Loss of rad21 in zebrafish did not affect the expression of the hox gene cdx4, 
which is important for specifying early haematopoietic cells from the mesoderm 
(Davidson & Zon, 2006), or its targets hoxa9a, hoxb4, hoxb6b and hoxb7a (Horsfield et 
al., 2007). In contrast, shRNA-mediated depletion of Rad21 in murine HSPCs led to de-
repression of 38 genes, including Hox, genes previously under the control of PRC2 
regulation resulting in increased self-renewal (Fisher et al., 2016). Both PRC and Hox 
gene groups are required for normal haematopoiesis and are implicated in myeloid 
leukaemia (Alharbi et al., 2012; Argiropoulos & Humphries, 2007; Di Carlo et al., 2019). 
Overexpression of HoxA9 leads to haematopoietic dysregulation through mechanisms 
such as enhancer reorganisation (Y. Sun et al., 2018). It would be interesting to determine 
if stag paralogues are required for PRC-mediated regulation of hox expression and if 
paralogue-specific requirements exist.  
 
6.3 A role for cohesin as a Wnt signalling modulator  
Loss of stag1b and stag2b in zebrafish led to craniofacial defects and displacement of 
pigment cells. Wnt signalling has multifaceted roles in embryonic development (Michael 
W. Klymkowsky et al., 2010; Schier & Talbot, 2005). A conserved critical role for the 
β-catenin-dependent canonical Wnt pathway has been established in HSPC emergence 
and amplification (Luis et al., 2011; Richter et al., 2017). In normal haematopoiesis, Wnt 
signals are maintained at optimal levels in HSPCs and are subsequently downregulated 
during differentiation. Aberrant activation of Wnt signalling is seen in AML patients and 
is associated with poor prognosis (Jiang et al., 2018; Ysebaert et al., 2006). Some studies 
have also identified opposing effects of increased Wnt signalling in downregulating 
HSPC production (Ming et al., 2012). The involvement of Wnt signalling in AML has 
led to its evaluation as a prognostic marker and as a target for therapy (Harb et al., 2019; 
Minke et al., 2009; Saenz et al., 2019; Taskesen et al., 2015). 
In zebrafish embryos expressing mutant NPM1c protein in isolation and with secondary 
loss of nipblb, aberrant activation of canonical Wnt signalling led to a myeloid skewing 
(Barbieri et al., 2016; Mazzola et al., 2019b). Furthermore, loss of Nibpl and Stag1 in 
mice showed similar abnormalities and Stag1 was among genes that were upregulated 
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upon Nibpl loss (Kawauchi et al., 2009; Newkirk et al., 2017; Remeseiro, Cuadrado, 
Gomez-Lopez, et al., 2012). These results raise the possibility that Wnt signalling may 
be aberrantly activated in stag1a mutants. Stag paralogues can impart Wnt-mediated 
haematopoietic phenotypes through topological dysregulation of transcription factor 
hubs that are critical for differentiation. In line with this, Wnt TCF7 has been shown to 
co-bind genomic regions with haematopoietic lineage master regulators such as GATA1 
and CEBPA (Trompouki et al., 2011).  
In summary, the above findings support non-overlapping roles for the stag paralogues in 
the transcriptional regulation of cell fate determination in haematopoiesis as well as in 
global embryonic development. Differential requirements of the four paralogues may be 
influenced by the level of robustness required to regulate various tissue-specific 
processes.    
 
6.4 Effects of tet2 disruption on early haematopoiesis 
Characterisation of tet2 mutant zebrafish carrying a protein variant that lacks the catalytic 
oxygenase domain and co-factor binding sites showed novel defects in primitive 
erythropoiesis. These results are consistent with morpholino-induced loss of tet2 (Ge et 
al., 2014) but contradict other tet2 mutant zebrafish models (E. Gjini et al., 2015; C. Li 
et al., 2015). However, findings from non-zebrafish systems strongly agree with a 
requirement for TET2 in normal erythropoiesis. Knockdown of TET family proteins in 
CD34+ haemopoietic cells revealed a role for TET2 in overall and TET3 in late-stage 
erythroid differentiation, respectively (H. Yan et al., 2017). TET2 expression was also 
observed during erythropoietin-induced erythroid differentiation of CD34+ cells derived 
from the bone marrow of healthy donors (Scopim-Ribeiro et al., 2017). Moreover, loss 
of TET2 has been reported to lead to increased HSC self-renewal and myelomonocytic 
skewing with concurrent loss of erythrocytes in multiple studies (Ko et al., 2011; Z. Li 
et al., 2011; Moran-Crusio et al., 2011; Pronier et al., 2011). Whether such effects on 
adult haematopoiesis are also seen in the tet2 zebrafish mutant model generated here 




6.5 Novel tools for haematopoiesis and AML research 
As described above, zebrafish are invaluable for studying the effect of gene loss on 
primitive haematopoiesis and processes such as HSPC emergence and amplification (de 
Pater & Trompouki, 2018). Existing in vitro cell line and in vivo mouse models 
predominantly characterise HSPC-derived haematopoiesis. While mutations in 
individual genes can disrupt haematopoiesis, they are not sufficient to drive 
leukaemogenesis. To evaluate the effect of cohesin loss in the background of other 
mutations, combinatorial zebrafish lines carrying mutations in the cohesin subunits 
stag1/2 or rad21 and either tet2 or RUNX1-RUNX1T1 translocation were generated. 
Understanding the effects of cohesin loss in combination with other mutations is useful 
for identifying synergistically dysregulated pathways for targeted therapy. For example, 
Vitamin C has been shown to restore tet2 function, and in addition, increase sensitivity 
to PARP inhibition (Cimmino et al., 2017; Ngo et al., 2019), a known vulnerability in 
cohesin-mutated tumours (Bailey et al., 2014).  
To accurately recapitulate in vivo somatic mutations seen in AML, zebrafish lines that 
continually generate de novo mutations in a tissue-restricted manner were developed. 
Using this system, zebrafish lines with tet2 mutations in macrophages or with stag2b 
mutations in early haematopoietic cells were generated. Characterisation of these lines is 
expected to reveal the cell-autonomous pathogenic mechanisms that may be involved in 
AML. The use of the draculin promoter is expected to overcome shortcomings such as 
low penetrance and long latency associated with existing zebrafish models of AML. 
Furthermore, once characterised, the above-mentioned mutant lines could serve as in vivo 
drug-testing platforms.  
A recent study analysing cancer drugs and their targets in clinical trials showed that most 
drugs were mischaracterised and targeted proteins were different from those reported. 
The off-target effects observed were attributed to the use of RNAi-based techniques for 
initial target selection (A. Lin et al., 2019). In a heterogeneous disease like AML, the 
accurate identification of the most relevant contributors to pathogenesis is crucial. As the 
mutant lines generated here were based on CRISPR-Cas9 mutagenesis, minimal off-




6.6 Future directions 
To understand the individual contributions of the zebrafish stag paralogues, I generated 
loss of function mutations in three of the four paralogues and characterised their effects 
on morphological development and embryonic haematopoiesis. I found that the 
paralogues had distinct requirements in different development processes and that stag1a 
and stag2b were required for transcriptional regulation of haematopoiesis. In-depth 
characterisation of the mutant lines including the presence of unintended off-target 
mutations determined by in silico analysis will be carried out. Although morpholinos 
were used for validation, rescue experiments using functional mRNA of each paralogue 
are required to further confirm the specificity of phenotypes observed. This is especially 
crucial given that loss of individual paralogues affects the expression of non-targeted 
paralogues.  
Follow-up characterisation mutant phenotypes will be carried out: developmental delay 
using anti-phosphohistone staining and Giemsa staining to determine mitotic defects; 
craniofacial abnormalities using Alcian Blue staining and neural crest phenotypes using 
WISH for appropriate markers. The hypothesis that stag2a may be important for germ 
cell development will be evaluated. As F1 mosaic mutants were used for evaluating the 
effects of stag2b loss on embryonic haematopoiesis, the penetrance of abnormal 
phenotypes in germline F2 mutants will be determined. Further characterisation of 
embryonic haematopoiesis using WISH including a time-series of runx1 expression, 
differentiation markers such as macrophage-specific mpeg, granulocyte-specific lyz and 
mpx, and T-cell-specific rag1 will be carried out. Where possible, WISH results will be 
validated using RT-PCR. The penetrance of myeloid disease in stag1a and stag2b adult 
mutant fish will be determined using flow cytometry. The finding that haematopoiesis 
was not perturbed but morphological development was obstructed in stag1b mutants 
provides an opportunity to exclusively study the non-haematopoietic effects of cohesin 
loss such as cell-fate switching and neural crest specification. 
I aimed to evaluate the effects of cohesin loss in the background of tet2 mutations and 
the RUNX1-RUNX1T1 translocation. With regard to the tet2 mutant line generated, loss 
of tet2 function will be established mutant embryos and adult fish using 5hMC dot blot 
assay. Whether the expression of the other two tet proteins, tet1 and tet3, is altered will 
to be determined using RT-PCR. A combined loss of tet2 and tet3 was previously 
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reported to cause defective HSPC development (C. Li et al., 2015). Compromised HSPC 
production in tet2 and stag1 mutants may be mediated through disruption of Notch and/or 
Wnt signalling leading to apoptosis. These processes can be characterised using 
appropriate WISH markers or transgenic lines (Evisa Gjini et al., 2019; Moro et al., 
2012). Defects in adult haematopoiesis in the stag1/2 and tet2 mutant lines generated will 
be evaluated through histology and flow cytometry of adult haematopoietic tissues such 
as peripheral blood, whole kidney marrow (WKM) and spleen.  
While preliminary findings from the characterisation of combinatorial mutant lines 
carrying cohesin mutations and the RUNX1-RUNX1T1 translocation indicated an 
expansion of the RBI and CHT, quantification using EdU-incorporation will be carried 
out. Combinatorial lines carrying cohesin and tet2 mutations were also generated but 
comprehensive characterisation has not been performed. Mutational screening remains 
to be carried out in the lineage-restricted transgenic mutant lines generated for tet2 and 
stag2b. This requires developing a high-throughput protocol for DNA extraction from 
peripheral blood and sorted macrophages extracted from zebrafish embryos and adult 
fish. Post-screening, aberrations in adult haematopoietic tissues could be evaluated using 
histology and flow cytometry.  
Transgenic lines could also be generated with macrophage-specific cohesin loss and 
draculin-specific tet2 loss. Different combinations of germline and/or tissue-specific 
mutants could be generated by crossing the different lines. The pathogenicity of different 
mutation combinations and the importance of mutation directionality could then be 
determined by profiling haematopoietic tissues in adult zebrafish. To track clonal 
evolution, the different combinatorial mutants could be crossed to the Zebrabow line, a 
Cre/Lox recombination-based lineage analysis tool (Henninger et al., 2017).  
 
6.7 Conclusion 
In conclusion, cohesin-Stag1 and cohesin-Stag2 have non-overlapping regulatory 
functions in driving cell fate decisions. Mutations in the two subunits lead to 
transcriptional dysregulation, affecting multiple processes including haematopoiesis. 
Therapies that reverse this dysregulation may be beneficial for patients with STAG2 
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Appendix I – Solutions 
Zebrafish 
 
50x E3 (1L) 
CaCl2 2.43 g 
MgSO4 4.07 g 
KCl 0.63 g 
NaCl 14.61 g 
MQ water make up to 1 L 
Solution was sterilised by autoclaving. The solution was diluted to a final concentration 
of 1x before use. 
 
Tricaine 
Tricaine powder 400 mg 
1M Tris-HCl pH 9.0 2.1 mL 
Milli-Q water make up to 100 mL 
Adjust pH to 7.0 using HCl. Store as 4.2 mL aliquots at -20 °C. Dilute in 100 mL of 1x 
E3 before use. 
 
In situ hybridisation 
DEPC-treated water 
1 mL of DEPC (diethyl pyrocarbonate) was added to 1 L of Milli-Q water. The solution 
was mixed by stirring overnight at room temperature and then autoclaved to inactivate 




10x Phosphate Buffered Saline (PBS) 
NaCl 80 g 
KCl 2 g 
NaH2PO4 17.8 g 
KH2PO4 2.4 g 
DEPC water make up to 1 L 
Adjust pH to 7.2 using HCl. The solution was sterilised by autoclaving and used at a final 
concentration of 1x. To make PBST, 50 µL of 100% Tween 20 was added per 50 mL of 
1x PBS. 
 
20 x Saline-Sodium Citrate (SSC) 
NaCl 175.32 g 
Na3C6H5O7 88.2 g 
DEPC water make up to 1 L 
Adjust pH to 7.0 using HCl. The solution was diluted to 5x before use. 
 
Hybridisation buffer (Hybe+) 
Formamide 25 mL 
20x SSC 12.5 mL 
Heparin (5 mg/mL) 500 µL 
Torula yeast RNA (50 µg/mL) 250 µL 
20% Tween 20 250 µL 
DEPC water make up to 50 mL 
Adjust the pH to 6.0 using 1M citric acid. To make hybe-, all above components except 




10x Maleic Acid Buffer (MAB) 
C4H8O7 116 g 
NaCl 87 g 
DEPC water make up to 1 L 
Adjust pH to 7.5 using NaOH pellets. The solution was diluted to 1x before use. 
 
2% Roche Blocking Buffer 
Roche blocking reagent 2g 
1x MAB 50 mL 
The reagent was dissolved by heating to 60 °C. The solution was stored in aliquots at -
20 °C. 
 
Triethanolamine – acetic anhydride 
0.1 M C6H15NO3-HCl 30 mL 
Acetic anhydride 75 µL 
  
Staining solution 
1M Tris HCl pH 9.5 5 mL 
2M MgCl2 1.25 mL 
5M NaCl 1 mL 
20% Tween 20 250 µL 





Luria-Broth (LB) and LB agar 
Tryptone 7.5 g 
Yeast extract 3.75 g 
NaCl 7.5 g 
Agar (for LB agar) 11.25 g 
Milli-Q water make up to 750 mL  
Solutions were sterilised by autoclaving. Appropriate antibiotics were added after the 
solution cooled down to 40 °C. 20-25 mL of LB agar was added per 10 cm petri dish and 
the plates were stored at 4 °C. 
 
DNA techniques 
50x Tris-Acetate EDTA (TAE) 
Tris 242 g 
Acetic acid 57.1 mL 
0.5 M EDTA pH 8.0 100 mL 
Milli-Q water make up to 1 L 
TAE buffer was used at a final concentration of 1x. 
 
6x DNA loading buffer 
Ficoll 400 2.5 g 
0.5 M EDTA 400 µL 
10% SDS 18 µL 
Orange G a pinch 
Milli-Q water make up to 10 mL 
Once dissolved, the solution was stored in aliquots at -20 °C.  
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Appendix figure 1. Locations of various features on the stag1a mRNA 
sequence. Shown here are the locations of functional STAG domain (dark 
orange); gene editing oligos, morpholino (MO in brown) and sgRNA (blue); and 




Appendix figure 2. Locations of various features on the stag1b mRNA 
sequence. Shown here are the locations of functional STAG domain (dark 
orange); gene editing oligos, morpholino (MO in brown) and sgRNA (blue); and 





Appendix figure 3. Locations of various features on the stag2a mRNA 
sequence. Shown here are the locations of functional STAG domain (dark 
orange); gene editing oligos, morpholino (MO in brown) and sgRNAs OC14 and 
OC16 (blue); and amplicons for riboprobe synthesis (purple) and real-time PCR 







Appendix figure 4. Locations of various features on the stag2b mRNA 
sequence. Shown here are the locations of functional STAG domain (dark 
orange); gene editing oligos, morpholino (MO in brown) and sgRNA (blue); and 




Appendix figure 5. Bioanalyser trace showing the size distribution of 
amplicons in the MiSeq library. Pooled samples were analysed using the High 
Sensitivity DNA assay on Bioanalyser 2100. Product-specific peaks are in the 






























































































































































































































































































































































































Appendix figure 6. CrispRVariants plots of the OC13 target loci in all four 
paralogues. Analysis of deep sequencing is shown at the A) stag1a target locus 
in three individual uninjected control embryos, C1-C3; B) stag1a target locus in 
























































individual uninjected control embryos, C1-C3; D) stag1b target locus in six 
individual injected crispants, CR1-CR6; E) stag2a target locus in one uninjected 
control embryos, C2. No reads were found in C1 and C3; F) stag2a target locus 
in six individual injected crispants, CR1-CR6; and G) stag2b target locus in five 
individual injected crispants, CR1, CR3-CR6. No reads were found in CR2 and 
also in the three uninjected controls C1-C3. Absence of reads in samples could 
have been due to overrepresentation of some targets over others during library 
preparation. Individual embryos were assigned unique barcodes and each 
embryo was used to generate amplicons for all four paralogue targets. Hence a 




Appendix figure 7. Chromatograms of the stag1b nz205 mutation. 
Nucleotide alignments for representative wild type homozygous, heterozygous 
and mutant homozygous samples are shown. Sequences are aligned to the 
target region in stag1b exon 3 on the reference genome. The 20 bp OC18 sgRNA 


































































Appendix figure 8. CrispRVariants plots of the OC16 target loci in all four 
























































uninjected control embryos, C1-C3 and B) six individual injected crispants, CR1-
CR6. See figure 3.12 for plot annotation details. 
 
 
Appendix figure 9. Chromatograms of the stag2b nz207 mutation. 
Nucleotide alignments for representative wild type homozygous, heterozygous 
and mutant homozygous samples are shown. Sequences are aligned to the 
target region in stag2b exon 3 on the reference genome. The 20 bp OC22 sgRNA 





Appendix figure 10. Late-stage abnormalities seen in stag1bnz205 mutants. 
Lateral views of a representative A) wildtype embryo with normal morphology 
and B) stag1bnz205 mutant homozygous embryo with ventrally-drooping lower jaw 
(black arrow) and defective swim bladder inflation (red arrow). Anterior is to the 
left. Scale bars are 100 µm. 
 
 
Appendix figure 11. Craniofacial abnormalities seen in stag2bnz207 mutants. 
Lateral views of a representative wildtype embryo with normal morphology and 
stag1bnz207 mutant homozygous embryo with mild abnormality in development of 





Appendix figure 12. Schematic of the tissue-specific CRISPR plasmid with 





Appendix figure 13. Schematic of the tissue-specific CRISPR plasmid with 
Cas9 mRNA expressed under the control of the macrophage-specific 





Appendix figure 14. Schematic of the tissue-specific CRISPR plasmid with 






Appendix figure 15. Chromatograms of the tet2 nz203 mutation. Nucleotide 
alignments for representative wild type homozygous, heterozygous and mutant 
homozygous samples are shown. Sequences are aligned to the target region in 
tet2 exon 6 on the reference genome. The 20 bp OC1 sgRNA with the PAM site 





Appendix figure 16. Preliminary analysis reveals a loss of 5hMC levels in 
tet2nz203 mutants. Immunofluorescence assay using anti-5hMC antibody on 
whole embryos showed reduced 5hMC expression in tet2nz203 mutants at 48 hpf. 





Appendix figure 17. Cell clumping in the circulation of Tg(runx1+23:runx1-
runx1t1:polyA) x stag1anz204 combinatorial mutants at 36 hpf. Movie 
sequences showing clumped cells (red arrows) in circulation demarcated by a 




Appendix table 1. List of accession identifiers for proteins used for phylogenetic 
analysis. 
Protein Accession ID 
Hs STAG1 NP_005853.2 
Hs STAG2 NP_001036214.1 
Gg STAG1 XP_015146838.1 
Gg STAG2 XP_004940885.1 
Mm Stag1 NP_001344193.1 
Mm Stag2 NP_001071180.1 
Xt stag1 NP_001121432.1 
Xt stag2 XP_002931833.2 
Dr stag1a NP_001349269.1 
Dr stag1b XP_692120.3 
Dr stag2a NP_001093498.1 
Dr stag2b XP_005173250.1 
 
Appendix table 2. Sequences of primers used.  
Description Sequence (5’-3') 
Expression primers 
stag1a RT-PCR_F CTGGACCTTACATGACCGGC 
stag1a RT-PCR_R TATCCAGCGTCATGGACACG 
253 
 
stag1b RT-PCR_F CCAGGTTGATGCAGAAAAGGTG 
stag1b RT-PCR_R GGCGTCCAGATGCTTTTCCAT 
stag2a RT-PCR_F AGCCGCTTCAAGGATCGAAT 
stag2a RT-PCR_R CAGCGTCAGCAGCTTAATGG 
stag2b RT-PCR_F CAATAGCAGAGATCCGGGCG 
stag2b RT-PCR_R GACACTTCAGACGCACCTCA 
tet2 RT-PCR_F  TTTCGAAGGCAGGTGCGTAT 
tet2 RT-PCR_F  CCTCGTCCTGTCACTGTTGG 
gata1a RT-PCR_F TTACTGCCACCCGTTGATGT 
gata1a RT-PCR_R  TTGGCGAACTGGACTGTGTC 
In situ hybridisation primers 
stag1a ISH_F CTTTGCCCTCACCTTCGGAT 
stag1a ISH_R GAGTTCTGCTCTCTCTCGCC 
stag1b ISH_F GTCTGAAGCATTCTGGGGCT 
stag1b ISH_R GGCATCCCTGTAACGGTGAA 
stag2a ISH_F AAGGGCGAAATGGCAAACTT 
stag2a ISH_R GACGCACCTCACCTTGCTTA 
stag2b ISH_F CATCCTCACTGTTGGCCTGT 
stag2b ISH_R GACACTTCAGACGCACCTCA 
runx1 ISH_F GGTAAGCTTCGGGGAAGATGAGCGAGGGTTT 
(Kalev-Zylinska et al., 2002) 
254 
 
runx1 ISH_R GGGCTGGGTGTGTGGGCTGAC (Kalev-Zylinska 
et al., 2002) 
gata1a ISH_F CCGGAATTCTCTGAGCCTTCTCGTTGGGTG 
(Ge et al., 2014) 
gata1a ISH_R CCGCTCGAGTGGCCTGTCCCATCTTGACG (Ge 
et al., 2014) 
pu.1 ISH (Lieschke et al., 2002) 
cmyb ISH (Thompson et al., 1998) 
col2a1 ISH_F TGAAGGGTGAGCGTGGTAAC  
col2a1 ISH_R AAGTGGAATCCGCCGTTCAT 
sox2 ISH_F ACACCAACTCCTCGGGAAAC 
sox2 ISH_R ATCGTGCCGTTAATCGTCGT 
Genotyping primers 
stag1a OC13_F CTGGCCCTCTGTGGAAGAAG 
stag1a OC13_R AGTGCTGGTGTGTCTGAAGG 
stag1b OC13_F ACCCTCTCACGATGACAGGA 
stag1b OC13_R TGTGCTGGTGTGTCTGAAGG 
stag2a OC13_F TGGTCCGACAGTGCCAGTA 
stag2a OC13_R CTGAATGATATCCAGCCCGAGT 
stag2b OC13_F TATTACAGGACAGCGGCGAC 
stag2b OC13_R CTAAAGGCTCGGACTTGCGA 
stag2a OC14_F TACTAACCAAGCCGATGGATGT 
255 
 
stag2a OC14_R GGTCGCGATGAACTCACACAA 
stag2a OC16_F CCCTTCAGAGGGATGACTGC 
stag2a OC16_R CGCTTCAACACACACCATCG 
stag1a OC17_F GCCTCGGAAGTCTCCATCAG 
stag1a OC17_R GCACACCTGCATAGCACTCT 
stag1b OC18_F GGCGGCTAATAAGAAGGCCA 
stag1b OC18_R AAGCAGCACACAACCTCGAA 
stag2b OC22_F GTCACTCTGCTTCAGGCGAA 
stag2b OC22_R TGACCTGCATGGCACTCTTC 
 














In vivo editing efficiency  
% (mutant/total embryos) 
T7E1 MiSeq 
OC6 stag2a 6 61.3 NA * NA * 0 (0/6) Not evaluated 
OC7 stag2a 18 67.86 NA * NA * 0 (0/4) Not evaluated 
OC8 stag2a 18 Not found NA * NA* 0 (0/6) Not evaluated 
OC9 stag2a 7 32.05 NA * NA* 0 (0/16) Not evaluated 
OC10 stag2a 2 60.05 NA * Not found* 0 (0/11) Not evaluated 
OC13 stag1a 6 59.61 NA * Not found* 83 (5/6) 0 (0/6) 
stag1b 0 (0/5) 0 (0/6) 
256 
 
stag2a 75 (9/12) 0 (0/6) 
stag2b 50 (2/4) 0.05 (1/6) 
OC15 stag2a 18 49.56 64 689 50 (2/4) Not evaluated 
OC19 stag1a 1 59.24 69 NA * 12 (1/8) Not evaluated 
OC20 stag2a 2 60.1 28 382 87 (7/8) Not evaluated 
OC21 stag1b 28 55.11 69 NA Unknown*
* 
Not evaluated 
OC23 stag2b 12 70.45 73 812 25 (2/8) Not evaluated 
* These sgRNAs lack 5’GG. ** Screening could not be optimised.  
 
Appendix table 4. Sequences of sgRNAs used. PAM sites are highlighted in 
blue. 
Oligo CRISPR 
ID 
Sequence 5'-3' 
OC6 ACCTGTGAGTCTGACAGGCCGG 
OC7 CTGACGTAGTAAAGCATCAAGG 
OC8 CTTGATGCTTTACTACGTCAGG 
OC9 TCTAAATTTGAGCATCAATTTGG 
OC10 CAGATCTTGAAGATCATGAAGGG 
OC13 CATCTATGATGAGTACATGATGG 
OC14 GGCGATGGCAGGTCCAGCGTGG 
OC15 GGAAGTCCTCCAGGAGGCGGTGG 
257 
 
OC16 GGGCAGTTTTCTCTTGCTGGCGG 
OC17 GGGCTTTATGGCAGTCCAGAGGG 
OC18 CGGGAGGAGGCCGAATGGAGTGG 
OC19 GAGAGGACTCACTGTAGCACCGG 
OC20 GGAAGGACACTCTCTGCTCTCGG 
OC21 GGTCTTCTTTTGTGCTGTGGCGG 
OC22 GGCCCTGGAGAGAAGGGAAAAGG 
OC23 GGTGGGCTGAATACACTAGGTGG 
 
 
